**Contents**

<table>
<thead>
<tr>
<th>Programme Overview by Day:</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday 27 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Techno College</td>
<td>8</td>
</tr>
<tr>
<td><strong>Sunday 28 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td>9</td>
</tr>
<tr>
<td><strong>Monday 29 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td>10-11</td>
</tr>
<tr>
<td><strong>Tuesday 30 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td>12-13</td>
</tr>
<tr>
<td><strong>Wednesday 31 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td>14</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Council</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Secretariat</td>
<td>15</td>
</tr>
<tr>
<td>Past Presidents</td>
<td>15</td>
</tr>
<tr>
<td>Honorary Members</td>
<td>16</td>
</tr>
<tr>
<td>On-site information</td>
<td>17-18</td>
</tr>
<tr>
<td>Social Programme</td>
<td>19</td>
</tr>
<tr>
<td>Location of Session Rooms and other Meeting Activities</td>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Thoracic Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td>21</td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td>22</td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td>23</td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td>30-31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Acquired Cardiac Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td>33</td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td>34-35</td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td>36-39</td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td>40-70</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Congenital Heart Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td>77</td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td>78</td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td>79-81</td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td>81-86</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>On-site information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Social Programme</td>
<td></td>
</tr>
<tr>
<td>Location of Session Rooms and other Meeting Activities</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Council</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Secretariat</td>
<td></td>
</tr>
<tr>
<td>Past Presidents</td>
<td></td>
</tr>
<tr>
<td>Honorary Members</td>
<td></td>
</tr>
<tr>
<td>On-site information</td>
<td></td>
</tr>
<tr>
<td>Social Programme</td>
<td></td>
</tr>
<tr>
<td>Location of Session Rooms and other Meeting Activities</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Thoracic Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td></td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td></td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Acquired Cardiac Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td></td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td></td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain of Congenital Heart Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Techno College</td>
<td></td>
</tr>
<tr>
<td>Postgraduate Courses</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme, Professional Challenges and Focus Sessions</td>
<td></td>
</tr>
<tr>
<td>Advanced Techniques</td>
<td></td>
</tr>
</tbody>
</table>
Sunday 28 October 2012

Postgraduate Education:
- Quality Improvement Programmes 104
- Basic Science Programme 104-106
- Leadership: Working within multi-disciplinary teams 106
- Nurses, Nurse Practitioners, Physician Assistants Programme 107-108

Monday 29 October 2012

Residents’ Sessions:
- Luncheon meeting 108-109
- Research in Cardiothoracic Surgery 109

Tuesday 30 October 2012

Residents’ Sessions:
- Cardiovascular Simulator Award presentations 110
- PASCaTS/EACTS Global Forum: Challenges of cardiothoracic surgery in the developing world: 111
- Teach the teacher 112

Focus Sessions:
- The patient keeps getting sicker, what do I do next? 112
- Acknowledgements 113
- Commercial Relationships/Conflict of Interest Disclosures 114-118

Satellite Meetings 119-120
- Alphabetical List of Exhibitors 121-123
- Exhibitor List 2012 124-144
Baxter Symposium

Tuesday, October 30th | 12:45–14:00 | Room 124

Current Principles and Practices to Minimize the Need for Blood Transfusion in Cardiac Surgery

12.45–13.00  **Introduction of session**  
Dr Erik Kuntze, Medical Director BioSurgery EMEA, Baxter Healthcare SA

13.00–13.30  **What does blood management mean?**  
Dr Per I. Johansson, Section for Transfusion Medicine, Capital Region Blood Bank, Denmark

13.30–14.00  **Blood management in practice.**  
Dr E Natour, Universitair Medisch Centrum Groningen UMCG, Netherlands

Baxter and Advancing Surgery, Enhancing Life are trademarks of Baxter International Inc., its subsidiaries or affiliates.
TEMPERATURE CONTROL IN A NEW DIMENSION

The HCU 40 Heater-Cooler Unit combines the latest proven technology with outstanding performance and unique usability. It delivers very precise, fast and independent regulation of patient and cardioplegia circuit temperatures – intuitively controllable with a full graphic color touch screen display. Always reliable, always safe.


As awarded by The Chicago Athenaeum: Museum of Architecture and Design.
Sternal ZipFix System. For stable fixation of the sternum.

- Easy to handle
- Larger implant to bone contact area in comparison to cerclage wires to reduce the risk of bone cut-through
- Made of PEEK for biocompatibility
- MR safe after removal of stainless steel needle

Please visit us at our booth 123 for hands-on product trial.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 111</th>
<th>Room 113</th>
<th>Rooms 115/116/117</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-10:10</td>
<td>Congenital Heart Disease</td>
<td>Thoracic Disease</td>
<td>Acquired Cardiac Disease</td>
</tr>
<tr>
<td>09:00-17:00</td>
<td>Minimally invasive thoracic surgery: advanced procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-18:00</td>
<td>Medical and surgical intervention and management of cardiac arrhythmias in congenital heart disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-15:50</td>
<td>Lunch; Visit Exhibition 13:15-14:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-15:50</td>
<td>Heart failure - devices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:20-18:10</td>
<td>Mitral valve surgery</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Sunday 28 October 2012 - Post Graduate Education

<table>
<thead>
<tr>
<th>Room 111</th>
<th>Room 112</th>
<th>Room 113</th>
<th>Room 114</th>
<th>Rooms 115/116/117</th>
<th>Rooms 118/119</th>
<th>Rooms 120/121</th>
<th>Rooms 122/123</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00 Quality improvement programmes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 16:30 Congenital Heart Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 16:25 Perfusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 16:30 Thoracic Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 - 16:20 Vascular Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 16:25 Acquired Cardiac Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 16:00 Basic Science</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 16:15 Nurses, Nurse Practitioners and Physician Assistants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:30 Session 1: Truncus arteriosus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:45 Session 1: Extracorporeal life support</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:30 Session 1: Thoracic trauma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 - 11:55 Session 1: Infections of the cardiovascular system</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:10 Session 1: Coronary surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 12:10 Session 1 002-003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:40 Session 1: Optimizing preoperative care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-12:45 Session 2: Extracorporeal circulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-12:45 Session 2: Theatre: making for a better tomorrow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:10 Session 2: Aortic valve repair in childhood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00 Session 2: Oncology - complex cases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:40 Session 2: Controversies of open and endovascular approaches</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:50 Session 2: Update on valves</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:20 Session 2 002-003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:20 Session 3: Minimally invasive repairs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30 Session 3: Cardiac assist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30 Session 3: Empyema - difficult cases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:20 Session 3: Thoracic vascular trauma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:20 Session 3: Left heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:20 - 16:00 Session 3 004-012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 16:00 Leadership: Working with multi-disciplinary teams</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15 - 14:35 Session 4: Innovations in patient care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:35 - 16:15 Session 5: Hands on sessions with industry and surgeons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room 111</td>
<td>Room 112</td>
<td>Room 113</td>
<td>Room 114</td>
<td>Room 115</td>
<td>Rooms 116/117</td>
<td>Rooms 118/119</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td>------------------------</td>
<td>--------------------------------</td>
<td>----------------</td>
<td>---------------</td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td>Professional Challenges:</td>
<td></td>
<td>Aortic Arch Disease:</td>
<td>Abstracts:</td>
<td>Professional Challenges:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is there a place for palliation</td>
<td></td>
<td>The search for sinus</td>
<td>Abstracts:</td>
<td>How to optimise coronary</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in the management of Fallots</td>
<td></td>
<td>rhythm</td>
<td>Abstracts:</td>
<td>revascularization: planning</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>tetralogy</td>
<td></td>
<td>024-029</td>
<td>Abstracts:</td>
<td>and execution</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>041-044</td>
<td></td>
<td></td>
<td></td>
<td>013-017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Professional Challenges:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Abstracts:</td>
<td>How to optimise coronary</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aortic valve repair at</td>
<td>revascularization: planning</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>the crossroads</td>
<td>and execution</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>073-078</td>
<td>057-060</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 - 11:45</td>
<td>Professional Challenges:</td>
<td></td>
<td>Aortic Arch Disease:</td>
<td>Abstracts:</td>
<td>Professional Challenges:</td>
<td></td>
<td>Focus:</td>
</tr>
<tr>
<td></td>
<td>Is there a place for palliation</td>
<td></td>
<td>The future of transcatheter</td>
<td>Abstracts:</td>
<td>How to optimise coronary</td>
<td></td>
<td>Antiplatelet</td>
</tr>
<tr>
<td></td>
<td>in the management of Fallots</td>
<td></td>
<td>mitral valve repair</td>
<td>Abstracts:</td>
<td>revascularization: planning</td>
<td></td>
<td>therapy</td>
</tr>
<tr>
<td></td>
<td>tetralogy</td>
<td></td>
<td>067-071</td>
<td></td>
<td>and execution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:30</td>
<td>The Presidential Address</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The contraindications of today</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>are the indications of tomorrow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Von Segesser, Lausanne Rooms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:00</td>
<td>Lunch; Visit Exhibition;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Satellite Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>repair 06-111</td>
<td>the role of the surgeon in</td>
<td>conventional and frozen</td>
<td>Abstracts:</td>
<td>refining risk assessment</td>
<td>cardiothoracic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>specific access route</td>
<td></td>
<td>Abstracts:</td>
<td></td>
<td>in progress</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstracts: Refining techniques</td>
<td>Euroscore II:</td>
<td></td>
<td>abstract</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>in minimal invasive</td>
<td>refining risk</td>
<td></td>
<td>session</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>mitral valve surgery</td>
<td>assessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>095-100</td>
<td>091-094</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 17:45</td>
<td>Combined Adult and Congenital</td>
<td>Focus: Is there a limit in the</td>
<td>Abstracts: Minimally</td>
<td>Abstracts:</td>
<td>Abstracts: Late breaking trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heart rejuvenation</td>
<td>repair of mitral &amp; tricuspid</td>
<td>invasive aortic valve</td>
<td>Abstracts:</td>
<td>I LB 001-005</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>regurgitation?</td>
<td>repair120-121</td>
<td>Abstracts:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Abstracts:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Multiple valves 118-119</td>
<td>Abstracts:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Late breaking trials I</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LB 001-005</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Rooms 120/121</td>
<td>Rooms 122/123</td>
<td>Rooms 133/134</td>
<td>Room Tres Torres: Hotel AC Barcelona Forum</td>
<td>Room Vallvidrera: Hotel AC Barcelona Forum</td>
<td>Room Montjuic: Hotel AC Barcelona Form</td>
<td>Rooms 211/212</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------</td>
<td>----------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td></td>
<td>Acquired</td>
<td>Acquired</td>
<td>Thoracic</td>
<td>Vascular</td>
<td>Vascular</td>
<td>Vascular</td>
<td>General</td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td></td>
<td></td>
<td>Abstracts:</td>
<td>09:00-17:00 Mentice Simulation Course</td>
<td>08:30-16:30 TEVAR Simulation Workshop</td>
<td>08:30-17:00 TEVAR pre-case planning Course with OsiriX</td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Break; Visit Exhibition</td>
</tr>
<tr>
<td>10:15 - 11:45</td>
<td>Heart transplants: the most effective treatment for end-stage heart failure 085-090</td>
<td>How to optimise transcatheter aortic valve implantation outcomes</td>
<td>Abstracts: Thoracic oncology II 079-084</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:30</td>
<td></td>
<td></td>
<td>The Presidential Address The contraindications of today are the indications of tomorrow L. Von Segesser, Lausanne Rooms 116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:00</td>
<td></td>
<td></td>
<td>Lunch; Visit Exhibition; Satellite Symposia</td>
<td></td>
<td>Residents’ Luncheon: Minimally invasive cardiothoracic surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15 - 15:45</td>
<td>Abstracts: Thoracic oncology III 112-117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td></td>
<td></td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 17:45</td>
<td>Thoracic nononcology I 128-133</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room 111</td>
<td>Room 112</td>
<td>Room 113</td>
<td>Room 114</td>
<td>Room 115</td>
<td>Rooms 116/117</td>
<td>Rooms 118/119</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>09:45 - 10:15</strong></td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:45</strong></td>
<td>Da Vinci Prize Winner Presentation - Rooms 116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:50 - 12:30</strong></td>
<td>The Honoured Guest Lecture: Can Medicine Save Pharma?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M Fishman, Cambridge MA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>President, Novartis Institutes for BioMedical Research - Room 116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:45 - 14:00</strong></td>
<td>Lunch; Visit Exhibition; Satellite Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:45 - 16:15</strong></td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Rooms 120/121</td>
<td>Rooms 122/123</td>
<td>Room 124</td>
<td>Rooms 127/128</td>
<td>Rooms 133/134</td>
<td>Room Tres Torres: Hotel AC Barcelona Forum</td>
<td>Room Vallvidrera: Hotel AC Barcelona Forum</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------</td>
<td>---------------</td>
<td>----------</td>
<td>---------------</td>
<td>---------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td>Acquired: The Hybrid approach 166-199</td>
<td>General Interest</td>
<td>Thoracic</td>
<td>General Interest</td>
<td>Thoracic</td>
<td>Abstracts: Oesophagus and mediastinum 154-159</td>
<td>08:30-17:00 Mentice Simulation Course</td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Da Vinci Prize Winner Presentation - Rooms 116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:30</td>
<td>The Honoured Guest Lecture: Can Medicine Save Pharma? M Fishman, Cambridge MA: President, Novartis Institutes for BioMedical Research - Rooms 116/117</td>
<td>Cardiovascular Simulator Award 12:00 -14:00</td>
<td>The Honoured Guest Lecture: Can Medicine Save Pharma? M Fishman, Cambridge MA: President, Novartis Institutes for BioMedical Research - Rooms 116/117</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:00</td>
<td>Lunch; Visit Exhibition; Satellite Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15 - 15:45</td>
<td>PASCatS/EACTS Global Forum</td>
<td>Teach the teacher</td>
<td>The patients getting sicker, what do I do next?</td>
<td>Focus Session: Pulmonary embolism: acute and chronic</td>
<td>Mentice Simulation Course</td>
<td>TEVAR Simulation Workshop</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Break; Visit Exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 17:45</td>
<td>Abstracts: Endocarditis 288-290</td>
<td>Abstracts: Thoracic non-oncology II 206-209</td>
<td>Mentice Simulation Course</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room 111</td>
<td>Room 113</td>
<td>Room 114</td>
<td>Room 115</td>
<td>Rooms 118/119</td>
<td>Rooms 120/121</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>---------------</td>
<td>---------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquired</td>
<td>Acquired</td>
<td>Acquired</td>
<td>Acquired</td>
<td>Vascular</td>
<td>Acquired</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-12:00</td>
<td>09:00-12:30</td>
<td>09:00-12:00</td>
<td>08:30-11:45</td>
<td>08:30-12:20</td>
<td>10:45-13:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Lateral thinking**

The mitral and tricuspid valves: repair techniques

Live-in-box minimal invasive cardiac symposium: How to do it?

Controversies and catastrophies in adult cardiac surgery

08:30-09:45

Interesting cases and small series on orphan aortic diseases and pathological mechanisms

10:00 -12:00

Clinical tips and tricks in vascular access for open and endovascular therapy

Wet Lab: Part II: Valve sparing aortic root replacement

---

<table>
<thead>
<tr>
<th>Rooms 122/123</th>
<th>Room 124</th>
<th>Rooms 127/128</th>
<th>Rooms 129/130</th>
<th>Rooms 131/132</th>
<th>Room 133/134</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquired</td>
<td>Thoracic</td>
<td>Thoracic</td>
<td>Congenital</td>
<td>Acquired</td>
<td>Acquired</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>09:00-12:15</td>
<td>09:00-10:30</td>
<td>09:00-12:00</td>
<td>09:00-13:00</td>
<td>09:00-10:30</td>
</tr>
</tbody>
</table>

Wet Lab: Valvular valve replacement strategies to deal with mitral repair using Gore-tex chords

Learning from experience

Wet Lab: Chest Wall Resection and or resection sleeve

Wet Lab: Operative techniques: Aortic Valve Repair and Maze procedure

New surgical treatment concepts for heart failure

Part I: Aortic valve repair for the non-expert: a stepwise approach
# Council

<table>
<thead>
<tr>
<th>Position</th>
<th>Name and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Ludwig K von Segesser, Lausanne, Switzerland</td>
</tr>
<tr>
<td>Vice President</td>
<td>José Luis Pomar, Barcelona, Spain</td>
</tr>
<tr>
<td>Secretary General</td>
<td>A Pieter Kappetein, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>Editor in Chief</td>
<td>Friedhelm Beyersdorf, Freiburg, Germany</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Ralph A Schmid, Berne, Switzerland</td>
</tr>
<tr>
<td>Past President</td>
<td>Ottavio R Alfieri, Milan, Italy</td>
</tr>
</tbody>
</table>

## Domain Chairs:

<table>
<thead>
<tr>
<th>Domain</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquired Cardiac Disease</td>
<td>John R Pepper, London, UK</td>
</tr>
<tr>
<td>Thoracic Disease</td>
<td>Paul E Van Schil, Antwerp, Belgium</td>
</tr>
<tr>
<td>Congenital Heart Disease</td>
<td>William J Brawn, Birmingham, UK</td>
</tr>
<tr>
<td>Vascular Disease</td>
<td>Martin Czerny, Berne, Switzerland</td>
</tr>
</tbody>
</table>

## Councillors

- Leslie Hamilton, Newcastle upon Tyne, UK
- Philippe G Dartevelle, Paris, France
- Peyman Sardari Nia, Breda, Netherlands
- Shinichi Takamoto, Tokyo, Japan
- Douglas E Wood, Seattle, USA

## Executive Secretariat

- EACTS House
  Madeira Walk
  Windsor
  Berkshire
  SL4 1EU, UK
- Tel: +44 (0)1753 832166
- Fax: +44 (0)1753 620407
- Email: info@eacts.co.uk
- www.eacts.org
Past Presidents

- 2011: Lisbon, Ottavio R Alfieri
- 2010: Geneva, Pascal R Vouhé
- 2009: Vienna, Erino Rendina
- 2008: Lisbon, Paul Sergeant
- 2007: Geneva, Siegfried Hagl
- 2006: Stockholm, Tom Treasure
- 2005: Barcelona, Torkel Åberg
- 2004: Leipzig, James Monro
- 2003: Vienna, Walter Klepetko
- 2002: Monaco, Marko Turina
- 2001: Lisbon, Marcos Murtra
- 2000: Frankfurt, Joachim Hasse
- 1999: Glasgow, David Wheatley
- 1998: Brussels, Eugène Baudet
- 1997: Copenhagen, Ernst Wolner
- 1996: Prague, Antoon Lerut
- 1995: Paris, Hans Borst
- 1994: The Hague, Armand Piwnica
- 1993: Barcelona, Jaroslav Stark
- 1992: Geneva, Ramiro Rivera
- 1991: London, Maurizio Cotrufo
- 1990: Naples, Hans Huysmans
- 1989: Munich, Fritz Sebening
- 1988: Bordeaux, Keyvan Moghissi
- 1987: Vienna, Francis Fontan

Honorary Members

- Robert H Anderson, London, UK
- John R Benfield, Los Angeles, USA
- Eugene H Blackstone, Cleveland, USA
- Aldo Castaneda, Guatemala
- Denton A Cooley, Houston, USA
- Tirone David, Toronto, Canada
- Thomas B Ferguson, St Louis, USA
- Vincent L Gott, Baltimore, USA
- Adib D Jatene, São Paulo, Brazil
- Bruce E Keogh, London, UK
- Floyd D Loop, Cleveland, USA
- D Craig Miller, Stanford, USA
- G Alexander Patterson, St Louis, USA
- F Griffith Pearson, Ontario, Canada
- Gaetano Thiene, Padova, Italy
- Stephen Spiro, London, UK
- Marko Turina, Zurich, Switzerland
- Lucio Parenzan, Bergamo, Italy
- William Williams, Toronto, Canada
- Patrick Wouters, Genk, Belgium
- Peter Greene, Baltimore USA
Admission Badges
All pre-registered delegates will have been sent an e-badge prior to the event containing a barcode. This will enable you to print out your badge on site. For organisation and security reasons, name badges must be worn at all times at the congress venue. Changes to name badges on-site will be charged at €25. A fee of €100 will be charged for the replacement of lost badges.

Banks and Credit Cards
There are no ATM’s located in the Congress Centre. The nearest ATM’s (dispensing Euros) are located in the Diagonal Mar shopping centre opposite the CCIB. General banking hours in Barcelona are 08:30-14:00 Monday to Friday and 08:30-13:00 on Saturday.

Certificates of Attendance
Certificates of attendance are available from the registration desks or alternatively via the EACTS user area.

Cloakroom
A manned cloakroom will be open throughout the opening hours of the Annual Meeting on Level -1. Items may be left at a nominal charge of €2 per item, per day.

Continuing Medical Education
The 26th EACTS Annual Meeting has been approved for CME by the European Accreditation Council for Continuing Medical Education (EACCME). For further information please contact the registration desks.

Currency
The currency in Spain is the Euro (€). Most ATM’s accept VISA and MasterCard credit cards and usually offer favourable exchange rates, although a daily limit of €300 may be applied.

Delegate Bags
Please ensure that your bag is clearly labelled with your name.

Dress
The dress code for the Annual Meeting and associated events is informal with the exception of the Presidential Dinner for which a suit and tie is recommended.

Facilities for the disabled
Exhibitors with any special needs who require details regarding the facilities available within the Centre should contact the Organisers.

First Aid/Emergency
A fully equipped first aid room manned by a nurse is located in the Congress Centre in the infirmary below escalators B. Should you require first aid assistance, please contact the registration desk or any uniformed member of the Meeting staff.

Insurance and Liability
Participants are encouraged to make their own arrangements in respect of health and travel insurance. Neither EACTS nor any of its appointed agencies can be held responsible for any personal injury, loss, damage, accident to private property or additional expense incurred as a result of delays or changes in air, rail, sea, road or other services, strikes, sickness, weather and any other cause.

Language
The official language of the EACTS and the Annual Meeting is English.

Lost and Found
Lost and found enquiries should be directed to the Messages & Information Desks in the registration area. To minimise losses, please ensure that any personal items, including delegate bags, are properly labelled.

Lunch and Refreshments
Techno-College, Saturday 27 October
Lunch and refreshment breaks are included in the delegate fee and will be available on Level 2 of the Centre.

Postgraduate Courses, Sunday 28 October
A morning refreshment break is included in the delegate fee. Lunch is not included but can be purchased from the cash catering points on Level 2 of the Centre.

Scientific programme, Monday 29 – Wednesday 31 October
Coffee and tea will be available in the exhibition area on the Ground Level during official programme breaks and is included in the registration fee. Lunch is not included, however, there will be a cash catering point in the exhibition area where delegates may purchase food and drinks.
Meeting Hours
EACTS Techno-College:
08:00-18:00 on Saturday 27 October
Postgraduate Courses:
08:30-16:30 on Sunday 28 October
Main scientific programme:
08:15-17:45 Monday 29 October & Tuesday 30 October;
08:30-13:00 Wednesday 31 October.

Messages
Messages should be handed in to staff at the Messages & Information Desk in the registration area. Delegates are reminded to check for messages on a regular basis throughout the meeting.

Photography in Session Rooms
The use of any photographic or recording device in the scientific sessions is strictly prohibited. This includes, but are not limited to, mobile telephones, digital and still cameras, video and/or audio recording devices.

Post Office/Shops
There is a Post Office on the lower level of the Diagonal Mar shopping centre opposite the CCIB. The centre is open from Monday to Saturday 10:00 to 22:00. The restaurants on the 3rd floor of the centre are also open on Sunday.

Public Telephones
There are no public telephones in the CCIB.

Public Transport
You can access the CCIB on the metro (Maresme-Fòrum station on the yellow line, L4); by bus (lines 7, 36, 41, 43 and 141) and the Trambesòs tram line (Forum station). All of these means of transport are just a few minutes’ walk from the CCIB. Information and schedules at: www.tram.cat/ and www.tmb.cat/ca/home

Registration and Information Desks
Registration and information desks will be open on the Ground Level of the Congress Centre at the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 26 October</td>
<td>14:00-18:00</td>
</tr>
<tr>
<td>Saturday 27 October</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Sunday 28 October</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Monday 29 October</td>
<td>08:00-17:00</td>
</tr>
<tr>
<td>Tuesday 30 October</td>
<td>08:00-17:00</td>
</tr>
<tr>
<td>Wednesday 31 October</td>
<td>08:00-12:00</td>
</tr>
</tbody>
</table>

To avoid unnecessary delay, you are strongly recommended to register and collect Meeting documentation on Friday 26 and Saturday 27 October if possible. Delegates who register prior to the event should report to the E-Badge area where they will be able to print out their badge and other relevant documentation.

Trade Exhibition
The Exhibition will take place in Halls 1, 2 & 3 of the CCIB and will be open as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday 28 October</td>
<td>16:30-19:00</td>
</tr>
<tr>
<td>Monday 29 October</td>
<td>09:00-17:00</td>
</tr>
<tr>
<td>Tuesday 30 October</td>
<td>09:00-17:00</td>
</tr>
<tr>
<td>Wednesday 31 October</td>
<td>09:00-12:00</td>
</tr>
</tbody>
</table>

Training Village
The following organisations will be holding training sessions in the Training Village in Hall 4 on the Ground Level of the Centre. For further information regarding these, please contact the relevant organisation:

Edwards Lifesciences
Medtronic International Trading Sàrl
Sorin Group
Ethicon

Disclaimer
The European Association for Cardio-Thoracic Surgery (EACTS) cannot accept any liability for death, injury, or any loss, cost or expense suffered or incurred by any person if such loss is caused or results from the act, default or omission of any person other than an employee or agent of EACTS. In particular, the EACTS cannot accept any liability for losses arising from the provision or non-provision of services provided by hotel companies or transport operators. Nor can EACTS accept liability for losses suffered by reason of war including threat of war, riot and civil strife, terrorist activity, natural disaster, weather, flood, drought, technical, mechanical or electrical breakdown within any premises visited by delegates and/or partners in connection with the Annual Meeting, industrial disputes, governmental action, regulation or technical problems which may affect the services provided in connection with the Annual Meeting. EACTS is not able to give any warranty that a particular person will appear as a speaker or panel list.

NO-SMOKING POLICY
Smoking is strictly prohibited in all meeting, catering and foyer area AT ALL TIMES.
Welcome Reception  
Sunday 28 October, from 17:00  
An informal reception at which drinks and canapés will be served. The reception will be held in the Exhibition area and is open to registered delegates, exhibitors and exhibition visitors.

Presidential Dinner  
Tuesday 30 October, from 19:30  
The Presidential Dinner will be held at the MNAC Museum - Museu Nacional d’Art de Catalunya in Barcelona. The MNAC forms part of the Palau Nacional building in the Parc de Montjuïc, one of Barcelona’s most emblematic buildings. The museum’s privileged location makes it one of Barcelona’s foremost vantage points for enjoying a unique panoramic view of the city.

Admission will be by invitation only which must be purchased in advance. Price €80 per person (subject to availability).

Coach transfers will be provided to and from the venue. Please refer to the timetable at the Socials Desk for further information.
## Location of Session Rooms and other Meeting Activities

<table>
<thead>
<tr>
<th>Activity</th>
<th>Location</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday 27 October</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Techno-College: Acquired Cardiac Disease</td>
<td>Rooms 115-117</td>
<td>P1</td>
</tr>
<tr>
<td>Techno-College: Congenital Heart Disease</td>
<td>Room 111</td>
<td>P1</td>
</tr>
<tr>
<td>Techno-College: Thoracic Disease</td>
<td>Room 113</td>
<td>P1</td>
</tr>
<tr>
<td>European Board of Cardiovascular Perfusion</td>
<td>Room 112</td>
<td>P1</td>
</tr>
<tr>
<td><strong>Postgraduate Courses - Sunday 28 October</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquired Cardiac Disease</td>
<td>Rooms 115-117</td>
<td>P1</td>
</tr>
<tr>
<td>Congenital Heart Disease</td>
<td>Room 111</td>
<td>P1</td>
</tr>
<tr>
<td>Perfusion</td>
<td>Room 112</td>
<td>P1</td>
</tr>
<tr>
<td>Thoracic Disease</td>
<td>Room 113</td>
<td>P1</td>
</tr>
<tr>
<td>Vascular Disease</td>
<td>Room 114</td>
<td>P1</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Rooms 118/119</td>
<td>P1</td>
</tr>
<tr>
<td>Nurses and Physician Assistants</td>
<td>Rooms 120/121</td>
<td>P1</td>
</tr>
<tr>
<td>Leadership: Working within multi-disciplinary teams</td>
<td>Rooms 122/123</td>
<td>P1</td>
</tr>
<tr>
<td><strong>Business Meetings - Sunday 28 – Monday 29 October</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday 29 October</td>
<td>Rooms 133/134</td>
<td>P1</td>
</tr>
<tr>
<td>EACTS General Assembly, 18:00-18:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exhibition</td>
<td>Halls 1, 2 &amp; 3</td>
<td>P0</td>
</tr>
<tr>
<td>EACTS Executive Secretariat</td>
<td>Rooms M215/M216</td>
<td>M2</td>
</tr>
<tr>
<td>EJCTS Publications Office</td>
<td>Room M218</td>
<td>M2</td>
</tr>
<tr>
<td>Speaker Preview Area</td>
<td>VIP Area</td>
<td>M1</td>
</tr>
<tr>
<td>Registration &amp; Information Desks</td>
<td>Entrance Hall</td>
<td>P0</td>
</tr>
<tr>
<td>Exhibition Desk</td>
<td>Entrance Hall</td>
<td>P0</td>
</tr>
<tr>
<td>Cloakroom</td>
<td>Foyer</td>
<td>P-1</td>
</tr>
<tr>
<td>Delegate Refreshments &amp; Cash Catering</td>
<td>Halls 1, 2 &amp; 3</td>
<td>P0</td>
</tr>
<tr>
<td>Training Village</td>
<td>Hall 4</td>
<td>P0</td>
</tr>
<tr>
<td>Hospitality/Meeting Rooms</td>
<td>Rooms M211 – M221</td>
<td>M2</td>
</tr>
</tbody>
</table>
Thoracic Disease Domain Programme

Chair:
Paul E. Van Schil, Antwerp
Philippe G. Darteville, Le Plessis-Robinson
Peyman Sardari Nia, Breda
Dragan Subotic, Belgrade
Cliff C. Choong, Melbourne
Pala Babu Rajesh, Birmingham
Ramon Rami-Porta, Barcelona
Mustafa Yuksel, Istanbul
G. Alexander Patterson, St. Louis
Marco Lucchi, Pisa
Godehard Friedel, Gerlingen
Peter B. Licht, Copenhagen
Jose Ribas M. De Campos, Sao Paulo

Ex officio
Ludwig K. Von Segesser, Lausanne
Ralph Alexander Schmid, Berne
A. Pieter Kappetein, Rotterdam

Saturday 27 October 2012
Techno College

Sunday 28 October 2012
Postgraduate Education:
Quality Improvement Programmes
Thoracic Disease Domain Programme

Monday 29 October 2012
Scientific Abstracts

Tuesday 30 October 2012
Scientific Abstracts

Focus session:
Pulmonary embolism: acute and chronic

Wednesday 31 October 2012
Advanced Techniques:
Learning from experience
Wetlab:
Chest wall resection and sleeve resection
Minimally invasive thoracic surgery: advanced procedures

Organisers: Thoracic Disease Domain
Moderators: P. Dartelleve, Paris; P. Licht, Odense

Session 1

Video-assisted thoracoscopic surgery lobectomy: summary of different available techniques
D. Gossot (Paris)

Robotic lobectomy: different techniques
B. Park (Hackensack)

Video-assisted thoracoscopic surgery lobectomy: technique and Edinburgh experience
W. Walker (Edinburgh)

Video-assisted thoracoscopic surgery lobectomy: technique and Innsbruck experience
T. Schmid (Innsbruck)

Video-assisted thoracoscopic surgery lobectomy: long-term results
P. Sardari Nia (Breda)

Danish experience video-assisted thoracoscopic surgery lobectomy
P. B. Licht (Odense)

The first completely portal robotic pulmonary resection using a new operative telesurgical system (Telelap ALF-X) in an ovine model: a step towards the future?
A. Lococo, V. Larocca, F. Marino, F. De Filippis, F. Lococo, S. Gidaro (Italy)

Session 2:

Anaesthesia for robotic surgery
F. Guarracino (Pisa)

Different techniques for minimally invasive mediastinal surgery
K. Kernstine (Duarte)

Robotic resection of mediastinal tumours: live-in-a-box and results
M. Lucchi (Pisa)

Video-assisted thoracoscopic surgery resection of mediastinal tumours: live-in-box and results
M. Zielinski (Zakopane)

Robotic/video-assisted thoracoscopic surgery resection of mediastinal tumours: pro
J. Rückert (Berlin)

Robotic/video-assisted thoracoscopic surgery resection of mediastinal tumours: con
P. G. Dartelleve (Le Plessis Robinson)

Live Surgery:

Moderators: A Mussi, Pisa; E. Rendina, Rome; R. Schmid, Berne

Video-assisted thoracoscopic surgery lobectomy, subxyphoidal approach
A. Yilmaz1, M. C. Ambrogi2 (1Nieuwegein, 2Pisa)

Robotic lobectomy
F. Melfi1, R. Schmid2 (1Pisa, 2Berne)

Robotic resection mediastinal tumour
F. Melfi1, R. Schmid2 (1Pisa, 2Berne)
### Plenary session: Quality improvement programmes

**Moderators:** L. K. Von Segesser, Lausanne; D. Pagano, Birmingham

**08:30**

Quality: an elusive and moving target  
_B. E. Keogh (London)_

**08:50**

Cost-effectiveness analysis: what is it and how can we use it to improve care?  
_D. J. Cohen (Kansas City)_

**09:10**

Measuring data and creating evidence: shortcomings of trials/Registry/observational studies; mortality is not the only endpoint  
_M. Utley (London)_

**09:30**

ProvenCare in lung cancer  
_D. Wood (Seattle)_

### 08:30-10:00  Postgraduate Education Room 113

**10:30-12:30  Session 1: Thoracic trauma**

**Moderators:** P. B. Rajesh, Birmingham; C. K. C. Choong, Melbourne

**10:30**

Pre-hospital care  
_R. Steyn (Birmingham)_

**10:50**

Civilian trauma, Central Europe  
_T. Molnar (Pecs)_

**11:10**

Road traffic accidents, Greece  
_K. Athanassiad (Athens)_

**11:30**

Military trauma  
_T. Graham (Birmingham)_

**13:30-15:00  Session 2: Oncology - complex cases**

**Moderators:** P. G. Dartevelle, Le Plessis Robinson; E. A. Rendina, Rome; G. Friedel; D. Wood, Seattle

Illustrative cases will be presented by each speaker and discussed in an interactive way.

**15:00-16:30  Session 3: Empyema - difficult cases**

**Moderators:** D. Subotic, Belgrade; C. K. C. Choong, Melbourne; P. B. Licht, Odense

Illustrative cases will be presented by each speaker and discussed in an interactive way.

**16:30**

Adjourn
Thoracic oncology I

Moderators: M. E. Dusmet, London; P. Van Schil, Antwerp

08:15 045
The role of preoperative computed tomography-guided hook-wire localization in thoracoscopic resection for ground-glass opacity pulmonary lesions: a prospective analysis
T. Ye, J. Zhou, H. Hu, G. Li, W. Li, L. Shen, H. Chen (China)
Discussant: M. Jimenez (Salamanca)

08:30 046
Surgical results of non-small-cell lung cancer with the appearance of ground-glass opacity
S. Cho, S. Jheon (Republic of Korea)
Discussant: P. Van Schil (Antwerp)

08:45 047
Innate immune function following major lung resection for bronchogenic carcinoma via video-assisted thoracoscopic surgery and thoracotomy
Discussant: S. Margaritora (Rome)

09:00 048
Operating on a suspicious lung mass without a preoperative tissue diagnosis: pros and cons
A. Sihoe, R. Hiranandani, H. Wong, E. Yeung (Hong Kong)
Discussant: R. Rami-Porta (Barcelona)

09:15 049
Is lobectomy really more effective than sublobar resection in surgical treatment of second primary lung cancer?
A. Zuin, L. Andriolo, G. Marulli, M. Schiavon, S. Nicotra, F. Calabrese, P. Romanello, F. Rea (Italy)
Discussant: P. De Leyn (Leuven)

09:30 050
Which is the most important prognostic factor in neuroendocrine tumours of the lung? A single-centre experience
A. Sandri, F. Guerrera, G. Bora, A. Oliaro, L. Delsedime, P. Lausi, S. Olivetti, P. L. Filosso (Italy)
Discussant: P. B. Licht (Odense C)

Thoracic oncology II

Moderators: P. G. Dartevelle, Le Plessis Robinson; P. De Leyn, Leuven

10:15 079
Prognostic stratification of stage IIIa pn2 non-small-cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014)
G. Aresu, G. Masullo, E. Baracchini, A. Follador, F. Grossi, A. Morelli (Italy)
Discussant: P. G. Dartevelle (Le Plessis Robinson)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Discussant</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>080</td>
<td>Enzyme-linked immunosorbent spot for monitoring of postoperative</td>
<td>P. Rybojad, A. Jablonka, B. Wilczyńska, J. Tabarkiewicz (Poland)</td>
<td>M. Lucchi (Pisa)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>immunosupression of patients with lung cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>081</td>
<td>Surgical management of malignant tumours invading the inferior vena</td>
<td>D. Fabre, P. Bucur, R. Houballah, E. Fadel, S. Mussot, O. Mercier, P. Dartevelle (France)</td>
<td>L. Spaggiari (Milan)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cava</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>082</td>
<td>Pneumonectomy with en bloc chest wall resection: is it worthwhile?</td>
<td>G. Cardillo, L. Spaggiari, D. Galetta, F. Carleo, L. Carbone, G. Ngome Enang, M. Martelli (Italy)</td>
<td>P. Van Schil (Antwerp)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Report on 34 patients from two institutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>083</td>
<td>Sleeve resections of the bronchus without pulmonary resection for</td>
<td>K. Nowak¹, W. Karenovics², A. Nicholson², S. Jordan², M. Dusmet³ (¹Germany, ²United Kingdom)</td>
<td>P. De Leyn (Leuven)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>endobronchial carcinoid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>084</td>
<td>Robot-assisted versus thoracotomy lymphadenectomy for early stage</td>
<td>F. Allidi, F. Melfi, O. Fanucchi, A. Picchi, F. Davini, A. Mussi (Italy)</td>
<td>R. Schmid (Bern)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>non-small-cell lung cancer: preliminary results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td></td>
<td>The Presidential Address</td>
<td>L. Von Segesser, Lausanne</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>112</td>
<td>Dynamic 4-dimensional computed tomography for preoperative assessment</td>
<td>C. K. C. Choong, S. Pasricha, S. Stuckey, J. Smith, J. Troupis (Australia)</td>
<td>A. Zuin (Padua)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of lung cancer invasion into adjacent structures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>113</td>
<td>Outcome after full-thickness chest wall resection for isolated breast</td>
<td>E. Fadel, D. Levy Faber, F. Kolb, S. Delaloge, P. Dartevelle (France)</td>
<td>G. Cardillo (Rome)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cancer recurrence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>114</td>
<td>Occult pleural dissemination of cancer cells detected using the</td>
<td>D. Kim, Y. Kim, Y. Park (Republic of Korea)</td>
<td>M. Dusmet (London)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>touch print cytology method during surgery shows survival impact</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Preoperative serum ICTP levels as a predictor of recurrence in patients with non-small-cell lung cancer
Y. Tanaka, S. Oura, T. Yoshimasu, F. Ota, K. Naito, Y. Hirai, M. Ikeda, Y. Okamura (Japan)
Discussant: L. Spaggiari (Milan)

Do the histological subtypes of non-small-cell lung cancer correlate with the clotting disorders present in patients submitted to radical surgical resection?
N. Theakos, G. Athanassiadis, S. Pispirigou, L. Zoganas, P. Behrakis (Greece)
Discussant: P. B. Licht (Odense)

Prediction of in-hospital mortality following pulmonary resections: improving on the Thoracoscop score risk model
M. Poullis, R. Page, M. Shackcloth, N. Mediratta (United Kingdom)
Discussant: D. Wood (Seattle)

Normalized cardiopulmonary function following the Nuss procedure for pectus excavatum: 3-year follow-up. A prospective, controlled study
Discussant: J. Wihlm (Strasbourg)

Omitting chest tube drainage after thoracoscopic major lung resection
K. Ueda, M. Hayashi, K. Hamano (Japan)
Discussant: P. Sardari Nia (Breda)

Early and late outcome after surgical treatment of benign tracheo-oesophageal fistulas
G. Marulli, M. Loizzi, G. Cardillo, L. Battistella, A. De Palma, G. Ngome Enang, D. Zampieri, F. Rea (Italy)
Discussant: A. Lerut (Leuven)

Pain control of thoracoscopic major pulmonary resection: is pre-emptive local bupivacaine injection able to replace intravenous patient-controlled analgesia?
H. C. Yang, J. Lee, I. Song, J. Lee, W. Choi, S. Cho, K. Kim, S. Jheon (Republic of Korea)
Discussant: N. Novoa (Salamanca)

Long-term results of pectoralis muscle flap reconstruction versus sternal rewiring following failed sternal closure
J. Zeitani, E. Pompeo, M. Scognamiglio, C. Arganini, G. Simonetti, L. Chiariello (Italy)
Discussant: P. Rajesh (Birmingham)

Two-stage unilateral versus one-stage bilateral single-port sympathectomy for palmar and axillary hyperhidrosis
C. Menna, M. Ibrahim, C. Andreotti, A. M. Ciccone, A. D’Andrilli, C. Paggi, F. Venuta, E. Rendina (Italy)
Discussant: A. Sihoe (Hong Kong)
Oesophagus and mediastinum

Moderators: D. Wood, Seattle; A. Lerut, Leuven

08:15  154
Assessing impact of quality of life on postoperative length of hospital stay after oesophagectomy for cancer of the oesophagus and gastro-oesophageal junction
J. Durnez, P. Nafteux, J. Moons, W. Coosemans, G. Decker, A. Lerut, H. Van Veer, P. De Leyn (Belgium)
Discussant: D. Wood (Seattle)

08:30  155
Effect of thoracic epidural analgesia on transpulmonary right-to-left shunt during general anaesthetic in oesophageal resection via left thoracotomy
I. Serkedjiev, K. Vasileva, T. Djendov, A. Hristova, A. Tcherveniakov (Bulgaria)
Discussant: N. Novoa (Salamanca)

08:45  156
The impact of positive circumferential margin on survival following oesophagectomy using the new 7th Edition TNM classification
M. Diab, T. Theologou, P. Kyaw, C. McCoy, J. McShane, N. Howes, R. Page, M. Shackcloth (United Kingdom)
Discussant: D. Wood (Seattle)

09:00  157
Accuracy of sentinel lymph node mapping for lymph node staging in oesophageal cancer using intraoperative subserosal injection of Tc-99 antimony sulfide colloid and blue dye
R. Bagheri (Iran)
Discussant: F. Melfi (Pisa)

09:15  158
Resection of thymomas with use of the new minimally-invasive technique of extended thymectomy performed through the subxiphoid-right video-thoracoscopic approach with double elevation of the sternum
M. Zielinski (Poland)
Discussant: M. Lucchi (Pisa)

09:30  159
Early and late results of the use of extended rethymectomy in the treatment of refractory myasthenia gravis: operative technique through resternotomy and less-invasive approaches
P. Gwozdz, J. Pankowski, M. Zielinski (Poland)
Discussant: A. Lerut (Leuven)

Thoracic transplantation

Moderators: E. A. Rendina, Rome; P. G. Dartelleve (Le Plessis Robinson)

10:15
Extracorporeal membrane oxygenation as rescue therapy after thoracic surgery
C. Aigner (Vienna)

10:30
Selection of patients for lung volume reduction surgery versus transplantation
F. Rea (Padua)
10:45
Endobronchial valves: current status
E. A. Rendina (Rome)

11:00
Transplantation of initially rejected donor lungs after ex vivo lung perfusion
A. Wallinder, S. Ricksten, G. Riise, M. Silverhorn, H. Lidén, C. Hansson (Sweden)
Discussant: L. Fazekas (Budapest)

11:15
Importance of early recognition of vascular anastomotic complications in lung transplantation
A. Bose, T. Butt, H. Muse, S. Clark (United Kingdom)
Discussant: J. Bekkers (Rotterdam)

11:30
Techniques and results of lobar lung transplantations
Discussant: G. Marulli, (Padua)

10:15-11:45 Abstracts
Room 124

Thoracic experimental
Moderators: R. Schmid, Bern; P. B. Rajesh, Birmingham

10:15
Novel biomarkers in chronic obstructive pulmonary disease/lung cancer
J. H. Ankersmit (Austria)

10:30
Response to acute hypoxia-reoxygenation in human pulmonary arteries
P. Ariyaratnam, R. Bennett, M. Loubani, S. Griffin, M. Chaudhry, M. Cowen, A. Morice (United Kingdom)
Discussant: M. Poullis (Liverpool)

10:45
Sepsis primes the lung to an exaggerated injury to pneumonectomy: a novel model of postoperative acute lung injury
R. Evans, B. Naidu (United Kingdom)
Discussant: C. K. C. Choong (Melbourne)

11:00
Adipose-derived mesenchymal stem cells attenuate cold ischaemia lung injury
Y. Bellido Reyes, P. Díaz-Agero Álvarez, M. García Arranz, J. García Sánchez-Girón (Spain)
Discussant: P. Rajesh (Birmingham)

11:15
Experimental evaluation of a new system for laser tissue welding applied to damaged lung
M. Schiavon, G. Marulli, A. Zuin, F. Calabrese, C. Breda, M. Loy, S. Nicotra, F. Rea (Italy)
Discussant: R. Schmid (Bern)

11:45-11:50 Da Vinci Prizewinner presentation
Rooms 116/117

11:50-12:30 The Honoured Guest Lecture
Rooms 116/117

Can Medicine save Pharma?
M. Fishman, Cambridge MA
President, Novartis Institutes for BioMedical Research
Pulmonary embolism: acute and chronic

Moderators: E. Mayer; Bad Neuheim; P. Rajesh, Birmingham

14:15
Chronic thromboembolic pulmonary hypertension: medical treatment
J A Barberá (Barcelona)

14:35
Is there a role for surgery in acute pulmonary embolism?
W. Harringer (Braunschweig)

14:55
Chronic pulmonary thromboembolic disease: surgical treatment
P. G. Dartevelle (Le Plessis Robinson)

15:15
Long-term results of pulmonary endarterectomy
E. Mayer (Bad Nauheim)

15:30
Discussion

Thoracic non-oncology II

Moderators: D. Subotic, Belgrade; K. Athanassiadi, Athens

16:15 277
Early lung volume reduction surgery for supernormal physical activity requirement
E. Pompeo, B. Cristino, T. C. Mineo, P. Rogliani, O. Schillaci (Italy)
Discussant: H. van Wetten (Nijmegen)

16:30 278
Implications of microcoil localization technique for video-assisted thoracoscopic surgical resection of sub-centimetre pulmonary nodules
O. Almousa, S. Alnassar, W. Hajjar, S. Rahal, A. Ala青海ed, I. Ahmed (Saudi Arabia)
Discussant: D. Subotic (Belgrade)

16:45 279
Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: institutional experience
B. Yildizeli, S. Gezer Taş, M. Yanartaş, B. Eldem, N. O. Emerek, H. Batrel, M. Yuksel, H. Sunar (Turkey)
Discussant: P. G. Dartevelle (Le Plessis Robinson)

17:00 280
Clinical feasibility of single-port video-assisted thoracic surgery using Alexis® wound retractor for primary spontaneous pneumothorax
D. K. Kang, H. Min, Y. H. Hwang, H. J. Jun (Republic of Korea)
Discussant: G. Cardillo (Rome)

17:15 281
The use of endobronchial valves for the management of complex air leaks
G. Elshafie, O. Nawayou, H. Fallouh, P. Vaughan, M. Komaszewska (United Kingdom)
Discussant: H. van Swieten (Nijmegen)

17:30 282
A meta-analysis of studies comparing conventional posterolateral thoracotomy and muscle-sparing thoracotomy: significantly better outcomes with the muscle-sparing approach
M. M. Uzzaman, J. D. Robb, P. Mhandu, H. Khan, D. Whitaker (United Kingdom)
Discussant: C. K. C. Choong (Melbourne)
Learning from Experience

Moderators: P. Sardari Nia, Schoten; F. Melfi Pisa; L. Molins, Barcelona; C. K. C. Choong Melbourne

09:00
Large cystic teratoma mimicking pleural empyema
C. K. C. Choong, S. Chouta, E. Hu, C. Daley, X. Li (Melbourne)

09:15 291-I
Surgical technique of lung segmental resection with two intersegmental planes
H. Iwata, K. Shirahashi, M. Yoshimasa, M. Matsui, H. Takemura (Japan)

09:30
Post-surgical tracheal necrosis: a rescue revision
S. Sanna, M. Taurchini, M. Monteverde, M. Mengozzi, D. Argnani, D. Dell’Amore (Forlì)

09:45 292-I
Lung-sparing surgery with pulmonary artery replacement by cryopreserved allograft
V. Díaz-Ravetllat, A. Gomez-Caro, M. Boada, J. M. Gimferrer, L. Molins (Spain)

10:00
Delayed relief of external tracheal compression by an innominate artery results in chronic tracheomalacia
T. Prior1, A. Hatem1, A. Hoschtitzcky1, R. Dhannapuneni1, P. Venugopal1, N. Alphonso1, A. Corno2 (1Liverpool, 2Riyadh)

10:15 293-I
Cervico-sternotomy with thoracotomy for metastatic adenopathy
A. Oliaro, E. Ruffini, P. L. Filosso, P. Lausi, A. Sandri (Italy)

10:30 Break

11:00
Use of a serratus anterior flap for an empyema cavity after lung resection, open window and thoracoplasty (re-redo surgery)
P. V. Botianu, A. Botianu (Targu-mures)

11:15 294-I
Isolated lung perfusion in combination with lung resection for the treatment of pulmonary metastases
P. Van Schil1, B. Stockman1, J. Hendriks1, W. Den Hengst1, B. Van Putte2, W. Van Boven2, I. Rodrigus1, M. Versteegh2 (1Belgium, 2Netherlands)

11:30
Salvage pulmonary embolectomy for embolized pulmonary artery sarcoma treated with surgical resection
K. H. Yap, M. Devbhandari, I. Kadir, S. Farid, R. Shah (Manchester)

11:45 295-I
Port-access thoracoscopic anatomical lung subsegmentectomy
H. Kato, H. Oizumi, M. Sadahiro (Japan)

12:00
Should early surgical intervention be a choice in the treatment of extensively drug-resistant tuberculosis?
A. Fazuludeen, D. B. Aneez, K. B. Joel Lim (Singapore)
Chest wall resection and sleeve resection

Organiser: E. Bishay, Birmingham; P. Rajesh, Birmingham; Ph. Dartevelle, Paris; P. Licht, Copenhagen

Learning objectives:
At the end of this wetlab, the candidate will be able to:
• Explain the indications for chest wall resection and sleeve resection
• Describe the different operative steps of both techniques
• Perform the techniques in a wetlab environment

Welcome
E. Bishay

Wetlab chest wall resection
E. Bishay; P. Rajesh

Wetlab sleeve resection
Ph. Dartevelle, P. Licht
Acquired Cardiac Disease Domain Programme

Chair:
John R. Pepper, London
Sacha P. Salzberg, Zürich
Sonia Maria Collins, Lund
Volkmar Falk, Zürich
Robert J.M. Klautz, Leiden
Philippe H. Kolh, Liege
Ugolini Livi, Udine
Francesco Maisano, Milan
David Paul Taggart, Oxford
Jarle Vaage, Oslo
Alexander Wahba, Trondheim

Ex officio
Ludwig von Segesser, Lausanne
A. Pieter Kappetein, Rotterdam

Saturday 27 October 2012
Techno College

Sunday 28 October 2012
Postgraduate Education:
Quality Improvement Programmes
Acquired Cardiac Disease Domain Programme
Perfusion Programme

Monday 29 October 2012
Scientific Abstracts
Professional Challenges:
How to optimize coronary revascularization: planning and execution

Focus Sessions:
Antiplatelet therapy in 2012: impact on cardiovascular surgical procedures
How to optimize transcatheter aortic valve implantation outcomes
The front door approach: the role of the surgeon in selecting the best patient-specific access route
Multiple valves
Minimally invasive aortic valve repair
Heart rejuvenation
Is there a limit in the repair of mitral & tricuspid regurgitation?

Tuesday 30 October 2012
Scientific Abstracts
Focus Sessions:
The new EACTS/ESC valve guidelines
Unanswered questions in right ventricular failure
Endocarditis
Aortic valve replacement: continuum of techniques towards small incision surgery

Wednesday 31 October 2012
Advanced Techniques:
Live-in-a-box minimally invasive cardiac symposium: How to do it?
Lateral thinking
The mitral and tricuspid valves: repair techniques
New surgical treatment concepts for heart failure
Controversies and catastrophies in adult cardiac surgery
Aortic valve repair for the non-expert: a stepwise approach

Wet lab training:
Valve-sparing aortic root replacement
Strategies to deal with mitral repair using Gore-tex chords
Acquired Cardiac Disease

Organisers: New Technology Commitee

08:05-10:10 Session 1: Aortic valve replacement

Moderators: E. Ferrari, Lausanne; H. Treede, Hamburg; T. Walther, Bad Nauheim

Transapical closure
V. Thourani (Atlanta)

Transapical aortic valve implantation: what’s new in 2012?
T. Walther (Bad Nauheim)

Live-in-a-box video presentations:
Aortic valve repair using a geometric annuloplasty ring
D. Mazzitelli (Munich)

Transaortic transcatheter aortic valve implantation
N. Moat (London)

Transfemoral transcatheter aortic valve implantation
A. Linke (Leipzig)

Live surgery:
Transaortic transcatheter aortic valve implantation
V. Bapat, (London)

Transapical aortic conduit
M. Billion1, J. Gammie2, S. Hoffmann1 (1Bad Rothenfelde, 2Baltimore)

10:10 Coffee

10:40-13:15 Session 2: Imaging/robotics/coronary artery bypass surgery

Moderators: V. Falk, Zürich; T. Folliguet, Paris; M. Mack, Dallas

Remote robotic catheter guidance for endovascular procedures
N. Cheshire (London)

Real-time holographic 3-D imaging for cardiac interventions
A. Kaufman (Yokneam)

Advanced imaging and image fusion for valve therapies
M. Enriquez-Sarano (Rochester)

External mesh for vein grafting
E. Ferrari (Lausanne)

Totally endoscopic coronary artery bypass in 2012
J. Bonatti (Baltimore)

Live-in-a-box video presentation:
External mesh for vein grafting
D. Taggart (Oxford)

Live surgery:
Transapical transcatheter aortic valve implantation with rotational angiography
J. Kempfert (Leipzig)

Zero ischaemia anastomotic device (animal case)
M. Bujsrogge1, D. Stecher1, S. Jacobs2 (1Utrecht, 2Zürich)

Sutureless valve implantation
M. Borger (Leipzig)
13:15  Lunch

14:15-15:50  Session 3: Heart failure - devices  
Moderators: G. Gerosa, Padua; M. Slaughter, Louisville; G. Wimmer-Greinecker, Bad Bevensen

Innovation Award presentation
Transapical left ventricular assist device implantation  
M. Slaughter (Louisville)
Total artificial heart: where are we?  
P. Jansen (Vélizy Villacoublay)
Extra-aortic counterpulsation system  
R. Cecere (Montreal)
Intramural wall augmentation of the failing ventricle  
G. Feltrin (Padua)

Live-in-a-box video presentations:
Minimally invasive left ventricular assist device implantation  
G. Gerosa (Padua)
Biventricular assist device implantation focus on right ventricular assist device  
M. Strüber (Leipzig)
New device for less invasive ventricular enhancement  
A. Wechsler (Philadelphia)

15:50  Coffee

16:20-18:10  Session 4: Mitral valve surgery  
Moderators: F. Maisano, Milan; P. Perier, Bad Neustadt/Saale; H. Vanermen, Aalst

Long term adjustable mitral annuloplasty  
M. Czesla (Stuttgart)
First-in-man transfemoral transcatheter mitral valve replacement  
tba
Septalisation of the anterior tricuspid papillary muscle in association with an annuloplasty: a new concept for the treatment of tricuspid regurgitation  
J. Couetil (Paris)

Live-in-a-box video presentations:
New atrial fibrillation ablation device  
C. Muneretto (Brescia)
Sutureless transatrial mitral band implantation  
H. Vanermen (Aalst)
Sutureless transfemoral mitral band implantation  
F. Maisano (Milan)
Transapical off-pump mitral valve repair  
G. Speziali, (Pittsburgh)

Live surgery
MitraClip procedure  
J. Seeburger (Leipzig)
Plenary session: Quality improvement programmes

Moderators: L. K. Von Segesser, Lausanne; D. Pagano, Birmingham

08:30
Quality: an elusive and moving target
B. E. Keogh (London)

08:50
Cost-effectiveness analysis: what is it and how can we use it to improve care?
D. J. Cohen (Kansas City)

09:10
Measuring data and creating evidence: shortcomings of trials/Registry/observational studies; mortality is not the only endpoint
M. Utley (London)

09:30
ProvenCare in lung cancer
D. Wood (Seattle)

10:30-12:10 Session 1: Coronary surgery

Moderators: P. Sergeant, Leuven; D. Taggart, Oxford

10:30
Triple-vessel disease: SYNTAX at 5 years
N. M. D. A. van Mieghem (Rotterdam)

10:40
Discussion

10:45
Left main disease: SYNTAX at 5 years
A.P. Kappetein (Rotterdam)

10:55
Discussion

11:00
Coronary trial: off-pump or on-pump coronary artery bypass grafting at 30 days
D. Taggart (Oxford)

11:10
Discussion

11:15
ASCERT study: Comparative effectiveness of revascularization strategies
F. Grover (Aurora)

11:20
Discussion
11:25 Bilateral internal thoracic artery grafting  
*F. Moraes (Recife)*

11:35 Discussant: S. Kendall, Middlesbrough

11:45 Hybrid coronary surgery  
*I. S. Modrau (Aarhus)*

11:55 Discussant: N. M. D. A. van Mieghem, Rotterdam

12:00 General discussion

**12:15 Break**

12:45-14:50 Session 2: Update on valves  
*Moderators: L. K. Von Segesser, Lausanne; J. R. Pepper, London*

12:45 Long-term results from transcatheter aortic valve implantation  
*T. Walther (Bad Nauheim)*

12:55 Discussant: J. Rich, Norfolk

13:10 GARY: real world Aortic Valve registry in Germany  
*F Mohr (Leipzig)*

13:20 Discussant: V. Thourani, Atlanta

13:35 Port-access for mitral surgery  
*S. Hunter (Middlesbrough)*

13:45 Discussant: R. Dion, Genk

14:00 MitraClip  
*F. Maisano (Milan)*

14:10 Discussant: H. Treede, Hamburg

14:25 Evidence for repair vs. replacement for functional mitral regurgitation

14:35 Discussant: S. Nashef, Cambridge

14:50 General discussion
15:00-16:20  Session 3: Left heart failure  
*Moderators: A. Haverich, Hannover; R. Lorusso, Brescia*

15:00  
The growing epidemic  
*J. L. Pomar (Barcelona)*

15:10  
Surgical restoration  
*L. Menicanti (Milan)*

15:20  
Discussant: G. Dreyfus, Monte-Carlo

15:35  
Hardware  
*G. Wieselthaler (Vienna)*

15:45  
Discussant: A Simon, Harefield

16:00  
Extracorporeal membrane oxygenation  
*F. Beyersdorf (Freiburg)*

16:10  
Discussant: G. J. Peek, Leicester

16:20  
General discussion

16:25  
Adjourn

*This course is supported with an unrestricted educational grant from St Jude Medical*

---

10:30-16:25  Postgraduate Education  
*Room 112*

**Perfusion**  
*Moderators: G. J. Peek, Leicester; A. Wahba, Trondheim*

10:30-11:45  Session 1: Extracorporeal life support

10:30  
Extracorporeal membrane oxygenation and extracorporeal support registries: what’s in it for us?  
*G. Peek (Leicester)*

10:50  
The present and future of sudden death and brain ischaemia: could we have saved Michael Jackson?  
*G. Trummer (Freiburg)*

11:25  
The role of the perfusionist in resuscitation  
*A. Philipp (Regensburg)*
11:45 - 12:45 Session 2: Extracorporeal circulation
Moderators: F. Merkle, Berlin; A. Liebold, Ulm

11:45
The scientific evidence for selective cerebral perfusion in complex aortic surgery
F. Emrich (Leipzig)

12:05
How to start a mini-bypass programme: tips and tricks
L. Harling (London)

12:25
RFVIIa in cardiothoracic surgery: an update
M. Herbertson (Southampton)

12:45 Lunch

13:45 - 15:05 Session 3: Cardiac assist
Moderators: G. Gerosa, Padua; C. Hamilton, Vogtareuth

13:45
Treatment of end-stage heart failure in the future: from transplant to ventricular assist device?
A. Zuckermann (Vienna)

14:05
Predictors of left ventricular assist device-induced sustained myocardial recovery
M. Dandel (Berlin)

14:25
Assist in acute right ventricular failure: right ventricular assist device or extracorporeal support?
G. Gerosa (Padua)

14:45
Going home: hospital discharge on ventricular assist device
N. Wrightson (Newcastle upon Tyne)

15:05 - 16:25 Session 4: Case reports - worst case scenarios
Moderators: J. Horisberger, Lausanne; A. Wahba, Trondheim

15:05
Challenging perfusion in a case of vein graft dissection
C. Nielsen (Aalborg)

15:25
Prolonged cerebral protection in a case of aortic dissection
R. Mrkonjic (Zagreb)

16:25 Adjourn
08:15-09:45 Professional Challenges

How to optimize coronary revascularization: planning and execution I

**Moderators:** F. Mohr, Leipzig; J. Rich, Norfolk

**08:15**
Assessing the lesion

*van Mieghem (Rotterdam)*

**08:30**
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of coronary artery bypass grafting and percutaneous coronary intervention in the SYNTAX study

*A. P. Kappetein*, *S. Head*, *M. Morice*, *A. Banning*, *P. Serruys*, *F. Mohr*, *K. Dawkins*, *M. Mack* (*Netherlands, France, United Kingdom, Germany, United States*)

**Discussant:** D. Taggart (Oxford)

**08:45**
Five-year follow-up of drug-eluting stent implantation versus minimally invasive direct coronary artery bypass for left anterior descending artery disease: a propensity score analysis

*D. Glineur*, *C. Hanet*, *S. Papadatos*, *P. Noirhomme*, *G. El Khoury*, *P. Y. Etienne* (Belgium)

**Discussant:** P. Sergeant (Leuven)

**09:00**
Preoperative SYNTAX score and graft patency after off-pump coronary bypass surgery

*T. Kinoshita*, *T. Asai*, *T. Suzuki* (Japan)

**Discussant:** V. Falk (Zürich)

**09:15**
A real-world comparison of second-generation drug-eluting stents versus off-pump coronary artery bypass grafting in three-vessel and/or left main coronary artery disease

*G. Yi*, *H. Joo*, *K. Yoo* (Republic of Korea)

**Discussant:** F. Mohr (Leipzig)

**09:30**
Distal anastomosis patency of the Cardica C-Port® system versus the hand-sewn technique: a prospective randomized controlled study in patients undergoing coronary artery bypass grafting

*N. Verberkmoes*, *S. Wolters*, *J. Post*, *M. Soliman-Hamad*, *F. Ter Woorst*, *E. Berreklouw* (Netherlands)

**Discussant:** M. Glauber (Massa)

08:15-09:45 Abstracts

**Abstracts Room 115**

Surgical remodelling of the left ventricle

**Moderators:** A. Calafiore, Riyadh; R. Lorusso, Brescia

**08:15**
Left ventriculoplasty for progressively deteriorated left ventricle with global akinesis due to ischaemic cardiomyopathy: Japanese surgical ventricular reconstruction group experience

*S. Wakasa*, *Y. Matsui* (Japan)

**Discussant:** L. Menicanti (Milan)
Experience, outcomes and impact of delayed indication for video-assisted wide septal myectomy in 69 consecutive patients with hypertrophic cardiomyopathy

T. Heredia Cambra, L. Doñate Bertolín, A. M. Bel Minguez, M. Perez Guillen, F. J. Valera Martínez, J. A. Margarit Calabuig, F. Marín, J. A. Montero Argudo (Spain)
Discussant: C. Simon (Bergamo)

Impact of surgical ventricular restoration on cardiac function, ischaemic mitral regurgitation and long-term survival

H. Fleming, R. Attia, J. Chambers, F. Shabbo (United Kingdom)
Discussant: T. Isomura (Kanagawa)

Preoperative regional left ventricular wall thickening with quantitative gated spect as a predictor of the mid-term surgical result of ischaemic and non-ischaemic cardiomyopathy

S. Kubota, S. Wakasa, Y. Shingu, T. Ooka, T. Tachibana, Y. Matsui (Japan)
Discussant: R. Jeganathan (Belfast)

Durability of epicardial ventricular restoration without ventriculotomy

A. Wechsler, J. Sadowski, B. Kapelak, K. Bartus, G. Kalinauskas, K. Rucinskas, R. Samalavicius, L. Annest (United States, Poland, Lithuania)
Discussant: H. Reichenspurner (Hamburg)

‘One step’ subendocardial implant of autologous stem cells during modified left ventricular restoration for ischaemic heart failure

Discussant: J. Kluin (Utrecht)

Effectiveness of biatrial pacing in reducing early postoperative atrial fibrillation after the maze procedure

W. Wang, A. Hamzei, X. Wang (United States, China)
Discussant: S. Salzberg (Zürich)

Minithoracotomy as a primary alternative for left ventricular lead implantation during cardiac resynchronization therapy: can the cardiac surgeon reduce the number of non-responders?

S. Putnik, M. Matković, M. Velinović, A. Mikić, V. Jovićić, I. Bilbija, M. Vranes, G. Milašinović (Serbia)
Discussant: W. Wisser (Vienna)

The association between early atrial arrhythmia and long-term success following surgical ablation for atrial fibrillation

N. Ad, L. Henry, S. Holmes, S. Hunt (United States)
Discussant: R. Almeida (Cascavel)
Pacemaker dependency after isolated aortic valve replacement: do conductance disorders recover over time?
H. Baraki, A. Ah Ahmad, S. Jeng-Singh, J. Schmitto, B. Fleischer, A. Martens, I. Kutschka, A. Haverich (Germany)
Discussant: C. Vicol (Munich)

Transcutaneous lead implantation connected to an externalized pacemaker in patients with implantable cardiac defibrillator/pacemaker infection and pacemaker dependency
S. Pecha, Y. Yildirim, B. Sill, A. Aydin, H. Reichenspurner, H. Treede (Germany)
Discussant: A. Lahti (Turku)

Concomitant surgical atrial fibrillation ablation and event recorder implantation: better monitoring, better outcome?
S. Pecha, T. Ahmadzade, T. Schäfer, H. Reichenspurner, F. Wagner (Germany)
Discussant: B. Osswald (Bad Oeynhausen)

Leaflet extension in rheumatic mitral valve reconstruction
J. Dillon, M. A. Yakub (Malaysia)
Discussant: S. Livesey (Southampton)

Towards an integrated approach to mitral valve disease: implementation of an interventional mitral valve programme and its impact on surgical activity
L. Conradi, M. Silaschi, H. Treede, S. Baldus, M. Seiffert, J. Schirmer, H. Reichenspurner, S. Blankenberg (Germany)
Discussant: F. Maisano (Milan)

Intraoperative transoesophageal echocardiography for predicting risk of systolic anterior motion after mitral valve repair for degenerative disease
R. Varghese, S. Itagaki, P. Trigo, A. Anyanwu, G. Fischer, D. Adams (United States)
Discussant: R. De Simone (Heidelberg)

Long-term echocardiographic follow-up and quality of life after early surgery in asymptomatic patients with severe mitral valve regurgitation: a single-centre experience
W. Van Leeuwen, S. Head, L. Van Herwerden, A. Bogers, A. P. Kappetein (Netherlands)
Discussant: M. Borger (Leipzig)

Is commissural closure for the treatment of mitral regurgitation durable? A long-term (up to 15 years) clinical and echocardiographic study
Discussant: L. Müller (Innsbruck)

Management of moderate functional mitral regurgitation at the time of aortic valve surgery
G. Freitas Coutinho, P. Correia, R. Pancas, M. Antunes (Portugal)
Discussant: H. Vanermen (Aalst)
New ideas in transcatheter aortic valve replacement

Moderators: T. Walther, Bad Nauheim; C. R. Smith, New York

08:15 051
Transapical access closure: the tap plug device
C. Huber, H. Brinks, V. Göber, F. Nietlisbach, P. Wenaweser, B. Meier, L. Englberger, T. Carrel (Switzerland)
Discussant: S. Bleiziffer (München)

08:30 052
Severe intra-procedural complications after transcatheter aortic valve implantation: calling for a heart-team approach
M. Seiffert, L. Conradi, R. Schnabel, J. Schirmer, S. Blankenberg, H. Reichenspurner, S. Baldus, H. Treede (Germany)
Discussant: L. Harling (London)

08:45 053
Transapical versus transfemoral transcatheter aortic valve implantation: outcome according to standardized endpoint definitions by the Valve Academic Research Consortium
S. Salizzoni, M. La Torre, F. Giordana, C. Moretti, P. Omede, G. Ferraro, M. D’Amico, M. Rinaldi (Italy)
Discussant: N. M. D. A. van Mieghem (Rotterdam)

09:00 054
Initial clinical results of the Braile Inovare transcatheter aortic prosthesis
Discussant: H. Treede (Hamburg)

09:15 055
Systematic transaortic approach for transcatheter aortic valve implantation: a valid alternative to transapical access in patients with no peripheral vascular option. One year single-centre experience
M. Romano, K. Hayashida, T. Lefèvre, T. Hovasse, B. Chevalier, D. Le Houérou, A. Farge, M. Morice (France)
Discussant: J. Grünenfelder (Zürich)

09:30 056
European experience of direct aortic transcatheter aortic valve implantation with a self-expanding prosthesis: evidence of a significant learning curve
G. Bruschi, M. Jahangiri, U. Trivedi, N. Moat (Italy, United Kingdom)
Discussant: H. Amrane (Leeuwarden)
How to optimize coronary revascularization: planning and execution II

Moderators: N. M. D. A. van Mieghem, Rotterdam; M. Mack, Dallas

10:15
Difference between the European and US guidelines
M. Mack (Dallas)

10:30 057
Impact of statin use on clinical outcomes after cardiac surgery: a systematic review of studies, with meta-analysis of over 90,000 patients
O. Liakopoulos, S. Stange, E. Kuhn, A. Deppe, I. Slottosch, Y. Choi, T. Wahlers (Germany)
Discussant: M. Thielmann (Essen)

10:45 058
Mortality risk and causes of death in coronary artery bypass surgery patients with pre- and postoperative atrial fibrillation: a 12-year follow-up
E. Fengsrud, A. Englund, A. Ahlsson (Sweden)
Discussant: P.P. Paulista (Sao Paulo)

11:00 059
Comparison of heart-type fatty acid binding protein and cardiac troponin I for early detection of myocardial infarction after coronary bypass surgery
S. Pasa, D. Wendt, M. Hösel, D. Dohle, K. Pilarczyk, H. Jakob, M. Thielmann (Germany)
Discussant: M. Sousa Uva (Lisbon)

11:15 060
Should moderate ischaemic mitral regurgitation be corrected at the time of coronary artery bypass grafting? Answer from a 10-year follow-up
V. Shumavets, Y. Ostrovski, A. Shket, A. Janushko, S. Kurganovich, I. Grinchuk, N. Semenova, O. Jdanovich (Belarus)
Discussant: A. Rastan (Rotenburg)

11:30 060A
Intensive care unit readmission after cardiac surgery: predictors and consequences
U. Boeken, J.-P. Minol, A. Assmann, A. Mehdiani, P. Akhyari, A. Lichtenberg (Germany)
Discussant: B. Rylski (Freiburg)

Mechanical support of the circulation

Moderators: J. R. Pepper, London; G. Gerosa, Padua

10:15 061
Who benefits from early ventricular assist device implantation?
T. Komoda, T. Drews, T. Krabatsch, H. Lehmkuhl, R. Hetzer (Germany)
Discussant: L. Martinelli (Milan)

10:30 062
The CardioWest total artificial heart as a bridge to transplantation: current results at La Pitié hospital
M. Kirsch, A. Nguyen, C. Mastroinai, M. Pozzi, S. Vamous, P. Léger, A. Pavié, P. Leprince (France)
Discussant: M. Iafrancesco (Birmingham)
The future of transcatheter mitral valve repair

Moderators: R. Haaverstad, Bergen; H. Treede, Hamburg

10:15

State-of-the-art with the MitraClip procedure

F. Maisano (Milan)

10:22

Residual mitral valve regurgitation after percutaneous mitral valve repair with the MitraClip® system: impact on follow-up outcome

G. D’Ancona, L. Paranskaya, S. Kische, H. Ince (Germany)
Discussant: O. Alfieri (Milan)

10:37

Mitral valve repair using multiple MitraClips: perioperative and short-term results using the “zipping” technique

S. Kische, G. D’Ancona, L. Paranskaya, I. Turan, H. Ince (Germany)
Discussant: H. Vanermen (Aalst)

10:52

Percutaneous or surgical mitral valve repair for functional mitral regurgitation: comparison of patient characteristics and clinical outcomes

L. Conradi, H. Treede, E. Lubos, M. Seiffert, J. Schirmer, S. Blankenberg, S. Baldus, H. Reichenspurner (Germany)
Discussant: A. Hensens (Enschede)

11:07

Clinical outcomes through six months in patients with degenerative mitral regurgitation treated with the MitraClip® device in the ACCESS-Europe phase I trial

F. Maisano1, O. Franzen2, S. Baldus3, J. Hausleiter3, C. Butter3, U. Schäefer3, G. Pedrazzini4, W. Schillinger4 (1Italy, 2Denmark, 3Germany, 4Switzerland)
Discussant: H. Treede (Hamburg)
Aortic valve repair at the crossroads

**Moderators:** E. Lansac, Paris; H. Schäfers, Hamburg/Saar

10:15 073
Does the geometric orientation of the aortic neoroot in patients with raphed bicuspid aortic valve disease undergoing valve repair plus root reimplantation affect valve function?

**P. Vallabhajosyula, T. Wallen, C. Komlo, W. Szeto, J. Bavaria (United States)**

Discussant: G. El Khoury (Brussels)

10:30 074
Long-term outcome of valve repair for concomitant aortic and mitral insufficiency: setting a new standard of care

**H. Vohra¹, R. Whistance², L. Dekerchove¹, D. Glineur¹, P. Noirhomme¹, G. El Khoury¹**

(¹Belgium, ²United Kingdom)

Discussant: M. Borger (Leipzig)

10:45 075
Impact of annuloplasty in bicuspid aortic valve repair: valve-sparing reimplantation is superior to subcommissural annuloplasty

**E. Navarra, L. De Kerchove, D. Glineur, P. Astarci, P. Noirhomme, G. El Khoury (Belgium)**

Discussant: M. Nosal (Bratislava)

11:00 076
Aortic valve reconstruction with autologous pericardium for dialysis patients


Discussant: E. Lansac (Paris)

11:15 077
Functional aortic annulus remodelling using a handmade prosthetic ring improves outcomes in aortic valve repair

**K. Fattouch, S. Castrovinci, G. Murana, G. Nasso, F. Guccione, P. Dioguardi, G. Bianco, G. Speziale (Italy)**

Discussant: E. Lansac (Paris)

11:30 078
Prospective analysis of long-term results of aortic valve repair and associated root reconstruction

**M. Jasinski, R. Gocol, M. Malinowski, D. Hudziak, M. Daja, S. Wos (Poland)**

Discussant: S. Leontyev (Leipzig)
10:15-11:45  Focus Session

Antiplatelet therapy in 2012: impact on cardiovascular surgical procedures
Moderators: J. B. Grau, Ridgewood; D. Taggart, Oxford

10:15
Comparative analysis of available antiplatelet therapies in current clinical management: what agents to choose from and why
H. Reichenspurner (Hamburg)

10:30
Applying current guidelines on antiplatelet therapy prior to coronary artery bypass grafting: What to do in the setting of previous percutaneous coronary intervention? What can be improved?
A. P. Kappetein (Rotterdam)

10:45
Should we place our post coronary artery bypass graft patients on antiplatelet drugs? Weighing the benefits and the complications through evidence-based research
I. George (Columbia)

11:00
Impact of pharmacogenetics in the clinical management of antiplatelet therapy
J. Quackenbush (Boston)

11:15
Antiplatelet therapy in high-risk patients and in those on warfarin therapy
E. Rodriguez (Greenville)

11:30
New frontiers in antiplatelet therapy: where we are and where we are going from here
D. Glineur (Brussels)

This session is supported with an unrestricted educational grant from AstraZeneca

10:15-11:45  Abstracts

Heart transplants: the most effective treatment for end-stage heart failure
Moderators: Ö. Friberg, Örebro; J.L. Pomar, Barcelona

10:15  085
Evolution of recipient and donor profiles in cardiac transplantation: single-centre ten year experience
C. D’Alessandro, M. Laali, E. Barreda, J. L. Golmard, J. Trouillet, P. Farahmand, P. Leprince, A. Pavié (France)
Discussant: C. Knosalla (Berlin)

10:30  086
Does the use of old donor grafts have an effect on morbidity and mortality in heart transplantation? practical implications
P. Farahmand, C. D’Alessandro, P. Demondion, S. Varnous, M. Laali, P. Leprince, A. Pavié (France)
Discussant: J.L. Pomar (Barcelona)
Six-year outcomes following heart transplantation: effect of preservation solution on survival and rejection
A. Cannata, L. Botta, T. Colombo, F. Macera, G. Masciocco, F. Turazza, M. Frigerio, L. Martinelli (Italy)
Discussant: A. Simon (Harefield)

Cardiac transplantation with non-heart-beating donors: haemodynamic and biochemical parameters at procurement predict recovery following cardioplegic storage in a rat model.
Discussant: T. Wahlers (Cologne)

High-risk donors in heart transplantation: are we pushing too far?
A. Aliabadi, M. Groemmer, F. Eskandary, T. Haberl, O. Salameh, D. Wiedemann, G. Laufel, A. Zuckermann (Austria)
Discussant: J. Dark (Newcastle upon Tyne)

Primary graft dysfunction versus primary graft failure: are all graft problems created equal?
A. Zuckermann, A. Aliabadi, D. Wiedemann, T. Haberl, O. Salameh, M. Groemmer, F. Eskandary, G. Laufer (Austria)
Discussant: A. Pavié (Paris)

How to optimize transcatheter aortic valve implantation outcomes
Moderators: A. Vahanian, Paris; V. Falk, Zürich

Which valve for which annulus size
N. M. D. A. van Mieghem (Rotterdam)

Valve positioning and deployment (The Berlin addition)
M. Pasic (Berlin)

Percutaneous valve leak assessment
(with echocardiography new Valve Research Consortium definition)
A. P. Kappetein (Rotterdam)

An alternative access approach
P. Etienne (Brussels)

Apical access and closure
T. Walther (Bad Nauheim)

This session is supported with an unrestricted educational grant from Edwards Lifesciences

The contraindications of today are the indications of tomorrow
L. Von Segesser, Lausanne

The Presidential Address
Rooms 116/117

Acquired Cardiac Disease
Monday
Euroscore II: refining risk assessment

Moderators: P. Sergeant, Leuven; W. Gomes, São Paulo

14:15
Development of EuroSCORE II
S. Nashef (Cambridge)
Discussant: D. Pagano (Birmingham)

14:30
Comparison of the Euroscore II and Society of Thoracic Surgeons 2008 risk tools
B. Kirmani, K. Mazhar, M. Pullan, B. Fabri (United Kingdom)
Discussant: M. Mack (Dallas)

14:45
Euroscore II does not improve prediction of mortality in high-risk patients: a study from two European centres
N. Howell¹, S. Head¹, E. Senanayake¹, A. Menon¹, N. Freemantle¹, T. Van Der Meulen², A. P. Kappetein², D. Pagano¹ (¹United Kingdom, ²Netherlands)
Discussant: J. J. M. Takkenberg (Rotterdam)

15:00
Comparison of original Euroscore, Euroscore II and STS risk models in an elderly cardiac surgical cohort
A. Kunt¹, M. Kurtcephe², M. Hidiroglu¹, L. Cetin¹, A. Kucuker¹, V. Bakuy², A. R. Akar¹, E. Sener¹ (¹Turkey, ²United States)
Discussant: P. Sergeant (Leuven)

15:15
Is the new Euroscore II a better predictor for transapical aortic valve implantation?
M. Haensig, D. Holzhey, M. Borger, S. Subramanian, G. Schuler, W. Shi, A. Rastan, F. Mohr (Germany)
Discussant: J. Obadia (Lyon-Bron)

15:30
The future of risk scoring
B. Bridgewater (Manchester)

Refining techniques in minimally invasive mitral valve surgery

Moderators: T. Folliguet, Paris; M. Glauber, Massa

14:15
Minimally invasive mitral valve surgery: influence of aortic clamping technique on early outcomes
A. Mazine, D. Bouchard, H. Jeanmart, J. Lebon, M. Pellerin (Canada)
Discussant: M. Kolowca (Rzeszow)

14:30
Mitral valve pathology in severely impaired left ventricles can be successfully managed using a right-sided minimally invasive surgical approach
J. Garbade, J. Seeburger, M. Barten, S. Lehmann, B. Pfannmüller, M. Misfeld, M. Borger, F. Mohr (Germany)
Discussant: E. Ferrari (Lausanne)
Non-inferiority of minimally invasive mitral repair versus median sternotomy for Barlow's disease: three-year clinical results
G. Nasso, V. Romano, K. Fattouch, R. Bonifazi, G. Visicchio, N. Di Bari, G. Balducci, G. Speziale (Italy)
Discussant: R. Stuklis (Adelaide)

Use of automatic knot-tying and cutting device is shortening aortic cross-clamp times in minimally invasive mitral valve surgery
B. Gersak, B. Robic (Slovenia)
Discussant: F. Van Praet (Aalst)

Minimally invasive mitral valve reconstruction on the fibrillating heart is an attractive surgical strategy for high-risk patients
J. Kilo, E. Ruttmann, H. Hangler, M. Grimm, L. Müller (Austria)
Discussant: F. Siclari (Lugano)

Antegrade and retrograde arterial perfusion strategies in minimally invasive mitral valve surgery: a propensity score analysis on 1280 patients
M. Murzi, A. G. Cerillo, A. Miceli, E. Kallushi, G. Bianchi, S. Bevilacqua, M. Solinas, M. Glauber (Italy)
Discussant: G. Wimmer-Greinecker (Bad Bevensen)
15:00
Dispelling myths around results of the transapical approach: beyond the learning curve in the PARTNER trial
A. P. Kappetein (Rotterdam)

15:10
Alternative surgical access: transaortic and subclavian
V. Bapat (London)

15:20
Transapical transcatheter aortic valve implantation in perspective
T. Walther (Bad Nauheim)

This session is supported with unrestricted educational grants from Edwards Lifesciences, JenaValve Technology GmbH, Medtronic International Trading Sàrl and Symetis S.A.

16:15-17:45 Abstracts Rooms 116/117

Late-breaking trials I
Moderators: O. Alfieri, Milan; G. Laufer, Vienna

LB 001 16:15
The Engager transapical aortic valve implantation system: first results from the multicentre European Pivotal Trial
H. Treede¹, S. Baldus¹, A. Linke¹, D. Holzhey¹, S. Bleiziffer¹, J. Börgermann¹, J.-L. Vanoverschelde², V. Falk³ (¹Germany, ²Belgium, ³Switzerland)
Discussant: N. Moat (London)

LB 002 16:30
Coronary artery bypass grafting versus percutaneous coronary intervention in a “real-world” setting: insights from the Cooperation Study
Discussant: T. Graham (Birmingham)

LB 003 16:45
Myocardial revascularization in the era of drug-eluting stent/off-pump coronary surgery: from the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft Registry Cohort-2
A. Marui, T. Kimura, T. Komiya, T. Kita, R. Sakata (Japan)
Discussant: D. Pagano (Birmingham)

LB 004 17:00
Off-pump transapical implantation of artificial chordae to correct mitral regurgitation (TACT trial); proof of concept
J. Seeburger¹, M. Rinaldì², R. Lange¹, M. Schoenburg¹, S. Nielsen³, O. Alfieri², F. W. Mohr¹, K. Aiditeis³ (¹Germany, ²Italy, ³Denmark, ⁴Lithuania)
Discussant: G. Lutter (Kiel)

LB 005 17:15
First-in-man evaluation of the new Apica ASC™ transapical access and closure device
J. Blumenstein¹, J Kempfert¹, A Van Linden¹, WK Kim¹, H Moellmann¹, V Thourani², T Walther¹ (¹Germany, ²United States)
Discussant: V. Subramanian (New York)
16:15-17:45 Focus Session  Room 114

Minimally invasive aortic valve repair
Moderators: A. Haverich, Hannover; A. Repossini, Brescia

16:15
The evidence base for minimally invasive aortic valve repair
M. Borger (Leipzig)

16:30
Sutureless valves
M. Shrestha (Hanover)
Discussant: L. Von Segesser (Lausanne)

16:45
Different approaches
M. Glauber (Massa)
Discussant: M Palmen (Leiden)

17:00
Aortic valve replacement with the Perceval S sutureless prosthesis: clinical outcomes in 140 patients
K. Zannis, T. Folliguet, G. Ghorayeb, M. Noghin, D. Czitrom, L. Mitchell-Heggs, F. Laborde (France)
Discussant: J. O. Solem (Lund)

16:15-17:45 Focus Session  Room 115

Multiple valves
Moderators: M. J. Antunes, Coimbra; A. Colli, Padua

16:15
Aortic stenosis and mitral regurgitation
R. Rosenhek (Vienna)

16:30
Tricuspid regurgitation and mitral regurgitation
J. Kluij (Utrecht)

16:45
Carcinoid syndrome
S. Rooney (Birmingham)

17:00
Outcomes in multiple valves
J. J. M. Takkenberg (Rotterdam)

17:15
Double valve replacement: biological versus mechanical prostheses
E. Elmistekawy, V. Chan, B. Lam, T. Mesana, M. Ruel (Canada)
Discussant: L. De Kerchove (Brussels)

17:30
Associations between valve repair and reduced operative mortality in mitral/tricuspid double valve surgery
J. S. Rankin, V. Thourani, R. Suri, X. He, S. O’Brien, C. Vassileva, M. Williams (United States)
Discussant: T. Doenst (Jena)
**Is there a limit in the repair of mitral & tricuspid regurgitation?**

**Moderators:** M. Castella Barcelona; J L Pomar, Barcelona

16:15  
Functional regurgitation in mitral and tricuspid valve disease  
*M. Sitges (Barcelona)*

16:30  
What are the differences in the left ventricle and right ventricle hemodynamic? Similarities and differences  
*B. Bijnens (Barcelona)*

16:45  
Surgical techniques and long term results in mitral regurgitation: Where do we stand?  
*R. De Paulis (Rome)*

17:00  
Operative Techniques and outcomes in functional tricuspid regurgitation  
*G. Dreyfus (Monte Carlo)*

17:15  
What are the factors in the development of recurrent tricuspid regurgitation?  
*F. Casselman (Aalst)*

17:15  
Discussion

This session is supported by an unrestricted educational grant from Edwards Lifesciences
Heart rejuvenation


16:15
Cardioplegia
D. Chambers (London)

16:35
Stem cells
P. Menasche (Paris)

16:55
Ex vivo heart and lung preservation
A. Simon (Harefield)

17:15
Preconditioning and its future
V. Venugopal (London)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Details</th>
</tr>
</thead>
</table>
| 08:15-09:45 | Focus Session               | Rooms 116/117 | The new EACTS/ESC valve guidelines  
Moderators: L. K. Von Segesser, Lausanne; P. Kolh, Liege  
08:15  
What everybody needs to know about the new valvular guidelines on aortic stenosis  
A. Vahanian (Paris)  
08:30  
What everybody needs to know about the new valvular guidelines on mitral and tricuspid valve disease  
O. Alfieri (Milan)  
08:45  
Discussion  
09:00  
Cardiac surgery in patients with porcelain aorta in the era of transcatheter valve implantation  
P. Urbanski, M. Raad, A. Diegeler (Germany)  
Discussant: J. R. Pepper (London)  
09:15  
Low incidence and minimal impact of paravalvular leak after conventional aortic valve replacement  
I. Zein El-Dean, M. El-Ghanam, E. Akowuah (United Kingdom)  
Discussant: G. Lutter (Kiel)  
09:30  
Why the VARC-2 guidelines are so important for studies in patients with aortic valvular disease  
S. Head (Rotterdam) |
| 08:15-09:45 | Abstracts                  | Room 115   | Training, risk factors and outcomes  
Moderators: L. Hamilton, Newcastle upon Tyne; J. Kluin, Utrecht  
08:15  
General risk factors  
D. Pagano (Birmingham)  
08:30  
Impact of the full implementation of the European Working Time Directive on surgical training in adult cardiac surgery  
B. Mahesh, L. Sharples, M. Codispoti (United Kingdom)  
Discussant: R. Sádaba (Pamplona)  
08:45  
Are we running out of thoracic or cardiac surgeons? Demography of thoracic and cardiac surgeons in France in 2012  
M. Laskar, A. Spinosi, M. Dahan (France)  
Discussant: M. Siepe (Freiburg) |
09:00 138
The operated heart in post-mortem computed tomography
B. Vogel, H. Gulbins, H. Reichenspurner, A. Heinemann, H. Vogel (Germany)
Discussant: D. Mathisen (Boston)

09:15 139
Planned levosimendan use during cardiac surgery: a propensity-matched comparison
M. Akay, A. U. Gullu, S. Senay, E. M. Okten, M. Kocyigit, F. Toraman, H. Karabulut,
C. Alhan (Turkey)
Discussant: P. Kurlansky (Miami)

09:30 139A
Prognostic value of nutritional screening tools for patients scheduled for cardiac surgery
S. Efremov, V. Lomivorotov, V. N. Lomivorotov, D. Nikolaev, P. Vedernikov,
V. Boboshko (Russian Federation)
Discussant: F. Sbraga (Barcelona)

08:15-09:45 Abstracts Room 114

Improving atrial transport
Moderators: W. Brinkman, Plano A. Ahlsson, Örebro

08:15 140
Left atrial appendage resection versus preservation during the surgical ablation of atrial fibrillation
Discussant: H. Rastegar (Boston)

08:30 141
Hybrid approach for the treatment of long-standing persistent atrial fibrillation: electrophysiological findings and clinical results
C. Muneretto, G. Bisleri, L. Bontempi, F. Rosati, A. Curnis (Italy)
Discussant: C. Kik (Rotterdam)

08:45 142
Impact of restoration of left atrial activity after the maze operation on clinical and echocardiographic outcomes
I. S. Kim, D. S. Jeong, P. W. Park, K. Sung, W. S. Kim, Y. T. Lee (Republic of Korea)
Discussant: T. Hanke (Lübeck)

09:00 143
Choice of lesion set during paroxysmal atrial fibrillation ablation in mitral valve patients based on continuous monitoring
A. Bogachev-Prokophiev, S. Zheleznev, A. Pivkin, A. Romanov, E. Pokushalov, V. Nazarov,
A. Karaskov (Russian Federation)
Discussant: V. Gulielmos (Thessaloniki)

09:15 144
Novel surgical ablation through a septal-superior approach for valvular atrial fibrillation: 7-year experience
S. Kainuma, T. Funatsu, H. Kondoh, M. Kainuma, M. Nishino, Y. Sawa, T. Daimon,
K. Taniguchi (Japan)
Discussant: G. Brandon Bravo Bruinsma (Zwolle)

09:30 145
Fibrosis and electrophysiological characteristics of atrial myocardium in patients with atrial fibrillation and structural heart disease
T. J. Van Brakel, T. Van Der Krieken, J. Van Der Laak, J. Smeets, H. Van Swieten (Netherlands)
Discussant: B. Rylski (Freiburg)
### Complex aortic valve surgery

**Moderators:** S. Takamoto, Tokyo; H. Schaff, Rochester

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Discussant</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>148</td>
<td>Incidence of thromboembolic complications in the Bentall procedure combining a Perimount valve with a Valsalva graft</td>
<td>S. Nardella, R. Scaffa, L. Weilert, A. Salica, A. Ricci, D. Maselli, A. Bellisario, R. De Paulis (Italy)</td>
<td>A. Albertini (Cotignola)</td>
</tr>
<tr>
<td>08:30</td>
<td>149</td>
<td>Ascending aortic distensibility, stiffness index beta and tissue doppler-based wall strain in bicuspid aortic valve patients</td>
<td>M. Kalinowski, M. Szulik, B. Rybus-Kalinowska, M. Kukla, A. Sliwinska, M. Zembala, Z. Kalas, T. Kukulski (Poland)</td>
<td>R. De Paulis (Rome)</td>
</tr>
<tr>
<td>08:45</td>
<td>150</td>
<td>Impact of cusp size on postoperative root geometry and aortic regurgitation after aortic root reimplantation surgery</td>
<td>T. Shimamoto, T. Komiya, G. Sakaguchi (Japan)</td>
<td>H. Schäfers (Homburg/Saar)</td>
</tr>
<tr>
<td>09:00</td>
<td>151</td>
<td>High-volume practice and regular follow-up reduces the mortality and morbidity of elective/urgent aortic root replacement</td>
<td>G. Soppa, J. Afoke, J. Van Besouw, M. Jahangiri (United Kingdom)</td>
<td>Y. Okita (Kobe)</td>
</tr>
<tr>
<td>09:15</td>
<td>152</td>
<td>Combined replacement of the ascending aorta and aortic valve in patients with a calcified aorta</td>
<td>D. Aicher, S. Knoll, H. Takahashi, H. Schäfers (Germany)</td>
<td>C. Hagl (Munich)</td>
</tr>
<tr>
<td>09:30</td>
<td>153</td>
<td>The stentless xenograft as an alternative to the pulmonary homograft in the Ross operation</td>
<td>J. Hechadi, L. De Kerchove, N. E. Colina Manzano, D. Glineur, P. Noirhomme, J. Rubay, G. El Khoury (Belgium)</td>
<td>W. C. Hargrove III (Philadelphia)</td>
</tr>
</tbody>
</table>

### Cardiopulmonary bypass

**Moderators:** T. Graham, Birmingham; H. Edmunds, Philadelphia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Discussant</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>160</td>
<td>Associated risk of factor VIIa application</td>
<td>A. Kiessling, J. Nitsch, U. Strouhal, M. Doss, A. Zierer, A. Moritz (Germany)</td>
<td>R. Ascione (Bristol)</td>
</tr>
<tr>
<td>08:30</td>
<td>161</td>
<td>Cardioplegia, cross-clamp fibrillation or off-pump for coronary artery bypass grafting? Insights from 8779 operations using principal component analysis</td>
<td>D. Ngaage, S. Rogers, A. Tang, F. Sogliani (United Kingdom)</td>
<td>J. Cremer (Kiel)</td>
</tr>
</tbody>
</table>
The hybrid approach

Moderators: A. Franco-Cereceda, Stockholm; S. Schueler, Newcastle upon Tyne

08:15 Tales from the hybrid suite
I. Modrau (Aarhus N)

08:30 Single-stage hybrid coronary revascularization with five-year angiographic follow-up
C. Adams, P. Teefy, G. Jablonsky, W. Kostuk, P. Jones, D. Burns, M. Chu, B. Kiaii (Canada)
Discussant: N. Al-Attar (Paris)

08:45 Hybrid revascularization in multivessel coronary artery disease
A. Repossini, I. Kotelnikov, A. Costetti, A. Moggi, C. Muneretto (Italy)
Discussant: J. Stolinski (Cracow)

09:00 Endoscopic vein harvesting for coronary artery bypass grafting: a systematic review with meta-analysis of 27,789 patients
A. C. Deppe, O. Liakopoulos, Y. Choi, I. Slottosch, E. Kuhn, S. Stange, M. Scherner, T. Wahlers (Germany)
Discussant: J. J. Andreasen (Aalborg)

09:15 Hyperthermal injury of saphenous vein conduits harvested by endoscopic technique exhibits structural and functional changes
W. Wang1, R. Staul1, X. Wang2 (1United States, 2China)
Discussant: M. Tamim (Dhahran)

09:30 The hybrid approach: doubling the risk of two procedures
R. Klautz (Leiden)
Expertise in mitral valve repair

Moderators: P. Perier, Bad Neustadt/Saale; R. J. M. Klautz, Leiden

10:15
Anterior leaflet repair
G. Dreyfus (Monte-Carlo)

10:30
Impact of mitral annular calcification on early and late outcomes following mitral valve repair of myxomatous disease
V. Chan, M. Ruel, S. Chaudry, T. Mesana (Canada)
Discussant: R. Dion (Genk)

10:45
Is rheumatic aetiology a predictor of poor outcome in the current era of mitral valve repair? Contemporary long-term results of mitral valve repair in rheumatic heart disease
M. Yakub, J. Dillon, K. K. Pau (Malaysia)
Discussant: E. Saadi (Porto Alegre)

11:00
Can the “edge-to-edge” technique provide durable results when used to rescue patients with suboptimal conventional mitral repair?
Discussant: F. Jatene (São Paulo)

11:15
Re-repair of the mitral valve for early and late recurrent mitral regurgitation after mitral valve repair
A. Anyanwu, S. Itagaki, R. Varghese, J. Castillo, J. Chikwe, D. Adams (United States)
Discussant: T. Mesana (Ottawa)

11:30
A systematic surgical strategy to attempt repair of anterior mitral leaflet prolapse for degenerative disease yields a near-100% repair rate
J. G. Castillo, A. Anyanwu, D. Adams (United States)
Discussant: M. Zembala (Zabrze)

Aortic valve replacement: continuum of techniques towards small incision surgery

Objectives:
Review which approach should be used to optimize the outcome for the individual patient. Consider the choices available, provide indications and review techniques.
Moderators: M Grimm, Innsbruck

10:15
Choosing the right approach for the right patient (full sternotomy, minimally invasive surgery, transcatheter valve implantation)?
T Carrel (Berne)

10:30
What does the future hold for small incision aortic valve surgery?
C Young (London)
10:45
Right anterior thoracotomy – Learn from the masters?
M. Glauber (Massa)

11:00
Mini cardiopulmonary bypass
A. Yilmaz (Nieuwegein)

11:15
Advantages of rapid deployment valves – for which patients?
M. Borger (Leipzig)

11:30
Cardiac protection in minimally invasive aortic valve surgery
P. Herijgers (Leuven)

This session is supported by an unrestricted educational grant from Edwards Lifesciences

10:15-11:45 Abstracts Room 114

Blood matters
Moderators: M. Jahangiri, London; F. Collart, Marseille

10:15 175
Weekly feedback with identification of physician-specific behaviour improves adherence to blood utilization protocol in cardiac surgery
C. Beaty, K. Haggerty, M. Moser, C. Robinson, T. George, G. Arnaoutakis, G. Whitman (United States)
Discussant: F. Siclari (Lugano)

10:30 176
Balancing the benefits and risks of blood transfusion in patients undergoing cardiac surgery: a propensity-matched analysis
J. Grau, C. Johnson, A. Mak, R. Shaw, M. Brizzio, J. Sperling, B. Mindich, A. Zapolanski (United States)
Discussant: M. Petricevic (Zagreb)

10:45 177
The risks associated with the transfusion of various blood products in aortic valve replacement
H. Bjursten, A. Dardahsti, B. Brondén, P. Ederoth, L. Algotsson (Sweden)
Discussant: A. Wahba (Trondheim)

11:00 178
Preoperative anaemia is a risk factor for mortality and morbidity following aortic valve surgery
E. Elmistekawy, T. Rouphael, F. Rubens, C. Hudson, B. McDonald, M. Boodhwani (Canada)
Discussant: A. El-Essawi (Braunschweig)

11:15 179
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism
K. Brehm, J. Schack, C. Hellmann, J. Geissler, F. Beyersdorf (Germany)
Discussant: K. Hekmat (Cologne)

11:30 180
Is blood post-coronary artery bypass surgery bad for long-term survival?
M. Poullis, M. Pullan, N. Mediratta, J. Chalmers (United Kingdom)
Discussant: P. Matt (Basel)
Quality improvement outcomes  
*Moderators: D. Fullerton, Denver; A. Saito (Tokyo)*

10:15  
Health economy  
*R. Osnabrugge (Rotterdam)*

10:30  187  
Does routine cerebral oximetry improve safety in ThruPort cardiac surgery?  
*M. Purohit, A. Heggie, J. Zacharias, A. K. Knowles (United Kingdom)*  
*Discussant: F. Casselman (Aalst)*

10:45  188  
Radical multidisciplinary approach to primary cardiac sarcomas  
*O. Shapira¹, A. Korach¹, U. Izhar¹, T. Koler¹, A. Murar¹, O. Wald¹, S. Blackmon², M. Reardon² (¹Israel, ²United States)*  
*Discussant: L. McGrath (Brown Mills)*

11:00  189  
Functional quality of life and survival after prolonged Intensive Care Unit stay following cardiac surgery  
*G. Soppa, C. Woodford, M. Yates, R. Shetty, M. Moore, O. Valencia, N. Fletcher, M. Jahangiri (United Kingdom)*  
*Discussant: C. Fegbeutel (Hannover)*

11:15  190  
Constrictive pericarditis: preoperative risk-adjusted survival after pericardiectomy  
*G. Szabo, C. Bulut, M. Karck (Germany)*  
*Discussant: S. Cebotari (Hannover)*

11:30  191  
Aortic valve bypass in Denmark  
*J. Lund, M. Jensen, N. Ihlemann, H. Arendrup (Denmark)*  
*Discussant: B. Osswald (Bad Oeynhausen)*
Extracorporeal life support

Moderators: G. Wieselthaler, Vienna; A. J. Rastan, Rotenburg

10:15 200
Clinical experience with the current Circulite® Synergy® system in chronic ambulatory heart failure
B. Meyns¹, F. Rega¹, A. Barbone², D. Ornaghi², M. Strueber³, J. Schmitto³, A. Simon⁴, E. Vitali⁵ (¹Belgium, ²Italy, ³Germany, ⁴United Kingdom)
Discussant: C. Schmid (Regensburg)

10:30 201
Performance characteristics of a new extracorporeal membrane oxygenator generation with different cannula types
T. Rolf, P. Tozzi, D. Delay, S. Qanadli, R. Prêtre (Switzerland)
Discussant: S. Mahr (Vienna)

10:45 202
Impact of an open-chest extracorporeal membrane oxygenator model for in situ simulated team training: a pilot study
I. Atamanyuk, O. Ghez, M. Lane, I. Saeed, J. Hall, T. Jackson, A. Desai, M. Burmester (United Kingdom)
Discussant: R. Cartier (Montreal)

11:00 203
Impact of early respiratory failure after mechanical circulatory support implantation in patients assisted by veno-arterial extracorporeal membrane oxygenation
D. Boulate, P. Leprince, M. Pozzi, G. Lebreton, E. Corvol, A. Combes, J. Chastre, M. Kirsch (France)
Discussant: T. Hrapkowicz (Zabrze)

11:15 204
Extracorporeal membrane oxygenation in cardiac transplantation: rescue or jinx?
M. Groemmer, A. Aliabadi, F. Eskandary, D. Wiedemann, G. Laufer, A. Zuckermann (Austria)
Discussant: H. Hirose (Philadelphia)

11:30 205
Oxygenated shunting from right to left: minimized atrio-atrial extracorporeal membrane oxygenation for mid-term lung assistance
A. Goetzenich, Y. Abusabha, H. S. Giessen, A. Amerini, A. K. Menon, M. Haushofer, J. Spillner, N. Hatam (Germany)
Discussant: D. Mercogliano (Alessandria)

11:45-11:50 Da Vinci Prizewinner presentation

11:50-12:30 The Honoured Guest Lecture
Can Medicine save Pharma?
M. Fishman, Cambridge MA
President, Novartis Institutes for BioMedical Research

Acquired Cardiac Disease 62 Tuesday
How durable is transcatheter aortic valve implantation?

Moderators: J. J. Andreasen, Aalborg; R. Lange, Munich

14:15 210
Left ventricular remodelling following transcatheter aortic valve implantation: a one-year follow-up study
A. Alassar, R. Sharma, H. Patel, N. Abdulkareem, O. Valencia, A. Marciniak, M. Jahangiri (United Kingdom)
Discussant: R. Yadav (London)

14:30 211
The impact of transcatheter aortic valve implantation on patient profile and on outcomes of aortic valve surgery programmes: a multi-institutional appraisal
A. D’Onofrio, O. Altieri, F. Alamanni, M. Fusari, V. Tarzia, G. Rizzoli, G. Gerosa (Italy)
Discussant: W. Gomes (São Paulo)

14:45 212
Adverse impact of pulmonary hypertension on postoperative course and survival after transapical aortic valve implantation
S. Buz, M. Pasic, A. Unbehaun, T. Drews, S. Dreysse, M. Kukucka, A. Mladenow, R. Hetzer (Germany)
Discussant: J. Herreros (Pamplona)

15:00 213
Effect of aortic annular size on outcome of transcatheter aortic valve implantation
T. Drews, M. Pasic, S. Buz, A. Unbehaun, M. Plass, A. Mladenow, R. Hetzer (Germany)
Discussant: S. Head (Rotterdam)

15:15 214
Transapical transcatheter aortic valve implantation after previous cardiac surgery: comparison with propensity-matched redo conventional aortic valve replacement
M. Wilbring, S. Tugtekin, U. Kappert, K. Matschke (Germany)
Discussant: W. Brinkman (Plano)

15:30 215
Is annular or valvular calcification predictive for paravalvular leaks after transcatheter aortic valve implantation?
F. Plank1, S. Mueller1, T. Bartel1, G. Friedrich1, T. Schachner1, N. Bonaros1, J. Leipsic2, G. Feuchtner1 (1Austria, 2Canada)
Discussant: M. Thielmann (Essen)

Extreme procedures: you can do it but should you do it?

Moderators: S. Gunaydin, Ankara; P. Gerometta, Milan

14:15 216
Postoperative complications in the elderly related to quality of life: does it really matter?
V. Kurfirst, A. Mokracek, J. Canadyova, M. Vambera, L. Pesl (Czech Republic)
Discussant: C. Muneretto (Brescia)

14:30 217
Early postoperative serum cystatin C predicts severe acute kidney injury following cardiac surgery
A. Kiessling, S. Wedde, U. Stock, A. Beiras-Fernandez, C. Reyher, A. Moritz (Germany)
Discussant: W. Mohl (Vienna)
14:15-15:45 Abstracts Room 114

Sternal wounds: the problem we like to ignore
Moderators: R. Deac, Targu-Mures; M. Bitner, Lodz

14:15 222
Suction-irrigation drainage: an underestimated therapeutic option for surgical treatment of deep sternal wound infections
H. Deschka, S. Erler, L. El-Ayoubi, G. Wimmer-Greinecker (Germany)
Discussant: K. Dossche (Aalst)

14:30 223
Reduction in sternal wound infection: back to basics
R. George, C. Efthymiou, D. O'Regan (United Kingdom)
Discussant: S. Collins (Lund)

14:45 224
Sternal wound complications: a single-centre study
C. Heilmann, R. Stahl, C. Schneider, G. Trummer, M. Olschewski, F. Beyersdorf (Germany)
Discussant: T. Langanay (Rennes)

15:00 225
Nitinol flexigrip sternal closure system and standard sternal steel wiring: insight from a matched comparative analysis
J. Bejko, T. Bottio, V. Tarzia, M. Gallo, M. De Franceschi, R. Bianco, M. Castoro, G. Gerosa (Italy)
Discussant: T. Elenbaas (Eindhoven)

15:15 226
A new cable-tie based sternal closure device: infectious considerations
L. Melly, B. Gahl, R. Meinke, P. Matt, F. Rueter, O. T. Reuthebuch, F. Eckstein, M. Grapow (Switzerland)
Discussant: T. Elenbaas (Eindhoven)

15:30 227
Ten-year experience of deep sternal wound infection after isolated coronary artery bypass grafting and evaluation of the efficacy of a microbial sealant for reducing such infections
Discussant: J. De Raet (Leipzig)

Impact of major non-cardiac complications on outcome following cardiac surgery procedures: logistic regression analysis in a very recent patient cohort
P. Rahmanian, A. Kroener, G. Langebartels, O. Oezel, J. Wippermann, T. Wahlers (Germany)
Discussant: L. Noyez (Nijmegen)

15:00 219
Prolonged intensive care treatment of octogenarians after cardiac surgery: a reasonable economic burden?
H. Deschka, C. Dogru, R. Schreier, G. Wimmer-Greinecker (Germany)
Discussant: W. Eichinger (Munich)

15:15 220
Total atroventricular block following aortic valve replacement: incidence and implications
P. Ghosn (Canada)
Discussant: C. Kik (Rotterdam)

15:30 221
Cardiac surgery in nonagenarians: only feasible, but also reasonable?
U. Boeken, A. Assmann, A. Mehdiani, J. Minol, P. Akhyari, A. Lichtenberg (Germany)
Discussant: M. Othman (Damascus)

14:45 218
Impact of major non-cardiac complications on outcome following cardiac surgery procedures: logistic regression analysis in a very recent patient cohort
P. Rahmanian, A. Kroener, G. Langebartels, O. Oezel, J. Wippermann, T. Wahlers (Germany)
Discussant: L. Noyez (Nijmegen)

15:00 219
Prolonged intensive care treatment of octogenarians after cardiac surgery: a reasonable economic burden?
H. Deschka, C. Dogru, R. Schreier, G. Wimmer-Greinecker (Germany)
Discussant: W. Eichinger (Munich)

15:15 220
Total atroventricular block following aortic valve replacement: incidence and implications
P. Ghosn (Canada)
Discussant: C. Kik (Rotterdam)

15:30 221
Cardiac surgery in nonagenarians: only feasible, but also reasonable?
U. Boeken, A. Assmann, A. Mehdiani, J. Minol, P. Akhyari, A. Lichtenberg (Germany)
Discussant: M. Othman (Damascus)
Off-pump coronary surgery

Moderators: T. M. Kieser, Calgary; A. P. Kappetein, Rotterdam

14:15
Critical appraisal of off-pump surgery
T. Kieser (Canada)

14:30
Revascularization in left main coronary artery disease: comparison of off-pump coronary artery bypass grafting versus percutaneous coronary intervention
S. Chung, D. S. Jeong, Y. T. Lee, W. S. Kim, K. Sung, P. W. Park (Republic of Korea)
Discussant: M. Emmert (Zürich)

14:45
Multicentre Spanish study of the role of off-pump surgery in preventing postoperative cerebrovascular accident after coronary artery bypass grafting
E. Martín, F. Homero (Spain)
Discussant: F. Barili (Cuneo)

15:00
Analysis of thirty-day outcomes of off-pump versus on-pump coronary artery bypass grafting: a large cohort study
L. Sajja, G. Mannam, S. B. Dandu, S. Pathuri, K. Sai Kiran, S. Sompalli (India)
Discussant: K. Kirali (Istanbul)

15:15
Usefulness of minimal luminal diameter and location of stenosis in selection of graft material in off-pump coronary revascularization: in situ arterial or aortocoronary vein graft?
Discussant: B. Fabri (Liverpool)

15:30
Impact of increasing degrees of renal impairment on outcomes of coronary artery bypass grafting: the off-pump advantage
R. Garcia Fuster, F. Paredes, A. García, E. Martín, S. Cánovas, O. Gil, F. Homero, J. Martínez (Spain)
Discussant: M. Lemma (Milano)

Unanswered questions in right ventricular failure

Moderators: M. De Bonis, Milan; L. A. Menicanti, Milan

14:15
The size of the problem and what is the risk
J. Dunning (Cambridge)

14:30
Making the diagnosis
S. Price (London)

14:45
The role of tricuspid repair
P. Perier (Bad Neustadt/Saale)
15:00
Right ventricular assist device versus biventricular assist device
A. Simon (Harefield)

15:15 245
Early and late changes in pulmonary artery pressure and right ventricular function after cardiac surgery in patients with preoperative pulmonary hypertension
F. Corciova, C. Corciova, G. Tinica (Romania)
Discussant: H. Vanermen (Aalst)

15:30 246
The impact of the right ventricle on two-year actual cardiac mortality in patients with ischaemic mitral regurgitation undergoing mitral valve surgery
M. Di Mauro¹, A. Iaco¹, D. Clemente², S. Romano², H. Al Amri², M. Penco², A. Calafiore²
(¹Saudi Arabia, ²Italy)
Discussant: F. Kargar (Tehran)

16:15-17:45 Abstracts Rooms 116/117

Late-breaking Trials II
Moderators: O. Aljassim, Dubai; M.R. Moon, Washington

LB 006 16:15
First-in-human application of direct epicardial shock wave therapy in coronary artery bypass grafting in ischaemic cardiomyopathy
J. Dumfarth¹, D. Zimpfer¹, H. Tschernich², C. Loewe¹, J. Holfeld¹, M. Grimm¹ (¹Austria, ²Germany)
Discussant: T. Mesana (Ottawa)

LB 007 16:30
Prevention of sternal wound complications after sternotomy: results from a large prospective randomized multicentre trial
M. Gorlitzer¹, F. Wagner², S. Pfeiffer², S. Folkmann¹, J. Meinhart¹, T. Fischlein²,
H. Reichenspurner², M. Grabenwöger¹ (¹Austria, ²Germany)
Discussant: W. Brinkman (Dallas)

LB 008 16:45
Do minimized perfusion circuits have any further impact on quality of life of patients? Results of one-year follow-up of the prospective randomized controlled multicentre trial comparing RocSafe RX™ to standard cardiopulmonary bypass
J. Skorpil¹, A. El-Essawi², A. Böning², W. Harringer², T. Hajek¹ (¹Czech Republic, ²Germany)
Discussant: T. Dessing (Nieuwegein)

LB 009 17:00
Minimally invasive surgical ablation versus catheter ablation for lone atrial fibrillation: results from the Standard study
G. Nasso, J. El Bilal, R. Bonifazi, V. Romano, F. Bartolomucci, G. Rosano, K. Fattouch,
G. Speziale (Italy)
Discussant: B. Osswald (Bad Oeynhausen)

LB 010 17:15
Triclosan-coated sutures reduce surgical site infections after open vein harvesting in coronary artery bypass graft patients: a prospective randomized controlled trial
A. Jeppsson¹, L. Thimour-Bergström¹, T. Gudbjartsson¹, C. Åneman¹, O. Friberg¹
(¹Sweden, ²Iceland)
Discussant: S. M. Collins (Lund)

LB 011 17:30
Early clinical outcomes of a new paediatric extracorporeal life support system (Endumo® 2000) in paediatric patients
T. Hoashi, K. Kagisaki, K. Yamashita, H. Ichikawa (Japan)
Discussant: P vd Woestjine (Rotterdam)
Novel techniques in mitral valve repair

Moderators: Y.A. Habibie, Jakarta; A. Diegeler, Bad Neustadt

16:15  253
Active mitral ring for continual post-surgery remote and reversible correction of residual mitral regurgitation on the beating heart
P. Tozzi, D. Locca, F. Gronchi, D. Hayoz, E. Ferrari, L. Von Segesser, R. Hullin (Switzerland)
Discussant: A. Ahlsson (Örebro)

16:30  254
Posterior ventricular anchoring neochordal repair of degenerative mitral regurgitation efficiently remolds and repositions posterior leaflet prolapse
Y. Woo, J. Macarthur (United States)
Discussant: H. Najm (Riyadh)
16:15
Propensity-matched analysis of bilateral versus single internal mammary artery in 7702 patients undergoing isolated coronary artery bypass grafting
A. Saito, N. Motomura, H. Miyata, M. Ono, S. Takamoto (Japan)
Discussant: P. Sergeant (Leuven)

16:30
Bilateral internal mammary artery grafting reverses the negative influence of gender on outcomes of coronary artery bypass graft surgery
P. Kurlansky, E. Traad, M. Dorman, D. Galbut, M. Zucker, G. Ebra (United States)
Discussant: V. Mendes (Solingen)

16:45
Remote outcomes in diabetic patients following coronary artery bypass revascularization using bilateral internal thoracic arteries: a meta-analysis
T. Yamamoto, K. Kajimoto, A. Amano (Japan)
Discussant: M. Loubani (Hull)

17:00
Bilateral internal thoracic artery grafting increases risk for mediastinitis: a meta-analysis of randomized and risk-adjusted observational studies
H. Yamamoto, H. Takagi, K. lwata, S. Goto, T. Umemoto (Japan)
Discussant: D. Loisance (Paris)
17:15  269
Late effects of radial artery versus saphenous vein grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis
T. A. Schwann1, L. Al-Shaar2, M. Engoren1, M. Bonnell1, C. Clancy1, A. Koubir1, R. Habib2 (1United States, 2Lebanon)
Discussant: T. van der Meulen (Rotterdam)

17:30  270
Does the addition of a radial artery improve survival in higher risk coronary artery bypass grafting?
P. Hayward, C. Yap, W. Shi, B. Buxton, D. Dinh, C. Reid, G. Shardey, J. Smith (Australia)
Discussant: N. Verberkmoes (Eindhoven)

16:15-17:45  Abstracts
Rooms 118/119

Left ventricular assist device management
Moderators: M. Morshuis, Bad Oeynhausen; B Torfason, Reykjavik

16:15  283
Prediction of outcome in patients with liver dysfunction after left ventricular assist device implantation
H. Nishi, T. Sakaguchi, S. Miyagawa, Y. Yoshikawa, S. Fukushima, T. Ueno, T. Kuratani, Y. Sawa (Japan)
Discussant: M. Strueber (Leipzig)

16:30  284
Comparison of haemolysis between CentriMag and RotaFlow rotary blood pumps during extracorporeal life support
D. Palanzo, A. El-Banayosy, E. Stephenson, C. Brehm, W. Pae (United States)
Discussant: T. Komoda (Berlin)

16:45  285
Elevated levels of preoperative interleukin-6 affect monocyte activation and multi-organ failure in left ventricular assist device patients
L. Botta, R. Caruso, J. Campolo, A. Cannata, F. Milazzo, M. Frigerio, L. Martinelli, O. Parodi (Italy)
Discussant: G. Wieselthaler (Vienna)

17:00  286
Is antiplatelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience
P. Litzler, H. Smail, V. Barbay, C. Nafeh-Bizet, M. Redonnet, J. Baste, F. Bouchart, J. P. Bessou (France)
Discussant: C. Heilmann (Freiburg)

17:15  287
Is Clostridium difficile infection a risk factor for patients requiring cardiac assist after heart surgery?
C. Binner, P. Dohmen, S. Schack, K. Binner-Oussenek, J. Garbade, F. Mohr (Germany)
Discussant: J. Dunning (Cambridge)
Endocarditis

Moderators: H. Jakob, Essen; M. Antunes, Coimbra

16:15
Guidelines for medical treatment: antimicrobial prophylaxis
B. Prendergast (Oxford)

16:30
Timing of surgery
P. Tornos (Barcelona)

16:45
Key surgical principles
R. Hetzer (Berlin)

17:00  288
Management and outcome of infective endocarditis with mycotic aneurysms evaluated by brain magnetic resonance imaging
Discussant: P. Tornos (Barcelona)

17:15  289
Long-term results of aortic root abscess treated with cavity gluing and annular reconstruction by patch
P. Farahmand, M. Laali, V. Renier, C. D’Alessandro, A. Rama, P. Leprince, A. Pavié (France)
Discussant: R. Speekenbrink (Eindhoven)

17:30  290
A tailored approach to active aortic valve endocarditis treatment: long-term follow-up
A. Vanermen, D. Glineur, L. De Kerchove, P. Noirhomme, G. El Khoury (Belgium)
Discussant: B. Prendergast (Oxford)
Live-in-a-box minimally invasive cardiac symposium:
How to do it?

Moderators: P. Sardari Nia, Breda; M. Siepe, Freiburg

09:00
How to do a transcatheter aortic valve implantation
M. Jahangiri (London)

09:20
How to do an off-pump aortic valve bypass
O. T. Reuthebuch, Basel

How to do a minimally invasive mitral valve repair
J. Seeberger (Leipzig)

09:40
How to do a mini aortic valve replacement
P. Sardari Nia (Breda)

10:10
How to do a mini-maze
W.-J. Van Boven (Amsterdam)

10:30 Break

11:00
How to do a thoracic endovascular aortic repair
M. Czerny (Berne)

11:20
How to do an endovascular coronary artery bypass
N. Bonaros, (Innsbruck)

11:40
How to do video-assisted thoracoscopic epicardial lead placement
B. Van Putte (Breda)

Lateral Thinking

09:00-09:08
Why are we here today? Introduction, background and goals of this session
J. Seeberger (Leipzig)

09:09-09:17
How simple ideas can influence our practice
O. Alfieri (Milan)

09:18-09:26
What do patients want and need?
M. Misfeld (Leipzig)

09:27-09:35
Societies (EACTS, AATS, STS, ESC ...): Lobby for whom?
V. Falk (Zürich)
09:00-12:30 Advanced Techniques

The mitral and tricuspid valves: repair techniques
Moderator: J. R. Pepper, London; P. van de Woestijne, Rotterdam

09:00
Pathophysiology of functional mitral and tricuspid regurgitation
K. M. J. Chan (London)

09:25
Assessment of functional mitral and tricuspid regurgitation
L. Pierard (Liege)

09:50
Natural history and medical treatment of functional mitral and tricuspid regurgitation
T. McDonagh (London)

10:15 Break
10:45 Surgical treatment of functional mitral regurgitation  
*R. Dion (Genk)*

11:10 Surgical treatment of functional tricuspid regurgitation  
*G. Dreyfus (Monte-Carlo)*

11:35 Newer approaches: when do percutaneous techniques offer a solution?  
*F. Maisano (Milan)*

11:35 An alternative surgical treatment to tricuspid regurgitation  
*J-P Couetil (Paris)*

11:55 Newer approaches: when do percutaneous techniques offer a solution  
*F. Maisano (Milan)*

12:15 Conclusion

This session is supported by an unrestricted educational grant from Edwards Lifesciences

---

09:00-13:00 Advanced Techniques

New surgical treatment concepts for heart failure

Organized by the Roland Hetzer International Cardiothoracic Vascular Surgery Society (RHICS)

*Moderators: F. Beyersdorf, Freiburg; R. Hetzer (Berlin)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Organ-conserving surgery</td>
<td><em>F. Beyersdorf (Freiburg)</em></td>
</tr>
<tr>
<td>09:20</td>
<td>Cardiac resynchronization therapy</td>
<td><em>C. Butter (Berlin)</em></td>
</tr>
<tr>
<td>09:40</td>
<td>Revascularization surgery</td>
<td><em>J. Ennker (Lahr)</em></td>
</tr>
<tr>
<td>10:00</td>
<td>State of the art in heart transplantation</td>
<td><em>R. Hetzer (Berlin)</em></td>
</tr>
<tr>
<td>10:20</td>
<td>Role of left ventricular assist device</td>
<td><em>M. Morshuis (Bad Oeynhausen)</em></td>
</tr>
<tr>
<td>10:40</td>
<td>Role of right ventricular assist device</td>
<td><em>T. Krabatsch (Berlin)</em></td>
</tr>
<tr>
<td>11:00</td>
<td>Role of biventricular assist device</td>
<td><em>E. Potapov (Berlin)</em></td>
</tr>
</tbody>
</table>

---

Wednesday 73 Acquired Cardiac Disease
11:20
Total artificial heart
*M. Loebe (Houston)*

11:40
Paediatric ventricular assist device
*V. Alexi-Meskishvili (Berlin)*

12:00
End-stage congenital heart disease
*E. M. Delmo Walter (Berlin)*

12:20
Regenerative medicine
*C. Stamm (Berlin)*

12:40
Panel discussion
*R. Hetzer (Berlin), F. Beyersdorf (Freiburg), G. Schuler (Leipzig), F. Musumeci (Rome), C. Mestres (Barcelona), H. Schafers (Homburg/Saar)*

08:30-11:45 Advanced Techniques Room 115

Controversies and catastrophies in adult cardiac surgery
*Organiser: M. Shrestha, Hannover
Moderators: R. Haaverstad, Bergen; G. Rajbhandary, Nepal; A. Martens, Hannover*

08:30
Introduction
*M. Shrestha (Hannover)*

08:40
Completion coronary angiogram after coronary artery bypass grafting: is it necessary?
*J. Bauersachs (Hannover)*

08:50
Presentation of single-centre data
*F. Fleissner (Hannover)*

09:00
Tissue-engineered valves: all smoke without fire?
*G. Gerosa (Padua)*

View from industry
*J. McKenna, (United Kingdom)*

09:20
Aortic valve endocarditis: when to operate?
*C. Mestres (Barcelona)*

09:40
Aortic valve replacement in high-risk patients: classical aortic valve replacement through mini-thoracotomy is superior to transcatheter aortic valve implantation
*M. Glauber (Massa)*

10:00
Closure of circumflex artery during MIC mitral valve operation: is the danger real?
*V. Falk, Zürich*

10:20 Coffee
10:40
Redo mitral valve replacement for reiterative desinsertion: what to do
T. Folliguet (Nancy)

11:00
Aortic valve in acute aortic dissection type A: to repair or replace?
C. Hagl (Munich)

11:20
Closing remarks
M. Shrestha (Hannover)

09:00-10:30 Advanced Techniques

Part I
Aortic valve repair for the non-expert: a stepwise approach
Moderators: D. Pagano, Birmingham; R. Sádaba, Pamplona

How to start an aortic valve repair programme
J. Vojacek (Hradec Králové)

How to select a good candidate
V. Delgado (Leiden)

How to repair a tricuspid aortic valve
E. Lansac (Paris)

How to repair a bicuspid aortic valve
G. Mecozzi, (Enschede)

Wetlab: Valve-sparing aortic root replacement
Organiser: D. Pagano (Birmingham)
Lead Convenors: M. Lewis, Brighton; E. Lansac, Paris; M. Redmond, Dublin

Learning objectives:
At the end of this wetlab, the candidate will be able to:
• describe the methods used to perform valve sparing root replacement
• explain the reasons that one technique might be used in place of another
• perform the techniques in a wetlab environment

Welcome
M. Lewis

Re-implantation techniques
M. Redmond (Dublin)

Re-modelling techniques including the Lansac Ring
E. Lansac (Paris)

Wetlab session
Summary, feedback and close
E. Lansac, M. Lewis

Limited to 40 participants
Attendees at the wet lab should attend Part I: Aortic valve repair for the non-expert, a stepwise approach

10:45-13:00 Wetlab Training Session

Part II
Wetlab Training Session
Rooms 120/121

Re-modelling techniques including the Lansac Ring
E. Lansac (Paris)

Limited to 40 participants
Attendees at the wet lab should attend Part I: Aortic valve repair for the non-expert, a stepwise approach
Strategies to deal with mitral repair using Gore-tex chords

Organiser: D. Pagano (Birmingham)
Lead Convenors: M. Lewis (Brighton)

Faculty:
P. Perier (Bad Neustadt/Saale), W. C. Hargrove III, Philadelphia, S. Livesey (Southampton), M. Lewis, (Brighton)

Learning objectives:
At the end of this wetlab, the candidate will be able to:
• Describe the methods used to repair the mitral valve using Gore-tex neochords and a mitral ring
• Explain the reasons why one technique might be used in place of another
• Perform the techniques in a wetlab environment

Programme (90 minutes per iteration)

Welcome:
M. Lewis
Anatomy of the mitral valve (Lecture, 10 minutes)
W. C. Hargrove III
Repair techniques (Lecture, 10 minutes)
P. Perier, W. C. Hargrove III

Wetlab session (70 minutes)
Summary, feedback and close
M. Lewis

Limited to 40 participants
Congenital Heart Disease Domain Programme

Chair: William J. Brawn, Birmingham
Gaetano Gargiulo, Bologna
Emile A. Bacha, New York
Victor Hraska, Sankt Augustin
Eero Jokinen, Helsinki
Patrick O. Myers, Boston
George Kirvassilis, Athens

Ex officio
A.P. Kappetein, Rotterdam
Ludwig K. Von Segesser, Lausanne

Saturday 27 October 2012
Techno College

Sunday 28 October 2012
Postgraduate Education:
Quality Improvement Programmes
Congenital Heart Disease Domain Programme

Monday 29 October 2012
Scientific Abstracts

Professional Challenges:
Is there a place for palliation in the management of Fallot’s tetralogy

Focus session:
Heart rejuvenation

Tuesday 30 October 2012
Scientific Abstracts
Congenital Domain initiatives
Focus session:
Complex transposition of the great arteries

Wednesday 31 October 2012
Advanced Techniques:
Wetlab Operative techniques: Aortic valve repair and the MAZE procedure
Congenital Heart Disease

Organisers: Congenital Heart Disease Domain

Medical and surgical intervention and management of cardiac arrhythmias in congenital heart disease

Moderators: W. Brawn, Birmingham; P. O. Myers, Geneva; C. Schreiber, Munich

13:30
Embryonic conduction tissue and possible morphological substrates for arrhythmias
M. Jongbloed (Leiden)

14:00
Postoperative arrhythmias in tetralogy of Fallot: incidence, risk stratification and role of catheter ablation
G. Hessling (Munich)

14:30
Can we change our surgical technique to reduce the incidence of arrhythmias?
V. Hraska (Sankt Augustin)

15:00
Heart failure, resynchronization, implantable cardioverter-defibrillator: an update from the Euripides registry
J. Janousek (Prague)

15:30 Coffee

15:50
Magnetic catheter navigation for treatment of arrhythmias in congenital heart disease
A. Kirstein Pedersen (Copenhagen)

16:20
Is there a rationale for right-sided maze in morphologic substrates such as Ebstein’s disease or tetralogy of Fallot?
S. Tsao (Chicago)

16:50
Risk factors for “Fontan” arrhythmias, interventional strategies and limitations
S. Tsao (Chicago)

17:30
How a surgeon can treat “Fontan” arrhythmias: to cook or to freeze?
M. Haw (Southampton)
Plenary session: Quality improvement programmes

Moderators: L. K. Von Segesser, Lausanne; D. Pagano, Birmingham

08:30
Quality: an elusive and moving target
B. E. Keogh (London)

08:50
Cost-effectiveness analysis: what is it and how can we use it to improve care?
D. J. Cohen (Kansas City)

09:10
Measuring data and creating evidence: shortcomings of trials/Registry/observational studies; mortality is not the only endpoint
M. Utley (London)

09:30
ProvenCare in lung cancer
D. Wood (Seattle)

10:30-12:30 Session 1: Truncus arteriosus

Moderators: P. R. Vouhé, Paris; W. Brawn, Birmingham

10:30
Morphology
A. Cook (London)

10:50
Echo diagnosis
M. Vogt (Munich)

11:10
Surgical repair
M. Hazekamp (Leiden)

11:30
Management of the truncal valve
C. Caldarone (Toronto)

11:50
Reconstruction of the right ventricular outflow tract and pulmonary arteries
O. Raisky (Paris)

12:10
Long-term outcomes and reinterventions
C. Schreiber (Munich)

12:30 Lunch
13:30-15:10 Session 2: Aortic valve repair in childhood
Moderators: R. Prêtre, Zürich; S. Qureshi, London

13:30
Morphology
A. Cook (London)

13:40
Aortic valve repair in Melbourne
C. Brizard (Melbourne)

13:50
Aortic valve repair in St Augustin
B. Asfour (Sankt Augustin)

14:10
Intraoperative evaluation of the repaired aortic valve
M. Vogt (Munich)

14:30
Panel discussion

15:30-16:30 Session 3: Minimally invasive repairs
Moderators: S. Sano, Okayama; B. Kreitmann, Marseille

15:30
Illustrative cases will be presented by each speaker and discussed in an interactive way
Presenters: B. Asfour, Sankt Augustin; V. Vida, Padua; Z. Zhuang, Shanghai

16:00
The future of minimally invasive surgery
M. Reddy (Stanford)

16:20
Panel discussion

This course is supported with an unrestricted educational grant from St Jude Medical
Is there a place for palliation in the management of Fallot’s tetralogy?

Moderators: V. Hraska, Sankt Augustin; D. Barron, Birmingham

08:15
Introduction: Video repair
V. Hraska (Sankt Augustin)

08:30
Methods of palliation
D. Barron (Birmingham)

08:45 041
Surgery following primary right ventricular outflow tract stenting for Fallot’s tetralogy: rehabilitation of small pulmonary arteries
Discussant: A.J.J.C. Bogers (Rotterdam)

09:00 042
Is there any need for the shunt in the treatment of tetralogy of Fallot?
C. Arenz, A. Laumeier, S. Lutter, H. Blaschczok, N. Sinzobahamvya, C. Haun, B. Asfour, V. Hraska (Germany)
Discussant: G. Stellin (Padua)

09:15 043
What is the relationship between age and outcome in tetralogy of Fallot repair?
B. Mimic, K. Brown, S. Khambadkone, T. Hsia, V. Tsang, M. Kostolny (United Kingdom)
Discussant: G. Sarris (Athens)

09:30 044
Neonatal right ventricle to pulmonary connection with autologous tissue as palliative procedure for pulmonary atresia with ventricular septal defect or severe tetralogy of Fallot
S. Gerelli, M. Van Steenberghe, D. Bonnet, M. Bojan, P. Vouhé, O. Raisky (France)
Discussant: F. Fynn-Thompson (Boston)
Is there a place for palliation in the management of Fallot’s tetralogy?

Modestors: J Comas, Madrid, G Sarris, Athens; M. Lo Rito, Birmingham

10:15
How to promote growth of the right ventricular outflow tract and pulmonary artery
V. M. Reddy (Stanford)

10:30
How to minimize postoperative repair morbidity
M. Hazekamp (Leiden)

10:45
How to judge quality of repair in the operating room
M. Vogt (Munich)

11:00
Impact of different management protocols on long-term outcome
C. Caldarone (Toronto)

11:20
Discussion

The Presidential Address

11:50-12:30

The contraindications of today are the indications of tomorrow
L. Von Segesser, Lausanne

Aspects of valve repair

Modestors: B. Kreitmann, Marseille; B. Asfour, Sankt Augustin

14:15
Repair of incompetent truncal valve: early and mid-term results
G. Perri, S. Filippelli, A. Polito, D. Di Carlo, S. Albanese, A. Carotti (Italy)
Discussant: B. Asfour (Sankt Augustin)

14:30
Reoperation for left atroventricular valve dysfunction after repair of atroventricular septal defect
E. Belli, M. Pontailler D. Kalfa, M. Ly, E. Garcia, E. Le Bret, R. Roussin, V. Lambert (France)
Discussant: C. Margarita (Marseille)

14:45
Repair of Ebstein’s anomaly in neonates and small infants: impact of right ventricle exclusion
S. Sano, S. Kasahara, Y. Fuji, S. Arai (Japan)
Discussant: O. Ghez (London)
15:00 109
A 17-year experience with mitral valve repair with artificial chordae in infants and children
S. Oda, T. Nakano, K. Hinokiyama, D. Machida, H. Kado (Japan)
Discussant: V. Tsang (London)

15:15 110
Preliminary results of the Ross procedure associated with autograft reinforcement using a reimplantation technique
M. Ly, D. Kalfa, A. Serraf, E. Garcia, A. Likey, A. Baruteau, E. Belli (France)
Discussant: J. Hörer (Munich)

15:30 111
Outcome of a valve repair-oriented strategy for the aortic valve in children
A. Abousteit, N. Prior, G. Soda, P. Reddy, R. Dhannapuneni, P. Venugopal, J. Lim, N. Alphonso (United Kingdom)
Discussant: R. Prêtre (Zürich)

16:15-17:45 Focus Session Room 111

Heart rejuvenation

16:15 Cardioplegia
D. Chambers (London)

16:35 Stem cells
P. Menasche (Paris)

16:55 Ex vivo heart and lung preservation
A. Simon (Harefield)

17:15 Preconditioning and its future
V. Venugopal (London)
08:15-09:45 Focus Session Room 111

Complex transposition of the great arteries
Moderators: E. Jokinen, Helsinki; C. P. Brizard, Parkville

08:15
Morphology focus on complex transposition
A. Cook (London)

08:30
Echocardiographic evaluation of complex transposition
M. Vogt (Munich)

08:45
Management of complex coronary arteries
P. Vouhé (Paris)

09:00
Right ventricular outflow tract and arch problems
C. Brizard (Melbourne)

09:15
Can all complex transpositions be primarily repaired – How?
V. M. Reddy (Stanford)

09:30
Discussion

10:15-11:45 Abstracts Room 111

Congenital initiatives
Moderators: W. Brawn, Birmingham; M. Siepe, Freiburg

10:15 192
Novel technical modification achieves pulmonary valve-sparing repair for severely hypoplastic pulmonary valve in patients with tetralogy of Fallot
H. Ito, N. Ota, M. Murata, Y. Tosaka, Y. Ide, M. Tachi, A. Sugimoto, K. Sakamoto (Japan)
Discussant: A. Syed (Tabuk)

10:30 193
Comparison between normothermic and hypothermic cardiopulmonary bypass for the arterial switch operation: are there any important differences?
Discussant: O. Raisky (Paris)

10:45 194
The Taussig-Bing anomaly: long-term results of total correction
F. Schwarz, H. Blaschczok, N. Sinzobahamvya, S. Sata, F. Korn, A. Weber, B. Asfour, V. Hraska (Germany)
Discussant: C. Brizard (Melbourne)

11:00 195
Contemporary surgical management of truncal valve regurgitation
Discussant: V. Hraska (Sankt Augustin)
Lateral tunnel Fontan completion for children with hypoplastic left heart syndrome without cross-clamping the aorta

T. Mroczek, J. Jarosz, M. Dudynska, J. Skalski, Z. Kordon (Poland)
Discussant: P. Van de Woestijne (Rotterdam)

Da Vinci Prizewinner presentation

Can Medicine save Pharma?

M. Fishman, Cambridge MA
President, Novartis Institutes for BioMedical Research

Congenital miscellaneous

Moderators: J. V. Comas, Madrid; G. Stellin, Padua

Late haemodynamics after complete repair of pulmonary atresia with major aortopulmonary collaterals

R. Mainwaring, V. M. Reddy, L. Peng, C. Kuan, F. Hanley (United States)
Discussant: J. Comas (Madrid)

Anatomical factors determining surgical decision-making in patients with transposition of the great arteries with ventricular septal defect and left ventricular outflow tract obstruction

Y. Kotani, O. Honjo, T. Bharucha, L. Mertens, A. Jegatheeswaran, C. Caldorone, A. Redington, G. Van Arsdell (Canada)
Discussant: M. Hazekamp (Leiden)

Retraining the left ventricle beyond the age of three months indicates a sub-optimal outcome of the second stage arterial switch operation

S. Li, K. Ma, S. Hu, J. Yan, X. Shen, Z. Hua, K. Yang (China)
Discussant: W. Brawn (Birmingham)

P ferventricular device closure of perimembranous ventricular septal defects in paediatric patients: technical and morphological considerations

K. Lin, D. Zhu, Q. An (China)
Discussant: C. Schreiber (Munich)

What to expect after repair of total anomalous pulmonary venous return: data from 193 patients and 2902 patient years

J. Hoerer, C. Neuray, M. Vogt, J. Kastner-Samprec, J. Cleuziou, R. Lange, C. Schreiber (Germany)
Discussant: F. Lacour-Gayet (New York)

Impact of mechanical support on outcomes of paediatric cardiac transplantation

Discussant: J. McGiven (Wellington)
Understanding the univentricular circulation

Moderators: P Vouhé, Paris; F. Fontan, Bordeaux; E. Jokinen, Helsinki

16:15 271
Simulation of Fontan for apicocaval juxtaposition
M. Yoshida¹, K. Pekkan¹, P. Menon¹, C. Chrysostomou¹, P. Wearden¹, Y. Oshima², Y. Okita², V. Morell¹ (¹United States, ²Japan)
Discussant: K. Matsuo (Ichihara)

16:30 272
Evaluation of neurodevelopment after the Fontan operation: risk factors for adverse outcomes
A. Sugimoto, N. Ota, K. Ibuki, M. Murata, Y. Tosaka, T. Yamazaki, Y. Fujimoto, K. Sakamoto (Japan)
Discussant: E. Jokinen (Helsinki)

16:45 273
Outcomes of double inlet left ventricle and similar morphologies: a single-centre comparison of initial pulmonary artery banding versus a Norwood-type reconstruction
M. Ruzmetov, D. Geiss, R. Fortuna (United States)
Discussant: M. Kostolny (London)

17:00 274
Ventricular morphology does not influence Fontan survival at 15 years: a study of 649 patients
M. Kanani, T. Jones, N. Khan, W. Brawn, D. Barron (United Kingdom)
Discussant: B. Maruszewski (Warsaw)

17:15 275
Computational modelling to optimize hybrid configuration for hypoplastic left heart syndrome
A. Young, T. Gourlay, S. McKee, M. Danton (United Kingdom)
Discussant: W. Brawn (Birmingham)

17:30 276
Treatment of right ventricle to pulmonary artery conduit stenosis in neonates with hypoplastic left heart syndrome
A. Muensterer, J. Kasnar-Samprec, J. Hoerer, J. Cleuziou, A. Eicken, R. Lange, C. Schreiber (Germany)
Discussant: B. Maruszewski (Warsaw)
Operative techniques
– aortic valve repair and the MAZE procedure

Co-ordinator: W. Brawn, London
Faculty: C. Brizard, Melbourne; V. Hraska, Sankt Augustin; S. Tsao, Chicago

Learning objectives:
• To understand the aortic valve repair procedures and the maze procedure pertaining to congenital heart malformations

Programme:
• Different techniques for aortic valve repair V. Hraska, Sankt Augustin; C. Brizard, Melbourne
• Maze procedure: B Brawn (Birmingham) S. Tsao (Chicago); A. Coane (AtriCure)

Target Audience:
• Surgeons performing congenital heart surgery in patients from infancy through to adulthood

Limited to 40 participants
Vascular Disease Domain Programme

Chair:
- Martin Czerny, Berne
- Joseph Bavaria, Philadelphia
- Michael Borger, Leipzig
- Thierry Carrel, Berne
- Christian Etz, Leipzig
- Ruggero De Paulis, Rome
- Michael Grimm, Innsbruck
- Mahmoud Loubani, Hull
- Davide Pacini, Bologna
- Paul Urbanski, Bad Neustadt

Ex officio
- Ludwig K. Von Segesser, Lausanne
- A. Pieter Kappetein, Rotterdam

Sunday 28 October 2012
Postgraduate Education:
Quality Improvement Programmes
Vascular Disease Domain Programme

Monday 29 October 2012
Scientific Abstracts
Professional Challenges:
- Aortic arch disease

Tuesday 30 October 2012
Scientific Abstracts
Professional Challenges:
- Is there an effective substitute for the aortic root
- Acute and chronic type A aortic dissection

Wednesday 31 October 2012
Advanced Techniques:
- Interesting cases and small series on orphan aortic diseases and pathological mechanisms
- Clinical tips and tricks in vascular access for open and endovascular therapy

Also available:
- TEVAR Simulation Workshop (Monday, Tuesday)
- Mentice Simulation Course (Monday Tuesday)
- TEVAR pre-case planning Course with OsiriX (Monday)
Plenary session: Quality improvement programmes
Moderators: L. K. Von Segesser, Lausanne; D. Pagano, Birmingham

08:30
Quality: an elusive and moving target
B. E. Keogh (London)

08:50
Cost-effectiveness analysis: what is it and how can we use it to improve care?
D. J. Cohen (Kansas City)

09:10
Measuring data and creating evidence: shortcomings of trials/Registry/observational studies; mortality is not the only endpoint
M. Utley (London)

09:30
ProvenCare in lung cancer
D. Wood (Seattle)

Vascular Disease

10:15-11:55 Session 1 Infections of the cardiovascular system
Moderators: M. Czerny, Berne; J. R. Pepper, London

10:15
Microbiology and guidelines on prophylaxis in native and prosthetic cardiovascular infection
P. Tornos (Barcelona)

10:35
Diagnostics of cardiovascular infections
L. Lonn (Copenhagen)

10:55
Surgery in native and prosthetic active infective endocarditis
M. Jahangiri (London)

11:15
Surgery in native and prosthetic active infective aortitis
T. Carrel (Berne)

11:35
Collateral damage of cardiovascular infection: bronchus, oesophagus and intestine
M. Grimm (Innsbruck)

12:00 Lunch

13:00-14:40 Session 2: Controversies of open and endovascular approaches
Moderators: M. Grimm, Innsbruck; J. Bavaria, Philadelphia

13:00
ESC-EACTS Position paper
M. Grabenwöger (Vienna)
13:20
Why we do need a European Registry of Aortic Disease
E. Weigang (Mainz)

13:40
Experimental and clinical pharmacology in aortic disease
K. Kallenbach (Heidelberg)

14:00
Why open surgery will remain the mainstay of thoracoabdominal aortic aneurysm treatment
M. A. A. M. Schepens (Brugge)

14:20
Why thoracic endovascular aortic repair will be the future treatment of thoracoabdominal aortic aneurysm treatment
M. Funovics (Vienna)

15:00-16:20 Session 3: Thoracic vascular trauma
Moderators: R. Haaverstad, Bergen; D. Pacini, Bologna

15:00
Secondary surgical interventions after thoracic endovascular aortic repair
R. Haaverstad (Bergen)

15:20
Patterns and locations for acute traumatic vascular injury
H. Jakob (Essen)

15:40
Diagnostic tools in predicting acute traumatic vascular injury
V. Mosquera Rodríguez (A Coruña)

16:00
Timing and type of treatment in acute thoracic vascular injury
R. Di Bartolomeo (Bologna)

16:20
Adjourn
Aortic arch disease I

Moderators: C. A. Mestres, Barcelona; P. P. Urbanski, Bad Neustadt

08:15
State of the art in aortic arch surgery
J. Bachet (Abu Dhabi)

08:30
Mid- to long-term results after aortic arch repair using a four-branched graft with antegrade selective cerebral perfusion
Discussant: M. Pasic (Berlin)

08:45
Is the branched graft technique better than the en bloc technique for total aortic arch replacement?
M. Shrestha, A. Martens, S. Behrend, I. Maeding, A. Haverich (Germany)
Discussant: D. Loisance (Paris)

09:00
Aortic arch reoperation: a single-centre experience of early and late outcome in 57 consecutive patients
M. Moz, S. Leontyev, M. Borger, M. Misfeld, F. Mohr (Germany)
Discussant: B. Mochtar (Maastricht)

09:15
Open aortic arch replacement in the era of endovascular techniques
P. Urbanski, M. Raad, A. Lenos, P. Bougioukakis, M. Zacher, A. Diegeler (Germany)
Discussant: H. Jakob (Essen)

09:30
The role of Willis circle variations during unilateral selective cerebral perfusion: a study of 500 circles
V. Papantchev, V. Stoinova, A. Alexandrov, D. Todorova-Papantcheva, S. Hristov, D. Petkov, G. Nachev, V. Ovtscharoff (Bulgaria)
Discussant: T. Sioris (Tampere)

08:30-16:30 Simulation Workshop

TEVAR Simulation Workshop

Objectives:
After the course, participants will be able to describe the rationale for doing TEVAR and list the procedural steps of the implantation of a Valiant Captivia stent graft for a thoracic aortic aneurysm and/or rupture

Participant Profile:
Surgeons interested in understanding the endovascular treatment of the thoracic aorta with the Medtronic Valiant Captivia stent graft with no/limited experience in this field

Logistics:
Slots of 1 hour for two registered Annual Meeting delegates at a time. Registration on a first-come, first-served basis via the Information Desk in the main registration foyer area

Note: This programme is repeated on Tuesday 30 October at the same time and in the same venue
Mentice Simulation Course

Objectives:
Utilizing the endovascular Mentice VIST-Lab simulator for an introduction to EVAR. You will perform a variety of different EVAR focused anatomies utilising the real devices in a safe and controlled environment.

Participant Profile:
Ideally the participants will have at least a basic knowledge of wire and catheterisation skills. The participants will be able to perform an EVAR on a variety of different anatomies with 2 or 3 part graft systems.

Logistics:
Slots of 1 hour for three registered Annual Meeting delegates at a time. Registration on a first-come, first-served basis via the Information Desk in the main registration foyer area.

Note: This programme is repeated on Tuesday 30 October at the same time and in the same venue

TEVAR pre-case planning Course with OsiriX

Objectives:
The objective of the course is to teach the participants how to:
- import images from a CT scan
- view one or multiple series of images from a study
- navigate through the most important commands and toolbars
- customize toolbars
- use the main analysis and measurement tools
- precisely perform the measurements with the MultiPlanar Reconstruction Display (MPR) and 3D volume rendering
- export images, videos or DICOM files

In TEVAR, pre-case planning is key for achieving clinical success - failing to plan is planning to fail. Before entering the operating room, an analysis of the case is mandatory to properly understand the pathology and choose the optimal treatment. This course aims to provide an understanding of the use of OsiriX for the analysis of the pathologies of the thoracic aorta and the planning of potential treatments. OsiriX is becoming a reference in the endovascular market because it is easy to use, it includes all the tools needed for analysis and pre-case planning such as multiplanar reconstruction, 3D reconstruction, centerline and sizing tools; more, a free version is available. The course aims to be predominantly practical. After a brief introduction, the participants will be using individual Mac computers to go through the course and practise all the concepts explained.

Logistics:
The course is restricted to 25 registered Annual Meeting delegates.

Registration:
Fee €80.00 including VAT. Registration on a first-come, first-served basis via the EACTS User area.
Aortic arch disease II:
Video session on all proven approaches for effectively treating the arch
*Moderators: W. Harringer, Braunschweig; T. Carrel, Berne*

10:15
Arch rerouting - single
*M. Czerny (Berne)*

10:25
Arch rerouting - double
*M. Grimm (Vienna)*

10:35
Arch rerouting - triple
*E. Weigang (Mainz)*

10:45
Conventional arch - island
*R. De Paulis (Rome)*

10:55
Conventional arch - branched
*P. Urbanski (Bad Neustadt)*

11:05
Conventional elephant trunk
*Y. Okita (Kobe)*

11:15
Frozen elephant trunk
*G. Weiss (Vienna)*

11:25 072
Should aortic arch replacement be performed during initial surgery for aortic root aneurysm in patients with Marfan syndrome?
*F. Schoenhoff, A. Kadner, M. Czerny, J. Schmidli, T. Carrel (Switzerland)*
Discussant: T. Dessing (Nieuwegen)

11:40
Discussion

11:50-12:30 The Presidential Address Rooms 116/117

The contraindications of today are the indications of tomorrow
*L. Von Segesser, Lausanne*
Elephant trunk: conventional and frozen

Moderators: C. Hagl (Munich); M. Karck, Heidelberg

14:15 101
Thirty years of classical elephant trunk: single-centre experience
M. Shrestha, H. Krueger, A. Martens, F. Fleissner, F. Ius, A. Haverich (Germany)
Discussant: M. A. A. M. Schepens (Brugge)

14:30 102
Conventional elephant trunk versus frozen elephant trunk technique in the treatment of patients with thoracic aortic disease: effect on neurological complications
S. Leontyev, M. Borger, C. Etz, M. Moz, J. Seeburger, F. Bakhtiary, M. Misfeld, F. Mohr (Germany)
Discussant: R. Di Bartolomeo (Bologna)

14:45 103
Hybrid repair of mega aortic syndrome with the lupiae technique
G. Esposito, S. Bichi, D. Patrini, P. Tartara, P. Gerometta, V. Arena (Italy)
Discussant: M. Grabenwöger (Vienna)

15:00 104
Total aortic arch replacement with frozen elephant trunk: 10-year single centre experience
M. Shrestha, F. Fleissner, F. Ius, M. Karck, A. Martens, M. Pichlmaier, A. Haverich (Germany)
Discussant: A. Saito (Tokyo)

15:15 105
One-stage repair in complex multisegmental thoracic aneurysmal disease: results of a multicentre study
C. Mestres1, K. Tsagakis2, D. Pacini3, R. Di Bartolomeo3, M. Grabenwöger4, M. Borger2, R. Bonser5, H. Jakob2 (1Spain, 2Germany, 3Italy, 4Austria, 5United Kingdom)
Discussant: S. Numata (Fukui)

Contemporary approaches in acute and chronic type B aortic dissection

Moderators: A. Martens, Hannover; R. Di Bartolomeo, Bologna

16:15 122
Outcome of open surgery for type B aortic dissection
M. Nozdrzykowski, J. Garbade, C. Etz, M. Misfeld, M. Borger, F. Mohr (Germany)
Discussant: C. Hagl (Munich)

16:30 123
Open aortic repair of distal arch and descending aortic aneurysm: contemporary outcomes in 250 patients
T. Fujikawa (Japan)
Discussant: B. Pfannmüller (Leipzig)

16:45 124
Clinical outcome of emergency surgery for acute type B aortic dissection with rupture
T. Minami, K. Imoto, K. Uchida, N. Karube, T. Yasutsune, T. Cho, E. Umeda, M. Masuda (Japan)
Discussant: W. Schiller (Bonn)
Incidence and risk factor analysis of aortic erosion after endovascular thoracic aortic repair for aortic dissection
K. Shimamura, T. Kuratani, Y. Shirakawa, K. Torikai, J. Yunoki, T. Sakamoto, Y. Watanabe, Y. Sawa (Japan)
Discussant: S. Folkmann (Vienna)

Fate of the distal true lumen after stent-grafting for type IIIb aortic dissection: a word of caution
F. Dagenais, P. Voisine, S. Mohammadi, E. Dumont (Canada)
Discussant: W. Morshuis (Nieuwegein)

Assessment of duration from onset to thoracic endovascular aortic repair in type B aortic dissection: impact of aortic remodelling as the predictive factor for aortic events
Y. Watanabe, T. Kuratani, K. Shimamura, Y. Shirakawa, K. Torikai, J. Yunoki, T. Ueno, Y. Sawa (Japan)
Discussant: K. Tsagakis (Essen)
Is there an effective substitute for the aortic root?

Moderators: J. Bachet, Abu Dhabi; J. A. Bekkers, Rotterdam

08:15
Don't be ashamed to do a Bentall
F. Musumeci (Rome)

08:30
Time testing for tissue valves
M. Borger (Leipzig)

08:45
The living valve
H. Sievers (Lubeck)

09:00
Keep your own valve
R. De Paulis (Rome)

09:15 146-I
Step-by-step way to minimal access aortic surgery
M. Shrestha, A. Martens, P. Stiefel, A. Leone, A. Junge, A. Haverich (Germany)

09:30 147
Valve-sparing aortic root repair in acute type a aortic dissection: how many sinuses have to be repaired?
P. Urbanski, H. Hijazi, W. Dinstak, A. Diegeler (Germany)
Discussant: T. Fischlein (Nürnberg)

08:30-16:30 TEVAR Simulation Workshop
Room Vallvidrera, Hotel AC Barcelona Forum
See Monday's Programme (page 92) for details

09:00-17:00 Mentice Simulation Course
Room Tres Torres, Hotel AC Barcelona Forum
See Monday's Programme (page 93) for details
Acute and chronic type A aortic dissection

Moderators: C. D. Etz, Leipzig; W. Morshuis, Nieuwegein

10:15 181
Risk analysis and improvement of strategies in patients who have acute type A aortic dissection with coronary artery dissection
K. Imoto, K. Uchida, T. Yasutune, T. Minami, T. Cho, E. Umeda, M. Masuda, S. Morita (Japan)
Discussant: C. Etz (Leipzig)

10:30 182
Transapical implantation of covered endostents into the ascending aorta and the aortic arch
R. Bader, P. Burchardt, A. Rad, M. Caspary, H. Krankenberg (Germany)
Discussant: J. Bachet (Abu Dhabi)

10:45 183
Prediction of intimal tear site by computed tomography findings in acute type A dissection: can surgeons do it?
K. Park, C. Lim, I. Park, D. J. Kim, Y. Jung, S. I. Choi, E. J. Chun, J. Y. Yoo (Republic of Korea)
Discussant: D. Maselli (Rome)

11:00 184
The effect of intermittent lower body perfusion on end-organ function during repair of acute Debakey type I aortic dissection under moderate hypothermic circulatory arrest
S. Song, K. Yoo (Republic of Korea)
Discussant: B. Rylski (Freiburg)

11:15 185
Distal aortic complications and late growth rates in Marfan aortas after proximal aortic repair
F. Kari, M. Russe, B. Rylski, P. Blanke, F. Beyersdorf, M. Siepe (Germany)
Discussant: F. Schönhoff (Bern)

11:30 186
Iatrogenic type A aortic dissection: insight from the German Registry for Acute Aortic Dissection type A
B. Rylski, I. Hoffmann, F. Beyersdorf, M. Südkamp, M. Siepe, B. Nitsch, M. Blettner, E. Weigang (Germany)
Discussant: T. Krüger (Tübingen)

11:45-11:50 Da Vinci Prizewinner presentation

11:50-12:30 The Honoured Guest Lecture

Can Medicine save Pharma?
M. Fishman, Cambridge MA
President, Novartis Institutes for BioMedical Research
Thoracic endovascular aortic repair and combined approaches

Moderators: E. Weigang, Mainz; J. Cremer, Kiel

14:15 228
The efficacy and long-term results of hybrid thoracic endovascular aortic repair into zone zero for aortic arch pathologies
Y. Shirakawa, T. Kuratani, K. Torikai, K. Shimamura, J. Yunoki, T. Sakamoto, Y. Watanabe, Y. Sawa (Japan)
Discussant: G. Esposito (Bergamo)

14:30 229
Next-gen fenestrated endograft to seek expansion of indications for arch aneurysm treatment
T. Azuma, Y. Yokoi, K. Yamazaki (Japan)
Discussant: M. Funovics (Vienna)

14:45 230
Usefulness of fenestrated stent graft for thoracic aortic arch aneurysms
Discussant: T. Schachner (Innsbruck)

15:00 231
The heart as access to the aorta
E. Weigang, H. Weiler, T. Friess, C. Vahl (Germany)
Discussant: C. Mestres (Barcelona)

15:15 232
Results for high-risk endovascular procedures in patients with non-dissected thoracic aortic pathology: intermediate outcomes
B. Rylski, P. Blanke, M. Siepe, F. Kari, W. Euringer, M. Südkamp, F. Beyersdorf (Germany)
Discussant: B. Zipfel (Berlin)

15:30 233
Deployment of proximal thoracic endograft in zone 0 of the ascending aorta: treatment options and early outcomes for aortic arch aneurysms in a high-risk population
O. Preventza, J. Coselli, R. Cervera, K. De La Cruz, S. Troccoli, F. Bakaeen (United States)
Discussant: M. Czerny (Berne)

Aortic diagnostics from a different point of view

Moderators: R. De Paolis, Rome; G. Laufer, Vienna

16:15 259
Deregulated gene expression of VEGFA and COL3A1 in aortic aneurysms of tricuspid aortic valves compared to bicuspid aortic valves
N. Abdulkareem, I. Drozdzov, A. Didangelos, A. Zampetaki, S. Sooranna, M. Johnson, M. Mayr, M. Jahangiri (United Kingdom)
Discussant: H. Brinks (Berne)

16:30 260
Aortic replacement based on computational fluid dynamic analysis
M. Poullis, R. Poole (United Kingdom)
Discussant: M. Grabenwöger (Vienna)
16:45  261
Intramural haematoma should be referred to as “thrombosed type aortic dissection”
K. Uchida, K. Imoto, N. Karube, T. Yasutsune, T. Minami, T. Cho, E. Umeda, M. Masuda (Japan)
Discussant: J. Bekkers (Rotterdam)

17:00  262
Is there any difference in aortic wall quality between patients with aortic stenosis and regurgitation?
J. Benedik¹, K. Pilarczyk¹, R. Flek², H. Baba¹, K. Tsagakis¹, J. Indruch², H. Jakob¹
¹(Germany, ²Czech Republic)
Discussant: A. Della Corte (Naples)

17:15  263
Evaluation of elastic properties of ascending aortic aneurysm using new functional magnetic resonance imaging indexes and aortic size index
Discussant: J. Holfeld (Innsbruck)

17:30  264
Detection of thoracic aortic prosthetic graft infection by FDG-positron emission tomography/computed tomography
Y. Tokuda, A. Usui, H. Oshima, Y. Narita, Y. Araki, M. Mutsuga (Japan)
Discussant: S. Leontyev (Leipzig)
08:30-09:45
Interesting cases and small series on orphan aortic diseases and pathological mechanisms
*Moderators: M. Czerny, Berne; A. Moritz, Frankfurt*

08:30
A touristic danger in the Alps: acute type A aortic dissection in alpine skiers
*N. Fischler, J. Holfeld, W. Schobersberger, A. Strasak, M. Grimm (Austria)*
*Discussant: R. Haaverstad (Bergen)*

08:45
Usefulness of coil treatment for type I endoleak in thoracic endovascular aortic repair using a fenestrated stent graft
*K. Hanzawa, T. Okamoto, O. Namura, M. Tsuchida, Y. Yokoi (Japan)*
*Discussant: B. Zipfel (Berlin)*

09:00
Arteria luzoria as a risk factor for spinal cord ischaemia
*L. Bockeria, V. Arakelyan, N. Gidaspov (Russian Federation)*
*Discussant: D. Kotelis (Heidelberg)*

09:15
Endovascular stent graft repair of the ascending aorta: assessment of a specific novel stent graft design in phantom, cadaver and clinical application
*M. Funovics¹, M. Popovic¹, G. Erman¹, J. Lammer¹ (Austria)*
*Discussant: C. Antona (Milan)*

09:30
Acute retrograde type A aortic dissection after complete debranching of the supra-aortic branches and stent grafting of the transverse aortic arch
*M. Luehr, C. Etz, L. Lehmkuhl, F. Mohr, M. Borger (Germany)*
*Discussant: L. Di Marco (Bologna)*

09:45
Break

10:00-12:00
Clinical tips and tricks in vascular access for open and endovascular therapy
*Moderators: E. Weigang, Mainz; M. Grabenwöger, Vienna*

10:00-10:15
Apical access
*E. Weigang (Mainz)*

10:15-10:30
Ascending aortic access
*J. Bavaria (Philadelphia)*

10:30-10:45
Carotid access
*R. Urbanski (Bad Neustadt)*

10:45-11:00
Subclavian access
*M. Grabenwöger (Vienna)*
11:00-11:15
Infrarenal access
*M. Grimm (Innsbruck)*

11:15-11:30
Retroperitoneal access
*M. Czerny (Berne)*

11:30-11:45
Femoral access
*T. Friess (Mainz)*

11:45-12:00
Percutaneous access using closure devices
*M. Funovics (Vienna)*
Programme of General Interest Sessions

Sunday 28 October 2012
Postgraduate Education:
Quality Improvement Programmes
Basic Science Programme
Leadership: Working within multi-disciplinary teams
Nurses, Nurse Practioners, Physician Assistants Programme

Monday 29 October 2012
Residents’ Sessions:
Luncheon meeting
Work in Progress: Research in Cardiothoracic Surgery

Tuesday 30 October 2012
Residents’ Sessions:
Cardiovascular Simulator Award presentations
Interactive case-mix session: the patient keeps getting sicker, what do I do next?

Focus sessions:
PASCaTS/EACTS Global Forum:
Challenges of cardiothoracic surgery in the developing world:
palliation to repair procedures
Teach the teacher
Plenary session: Quality improvement programmes

**Moderators:** L. K. Von Segesser, Lausanne; D. Pagano, Birmingham

**08:30**
Quality: an elusive and moving target  
*B. E. Keogh (London)*

**08:50**
Cost-effectiveness analysis: what is it and how can we use it to improve care?  
*D. J. Cohen (Kansas City)*

**09:10**
Measuring data and creating evidence: shortcomings of trials/Registry/observational studies; mortality is not the only endpoint  
*M. Utley (London)*

**09:30**
ProvenCare in lung cancer  
*D. Wood (Seattle)*

**10:00-16:00 Postgraduate Education** Rooms 118/119

**Basic Science**

**10:00-12:10 Session 1**  
**Moderators:** P. Dohmen, Leipzig; G. Gerosa, Padua

**10:00**
Overview of tissue engineering: what do we need?  
*P. Dohmen (Berlin)*

**10:15**
Stem cells  
*G. Steinhoff (Rostock)*

**10:30**
Pluripotent stem cells  
*G. Gerosa (Padua)*

**10:45**
Are allografts suitable scaffolds for tissue engineering?  
*F. Smit (Bloemfontein)*

**11:00**
Synthetic scaffolds vs. decellularized scaffolds including bioreactors  
*S. Cebotari (Hannover)*

**Abstracts**

**Withdrawn 001**

**11:20 002**
Improved myocardial engraftment of induced pluripotent cell-derived cardiomyocytes by co-transplantation with mesenchymal stem cells  
*y. Choi, K. Neef, V. Lenerz, T. Saric, O. Liakopoulos, C. Stamm, T. Wittwer, T. Wahlers (Germany)*
A novel native-derived coronary artery model
H. Aubin, A. Kranz, J. Huelsmann, A. Lichtenberg, P. Akhyari (Germany)

13:00 - 14:20 Session 2
Moderators: F. E. Smit, Bloemfontein; G. Lutter, Kiel

13:00 Experimental data on tissue engineered aortic valves
J. Honge (Aarhus)

13:15 Clinical results with in vitro unseeded tissue engineered heart valves
A. Haverich (Hannover)

13:30 Clinical experience with tissue engineered valves based on decellularized scaffolds
J. Kluin (Utrecht)

13:45 Transcatheter tissue engineered heart valves
G. Lutter (Kiel)

14:05 Summary, conclusions
P. Dohmen (Berlin)

14:20 - 16:00 Session 3
Moderators: M. Kaljusto, Oslo; B. H. Walpoth, Geneva

14:20 Annular dilatation and loss of sinotubular junction in aneurysmal aorta: implications for leaflet quality at the time of surgery. A combined static stress and fluid interaction finite element study
L. Weltert, M. De Tullio, A. Salica, S. Nardella, R. Scaffa, D. Maselli, R. Verzicco, R. De Paulis (Italy)

14:30 Haemodynamic, cinematic and morphological effects of aortic interleaflet triangle annuloplasty in aortic valve repair
A. Mangini, C. Romagnoni, M. Contino, R. Vismara, A. Leopaldi, M. Lemma, G. Gelpi, C. Antona (Italy)

14:40 Straight versus valsalva graft: importance of pulsatility and eddy currents during systole. An in vitro study
A. Salica, G. Pisani, O. Ieropoli, R. Scaffa, E. M. Dell’Amico, D. Maselli, U. Morbiducci, R. De Paulis (Italy)

14:50 External aortic root support: A histological and mechanical study in sheep
P. Verbrugghe¹, E. Verbeek¹, J. Pepper², T. Treasure³, B. Meyns¹, B. Meuris¹, P. Herijgers¹, F. Rega³ (“Belgium, “United Kingdom)

15:00 Direct percutaneous transapical left ventricular puncture: feasibility and prediction study using computed tomography coronary angiography
T. Modine, M. Kilani, G. Fayad, J. M. Elarid, M. Koussa, J. P. Beregi (France)
The influence of acute matrix metalloproteinase activity on myocardial dysfunction associated with urgent cardiac surgery: cardioprotective effects of inhibition

E. Teh, D. Chambers (United Kingdom)

The anti-atherogenic potential of aspirin and clopidogrel in hypercholesterolaemic male rabbits

F. Al-Amran, N. Hadi, B. Mohammad, H. Tahir, H. Hamza (Iraq)

Prevention of arterial graft spasm using vasodilator-eluting biodegradable nano-scaled fibre in rats

K. Yagami, A. Ogata, M. Satake, H. Kaneko, H. Oshima, A. Usui, Y. Narita (Japan)

Shock wave therapy differentially activates endothelial cells: implications for the control of inflammation

J. Holfeld¹, C. Tepeköylü¹, A. Urbschat², K. Zacharowski², M. Grimm¹, P. Paulus² (¹Austria, ²Germany)

Leadership: Working within multi-disciplinary teams

Programme Introduction:
The aims of this programme are to give an overview of the stages through which teams develop and the role of the leader at each stage. It also heightens the delegates appreciation of their own supporting role to help their team achieve its' goals. As most healthcare situations require a number of disciplines to work together, it is important that delegates also understand that there will be conflicting priorities, agendas and personal interests within the confines of the team.

Learning Objectives:
By the end of this programme, delegates can:

- List the components which enable a team to perform effectively
- Understand the importance to the team focus of values, culture and goals
- Apply the knowledge of different types of teams to plan and prepare for successful outcomes
- Discover leadership skills needed to work within multi disciplines, and know when to use which style and in which situation
- Understand the different team roles (including their own) and how to ensure there is balance within the team.

The programme agenda:
Introduction, agenda, outline expectations and aims
What makes a high performing team?
Setting goals, values, standards and objectives
Primary and secondary teams
Leading and Managing different disciplines: Agendas; Priorities; Politics; Power
Leadership skills required for multi-disciplinary projects
Your team roles
Reflection, feedback and action plans.
Nurses, Nurse Practitioners and Physician Assistants

08:30
Welcome
L. Hamilton (Newcastle upon Tyne)

08:35-09:40 Session 1: Optimizing preoperative care
Moderators: M. Brunott, Rotterdam; T. Bartley, Birmingham

08:35
Nurse-driven outpatient clinics, preoperative assessment
S. Laidler (Newcastle upon Tyne)

08:55
EuroSCORE II: importance and rationale
S. Nashef (Cambridge)

09:15
Options for improving physical fitness: is there evidence?
P. Agostini (Birmingham)

09:40-11:20 Session 2: Theatre: making for a better tomorrow
Moderators: R. van Valen, Rotterdam; D. Bordinggaard, Odense C

09:40
NOTTS/teamwork in operating room
tba

10.00
Surgical site infections
J. Tanner (Leicester)

10.20
Radial artery harvesting: what can go wrong?
C. Ruiz

10:40
Working in a hybrid room: vision and reality
M. Steen and B. E. Mikkelsen (Odense C)

11.00
The role of the anaesthesia nurse, a vital one
J. W. Nieland and T. Haverkam (Zwolle)

11:20-12:20 Session 3: Postoperative quality improvement
Moderators: D. Bordinggaard, Odense C; J. Tanner (Leicester)

11.20
Interventions by nurses: proven safe and effective?
D. Danitsch (North Staffordshire)

11.40
MRSA management
M. Stenger (Odense C)
12:00
The impact of the cardiothoracic ward Nurse Practitioner
D. Southey (Wolverhampton)

12:20
Lunch

13:15-14:35 Session 4: Innovations in patient care
Moderator: R. van Valen (Rotterdam)

13:15
Nurse perfusionists in Spain
M. Mata (Barcelona)

13:35
Chest tubes and thoracic surgery: have things changed?
A. Maat (Rotterdam)

13:55
Extracorporeal life support in Intensive Care Unit of Emergency Room
J. Lipton (Rotterdam)

14:15
3D ultrasound: preoperative and perioperative benefits
A. Nierich (Zwolle)

14:35-16:15 Session 5: Hands on sessions with industry and surgeons
Introduction
R. van Valen (Rotterdam); D. Bordinggaard (Odense C)

<table>
<thead>
<tr>
<th>Sternal closure devices</th>
<th>Synthes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extra corporeal life support</td>
<td>Maquet</td>
</tr>
<tr>
<td>Drainage systems</td>
<td>Atrium</td>
</tr>
</tbody>
</table>

16:15
Adjourn
Research in Cardiothoracic Surgery: Work in Progress abstract session
Moderators: P. Sardaria Nia, Breda; M. Siepe, Freiburg

14:15
P-MED: A novel closed-circuit, minimally invasive paediatric extracorporeal circulation. From conception to clinical application
P. Curcic, I. Knez, I. Ovcina, J. Krumnikl, T. Marko, H. Suppan, H. Mächler, D. Dacar (Austria)

14:30
Tissue engineering of the right heart outflow tract by a cell-seeded bioabsorbable poly-l-lactic acid valved tube
D. Kalfa, M. Bon, V. Vanneaux, V. Bellamy, J. Larghero, P. Bruneval, P. Menasché (France)

14:45
Nanotechnology-engineered decellularized xenogeneic tissues: new replacement options for the treatment of heart valve failure in paediatric and adult patients
L. Iop, P. Aguiari, S. Facciolo, F. Naso, T. Bottio, M. Dettin, G. Gerosa (Italy)

15:00
Genetic basis of hypoplastic left heart syndrome: molecular defects interfering with development of valvular and ventricular chambers
D. Federici, M. E. Sana, L. Galletti, D. Marchetti, L. Pezzoli, S. Marcora, M. Iascone, P. Ferrazzi (Italy)

15:15
Spinal arteriogenesis: a large animal model
F. A. Kari1, K. Förster1, M. Siepe1, U. Göbel1, R. B. Griep2, F. Beyersdorf3
(1Germany, 2United States)

15:30
Pathogenetic role of endothelial nitrous oxide synthase uncoupling in pulmonary ischaemia and reperfusion injury
J. F. Gielis, T. Van Assche, J. Hendriks, P. Lauwers, P. Cos, P. Van Schil (Belgium)
Cardiovascular Simulator Award

Moderators: P. Cartwright, Leeds; J. R. Sádaba, Pamplona

12:00
Welcome and overview of Cardiovascular Simulator Award initiative
J. R. Sádaba (Pamplona)

12:05
Simulation in surgical training
M. Umezu (Tokyo)

12:20
Valladolid simulator & DTL platform
M. Palata (Prague)

12:30
2012 Cardiovascular Simulator Award: introduction
P. Sergeant (Leuven)

12:35-13:30
2012 submission presentations (strictly 5 minutes each): all applicants to supply standard slides/format to time is controlled

Scholars

13:30
Jury deliberations
(Jury/all)

13:45
Winner announcement & close
J. R. Sádaba (Pamplona)
PASCaTS/EACTS Global Forum. Challenges of cardiothoracic surgery in the developing world: palliation to repair procedures

*Moderators: F. Fynn-Thompson, Boston; J. Pomar, Barcelona*

**14:15**
Welcome
*W. Koen (Cape Town)*

**14:20**
Challenges of integrating a new cardiac programme into a tertiary healthcare system in the developing world: Ghana experience
*F. Fynn-Thompson (Kumasi/Boston)*

**14:30**
Challenges of integrating a new cardiac programme into a tertiary healthcare system in the developing world: Rwanda experience
*R. Bolman III (Kigali/Boston)*

**14:40**
Challenges of integrating a new cardiac programme into a tertiary healthcare system in the developing world: Palestinian experience
*B. Sethia (East Jerusalem/London)*

**14:50**
The changing profile of rheumatic valve disease: patient survival after mechanical valve replacement versus repair in South Africa
*F. Smit (Bloemfontein)*

**15:05**
Surgical options for end-stage cardiomyopathy in South Africa: 12-year experience
*W. Koen (Cape Town)*

**15:20**
Round table discussion:
Sustainable cardiac programmes in the developing world: priority of action
*D. Anderson¹, F. Fynn-Thompson², J. Pomar³, B. Sethia¹ (¹London, ²Boston, ³Barcelona)*

**15:40**
Concluding remarks
*C. Mestres (Barcelona)*
Teach the teacher

Moderator: J. R. Pepper, London; J. Maessen, Rotterdam

14:15
Debate: “This house believes that we can train cardiac surgeons within the rules of EWTD”
Pro: P Sergeant (Leuven)
Con: A Simon (London)
Chair: Tim Graham (Birmingham)

14:45
The supervision of training in the Netherlands
J Maessen (Rotterdam)

15:00
Building a national selection programme
S. Hunter (Middlesbrough)

15:10
The trainee’s view:
W. van Leeuwen (Rotterdam)

15:20
Training for an academic career
D. Pagano (Birmingham)

15:30
Explanation of interactive activities
J. R. Pepper (London)

The patient keeps getting sicker: what do I do next?

Moderators: L. Hamilton, Newcastle upon Tyne; J.R. Sádaba, Pamplona

Speakers:
S. Nashef (Cambridge)
P. Rajesh (Birmingham)
R. Lorusso (Brescia)
Acknowledgements

The EACTS acknowledges the generous support of the Techno-College by unrestricted educational grants from the organisations listed:

Edwards Lifesciences SA
Medtronic International Trading Sàrl

Abbott Vascular International BVBA
Bioventrix Inc
Correx Inc
HeartWare Inc
NeoChord Inc
St Jude Medical
Symetis SA

BioStable Science & Engineering, Inc
ESTECH Inc
Sunshine Heart
Valtech Cardio

Kips Bay Medical Inc
Techno-College

M. Enriquez-Sarano (USA)
Advanced imaging and image fusion for valve therapies
Relationship Disclosure: Valtech (Consultant); Abbot Vascular (Research)

A. Wechsler (USA)
The Revivent device for less invasive ventricular enhancement
Relationship Disclosure: Bioventrix (Consultant)

G. Speziali (USA)
Transapical off pump mitral valve repair
Relationship Disclosure: Neochord

Presidential Address
L. K. von Segesser (Switzerland)
Smartcanula LLC (founder), Symetis SA (shareholder), Mitralflex SA (shareholder)

Scientific Abstracts

008  Direct percutaneous transapical left ventricular Puncture: feasibility and prediction study using Computed tomography coronary angiography
T. Modine, M. Kilani, G. Fayad, J. M. Elarid, M. Koussa, J. P. Beregi (France)
Relationship Disclosure: Thomas Modine and Jean Paul Beregi are Consultants for Medtronic.

013  Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of coronary artery bypass grafting and percutaneous coronary intervention in the syntax study
A. P. Kappetein, S. Head, M. Morice, A. Banning, P. Serruys, F. Mohr, K. Dawkins, M. Mack (Netherlands, France, United Kingdom, Germany, United States)
Relationship Disclosure: Boston Scientific sponsored the SYNTAX study.

017  Distal anastomosis patency of the cardica c-port® system versus the hand-sewn technique: a prospective randomized controlled study in patients undergoing coronary artery bypass grafting
N. Verberkmoes, S. Wolters, J. Post, M. Soliman-Hamad, F. Ter Woorst, E. Berreklouw (Netherlands)
Relationship Disclosure: Part of this work is funded by Cardica Inc. The company distributed C-Port for free and funded our research nurse to arrange logistics of the study.

022  Durability of epicardial ventricular restoration without ventriculotomy
A. Wechsler, J. Sadowski, B. Kapelak, K. Bartus, G. Kalinauskas, K. Rucinskas, R. Samalavicius, L. Annest (United States, Poland, Lithuania)
Relationship Disclosure: A. Wechsler is a consultant to Bioventrix; L. Annest is Chief Medical Officer for Bioventrix.
033 Open aortic arch replacement in the era of endovascular techniques
P. Urbanski, M. Raad, A. Lenos, P. Bougioukakis, M. Zacher, A. Diegeler (Germany)

Relationship Disclosure: Dr. Urbanski discloses a financial relationship with Maquet Intervascular Company.

051 Transapical access closure: the tap plug device
C. Huber, H. Brinks, V. Gober, F. Nietlisbach, P. Wenaweser, B. Meier, L. Englberger, T. Carrel (Switzerland)

Relationship Disclosure: Dr. Huber is Proctor for Edwards Lifesciences and Consultant for Medtronic.

055 Systematic transaortic approach for transcatheter aortic valve implantation: a valid alternative to transapical access in patients with no peripheral vascular option. one year single-centre experience
M. Romano, K. Hayashida, T. Lefevre, T. Hovasse, B. Chevalier, D. Le Houerou, A. Farge, M. Morice (France)

Relationship Disclosure: M. Romano, Proctor, Edwards Lifesciences; T. Lefèvre, Proctor Edwards Lifesciences.

063 Long-term results with a total artificial heart: is it prime time for destination therapy?
G. Gerosa, G. Torregrossa, P. Leprince, F. Beyersdorf, R. Hetzer, J. Gummert, D. Duveau, J. Copeland (Italy, France, Germany, United States)

Relationship Disclosure: Pascal Leprince, Proctor, Syncardia; Daniel Duveau, Proctor Syncardia; Jack Copeland, relationship with Syncardia Systems.

065 Circulatory support in elderly chronic heart failure patients using the circulite® synergy® system
A. Barbone, F. Rega, D. Ornaghi, E. Vitali, B. Meyns (Italy, Belgium)

Relationship Disclosure: Bart Meyns, Circulite Scientific, Medical Advisor and grant/research support; Filip Rega, CircuLite grant/research support; Alessandro Barbone, CircuLite grant/research support; Diego Ornaghi, CircuLite grant/research support; Ettore Vitali, CircuLite grant/research support.

070 Clinical outcomes through six months in patients with degenerative mitral regurgitation treated with the Mitraclip® device in the access-Europe phase I trial
F. Maisano, O. Franzen, S. Baldus, J. Hausleiter, C. Butter, U. Schaefer, G. Pedrazzini, W. Schillinger (Italy, Denmark, Germany, Switzerland)

Relationship Disclosure: Abbott Vascular Structural Heart: Modest research/research grants.

080 Enzyme-linked immunosorbent spot for monitoring of postoperative immununospression of patients with lung cancer
P. Rybojad, A. Jabłonka, B. Wilczyńska, J. Tabarkiewicz (Poland)

Relationship Disclosure: This research was supported by grants from the Polish Ministry of Science and Higher Education: NN403 199637 and NN402 474037.

105 One-stage repair in complex multisegmental thoracic aneurysmal disease: results of a multicentre study
C. Mestres, K. Tsagakis, D. Pacini, R. Di Bartolomeo, M. Grabenwoger, M. Borger, R. Bonser, H. Jakob (Spain, Germany, Italy, Austria, United Kingdom)

Relationship Disclosure: Dr. Jakob discloses that he has a financial relationship with Jotec GmbH.
Aortic valve replacement in geriatric patients with small aortic roots: are sutureless valves the future?
M. Shrestha, K. Hoeftler, I. Maeding, L. Hannelore, B. Borchert, B. Christoph, S. Sarikouch, A. Haverich (Germany)

Relationship Disclosure: Perceval valves were implanted as a part of a multicentre European study. The institution received unrestricted grant from Sorin for the conduct of the study. M. Shrestha has a consultant contract (Speaker, Proctor) with Sorin.

Fate of the distal true lumen after stent-grafting for type IIIb aortic dissection: a word of caution
F. Dagenais, P. Voisine, S. Mohammadi, E. Dumont (Canada)

Relationship Disclosure: Francois Dagenais: Consultant for Medtronic Inc.

Hybrid approach for the treatment of long-standing persistent atrial fibrillation: electrophysiological findings and clinical results
C. Muneretto, G. Bisleri, L. Bonnettempi, F. Rosati, A. Curnis (Italy)

Relationship Disclosure: Drs. Muneretto and Bisleri disclose a financial interest with Estech (Consultants, Proctors).

Valve-sparing aortic root repair in acute type a aortic dissection: how many sinuses have to be repaired?
P. Urbanski, H. Hijazi, W. Dinstak, A. Diegeler (Germany)

Relationship Disclosure: Dr Urbanski discloses a financial relationship with Maquet InterVascular.

Re-repair of the mitral valve for early and late recurrent mitral regurgitation after mitral valve repair
A. Anyanwu, S. Itagaki, R. Varghese, J. Castillo, J. Chikwe, D. Adams (United States)

Relationship Disclosure: David Adams receives royalties from Medtronic and Edwards Lifesciences.

A systematic surgical strategy to attempt repair of anterior mitral leaflet prolapse for degenerative disease yields a near-100% repair rate
J.G. Castillo, A. Anyanwu, D. Adams (United States)

Relationship Disclosure: David H Adams serves as a Consultant and inventor for Edwards Lifesciences and Medtronic.

The risks associated with the transfusion of various blood products in aortic valve replacement
H. Bjursten, A. Dardahstti, B. Bronden, P. Ederoth, L. Algotsson (Sweden)

Relationship Disclosure: Henrik Bjursten has a vested interest in ErySaveAB (a start-up company working on autologous blood salvage). Lars Algotsson lectures for Orion PharmaAB and Abbott Scandinavia AB. The other authors have no conflicts of interest to report.

Iatrogenic type A aortic dissection: insight from the German registry for acute aortic dissection type A
B. Ryslki, I. Hoffmann, F. Beyersdorf, M. Sudkamp, M. Siepe, B. Nitsch, M. Blettner, E. Weigang (Germany)

Relationship Disclosure: Maria Blettner is a Consultant for AstraZeneca.
200 Clinical experience with the current circulite® synergy® system in chronic ambulatory heart failure
B. Meyns, F. Rega, A. Barbone, D. Ornaghi, M. Strueber, J. Schmitto, A. Simon, E. Vitali (Belgium, Italy, Germany, United Kingdom)

Relationship Disclosure: Bart Meyns, Circulite Scientific, Medical Advisor and grant/research support; Filip Rega, Circulite grant/research support; Alessandro Barbone, Circulite grant/research support; Diego Ornaghi, Circulite grant/research support; Andre Simon, Circulite grant/research support.

209 Experimental evaluation of a new system for laser tissue welding applied to damaged lung
M. Schiavon, G. Marulli, A. Zuin, F. Calabrese, C. Breda, M. Loy, S. Nicotra, F. Rea (Italy)

Relationship Disclosure: Dr. Schiavon, Dr. Marulli and Prof. Rea are owners of the patent PCT/IB2006/003382 A method for the Pulmonary aerostasis and a device for its application.

212 Adverse impact of pulmonary hypertension on postoperative course and survival after transapical aortic valve implantation
S. Buz, M. Pasic, A. Unbehaun, T. Drews, S. Dreyssse, M. Kukucka, A. Mladenow, R. Hetzer (Germany)

Relationship Disclosure: Prof. Pasic, Drs. Unbehaun, Drews, Buz and Dreyssse have been Proctors to Edwards Lifesciences since July 2009. There are no other disclosures.

253 Active mitral ring for continual post-surgery remote and reversible correction of residual mitral regurgitation on the beating heart
P. Tozzi, D. Locca, F. Gronchi, D. Hayoz, E. Ferrari, L. von Segesser, R. Hullin (Switzerland)

Relationship Disclosure: Study partially funded by Mitralflex Sàrl. P Tozzi Mitralflex shareholder; D. Locca none; F. Gronchi none; D. Hayoz Mitralflex shareholder; E. Ferrari none; L. von Segesser Mitralflex shareholder; R. Hullin none.

255 Improving mitral valve coaptation with adjustable rings: outcomes from the European multicentre feasibility study with a new-generation adjustable annuloplasty ring system
F. Maisano, V. Falk, M. Borger, H. Vanermen, O. Alfieri, J. Seeburger, M. Mack, F. Mohr (Italy, Switzerland, Germany, Belgium, United States)

Relationship Disclosure: All authors except F. Mohr are consultants for ValtechCardio or receive grants from ValtechCardio.

285 Elevated levels of preoperative interleukin-6 affect monocyte activation and multi-organ failure in left ventricular assist device patients
L. Botta, R. Caruso, J. Campolo, A. Cannata, F. Milazzo, M. Frigerio, L. Martinelli, O. Parodi (Italy)

Relationship Disclosure: This study has been performed as part of the European Study “SensorART: A remote controlled Sensorized Artificial heart enabling patients empowerment and new therapy approaches”
286  Is antiplatelet therapy needed in continuous flow left ventricular assist device patients? a single-centre experience
P. Litzler, H. Smail, V. Barbay, C. Nafeh-Bizet, M. Redonnet, J. Baste, F. Bouchart, J.P. Bessou (France)

Relationship Disclosure: P.Y. Litzler and J.P. Bessou report consulting fees from Thoratec.

LB 001  The Engager transapical aortic valve implantation system: first results from the multicentre European pivotal trial
H. Treede, S. Baldus, A. Linke, D. Holzhey, S. Bleiziffer, J. Borgermann, J.-L. Vanoverschelde, V. Falk (Germany, Belgium, Switzerland)

Relationship Disclosure: All authors were Participating Investigators in the Engager European Pivotal Trial sponsored by Medtronic.

LB 005  First-in-man evaluation of the new apica asc™ transapical access and closure device
J. Blumenstein, J Kempfert, A Van Linden, WK Kim, H Moellmann, V Thourani, T Walther (Germany, United States)

Relationship Disclosure: Vinod Thourani, discloses that he is Co-founder and has a financial relationship with Apica Cardiovascular Limited. All other authors have nothing to disclose.

LB 007  Prevention of sternal wound complications after sternotomy: results from a large prospective randomized multicentre trial
M. Gorlitzer, F. Wagner, S. Pfeiffer, S. Folkmann, J. Meinhart, T. Fischlein, H. Reichenspurner, M. Grabenwoger (Austria, Germany)

Relationship Disclosure: This work is funded by Medical Scientific Fund of the Mayor of the City of Vienna.

LB 010  Triclosan-coated sutures reduce surgical site infections after open vein harvesting in coronary artery bypass graft patients: a prospective randomized controlled trial
A. Jeppsson, L. Thimour-Bergstrom, T. Gudbjartsson, C. Aneman, O. Friberg (Sweden, Iceland)

Relationship Disclosure: The study is an investigator-initiated and investigator-driven study performed with financial support from Ethicon. The study sponsor had no influence on the analysis and interpretation of data, in the writing of the abstract, or in the decision to submit
### Satellite Meetings

**Monday 29 October, 12:45-14:00**

<table>
<thead>
<tr>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abbot Vascular International BVBA</strong> Scrub-in with MitraClip</td>
<td>Rooms 122/123</td>
</tr>
<tr>
<td><strong>Berlin Heart</strong> EXCOR® Pediatric – Standard in Treating Children</td>
<td>Rooms 127/128</td>
</tr>
<tr>
<td>with Severe Heart Failure</td>
<td></td>
</tr>
<tr>
<td><strong>Coroneo Inc</strong> Aortic Valve Repair</td>
<td>Rooms 131/132</td>
</tr>
<tr>
<td><strong>Edwards Lifesciences SA</strong> 50 years of AVR and 10 years of TAVI</td>
<td>Room 112</td>
</tr>
<tr>
<td><strong>JOTEC GmbH</strong> The Future of Aortic Surgery</td>
<td>Rooms 120/121</td>
</tr>
<tr>
<td><strong>Maquet Cardiovascular</strong> Advances in Less Invasive Coronary Artery</td>
<td>Rooms 118/119</td>
</tr>
<tr>
<td>Bypass Grafting (CABG): Delivering Superior Clinical Outcomes</td>
<td></td>
</tr>
<tr>
<td>with Reduced Morbidity</td>
<td></td>
</tr>
<tr>
<td><strong>Medistim ASA</strong> Clinical and economic outcomes from implementing</td>
<td>Room 124</td>
</tr>
<tr>
<td>quality assessment procedures in coronary revascularization</td>
<td></td>
</tr>
<tr>
<td><strong>Medtronic International Trading Sàrl</strong> After more than 1,000</td>
<td>Room 113</td>
</tr>
<tr>
<td>implants with the 3f Enable valve, what have we learned?</td>
<td></td>
</tr>
<tr>
<td><strong>Sorin Group</strong> The Future of Cardiac Surgery is MICS</td>
<td>Room 114</td>
</tr>
<tr>
<td><strong>St Jude Medical</strong> Aortic Stenosis: Treatment Options and</td>
<td>Room 111</td>
</tr>
<tr>
<td>Perspectives</td>
<td></td>
</tr>
<tr>
<td><strong>Symetis SA</strong> ACURATE TA™: The Self-Positioning TAVI Technology</td>
<td>Rooms 129/130</td>
</tr>
<tr>
<td><strong>Vascutek Ltd</strong> Innovative Product Designs and Emerging</td>
<td>Rooms 133/134</td>
</tr>
<tr>
<td>Implantation Techniques</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday 30 October, 12:45-14:00

<table>
<thead>
<tr>
<th>Company/Institution</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxter Healthcare SA</td>
<td>124</td>
</tr>
<tr>
<td>Current Principles and Practices to Minimize the Need for Blood Transfusion in Cardiac Surgery</td>
<td></td>
</tr>
<tr>
<td>B Braun Surgical SA</td>
<td>133/134</td>
</tr>
<tr>
<td>New Trends on Valve Repair</td>
<td></td>
</tr>
<tr>
<td>Edwards Lifesciences SA</td>
<td>112</td>
</tr>
<tr>
<td>Choosing between different heart valves: What is durability data telling us?</td>
<td></td>
</tr>
<tr>
<td>JenaValve Technology GmbH</td>
<td>122/123</td>
</tr>
<tr>
<td>TAVI - Answers to questions you always wanted to ask - The Great Debate</td>
<td></td>
</tr>
<tr>
<td>Medos AG</td>
<td>129/130</td>
</tr>
<tr>
<td>Unmet Clinical Needs in Cardiac Surgery in 2012</td>
<td></td>
</tr>
<tr>
<td>Medtronic International Trading Sàrl</td>
<td>113</td>
</tr>
<tr>
<td>Introducing the Next Generation TAVI platform</td>
<td></td>
</tr>
<tr>
<td>Neomend</td>
<td>125</td>
</tr>
<tr>
<td>Neomend Progel® technology: a novel surgical sealant and adhesion barrier.</td>
<td></td>
</tr>
<tr>
<td>Philips Healthcare</td>
<td>120/121</td>
</tr>
<tr>
<td>Imaging Horizons in the Hybrid OR</td>
<td></td>
</tr>
<tr>
<td>Siemens AG Healthcare Sector</td>
<td>131/132</td>
</tr>
<tr>
<td>Innovations for the hybrid OR in CTVS</td>
<td></td>
</tr>
<tr>
<td>Sorin Group</td>
<td>114</td>
</tr>
<tr>
<td>Realities in Clinical Outcomes After AVR</td>
<td></td>
</tr>
<tr>
<td>St Jude Medical</td>
<td>111</td>
</tr>
<tr>
<td>Sizing in Valve Repair: Less Proximation - More Accuracy</td>
<td></td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth No:</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>A&amp;E Medical Corporation</td>
<td>27</td>
</tr>
<tr>
<td>AATS-American Association For Thoracic Surgery</td>
<td>39</td>
</tr>
<tr>
<td>Abbott Vascular International BVBA</td>
<td>115</td>
</tr>
<tr>
<td>Andocor NV</td>
<td>17</td>
</tr>
<tr>
<td>Asanus Medizintechnik GmbH</td>
<td>28/29</td>
</tr>
<tr>
<td>Atricure Europe BV</td>
<td>45</td>
</tr>
<tr>
<td>B Braun Surgical SA</td>
<td>114</td>
</tr>
<tr>
<td>Baxter Healthcare SA</td>
<td>13/14</td>
</tr>
<tr>
<td>Berlin Heart GmbH</td>
<td>82</td>
</tr>
<tr>
<td>BioCer Entwicklungs-GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Biomet Microfixation</td>
<td>12</td>
</tr>
<tr>
<td>Bioventrix Inc</td>
<td>92/93</td>
</tr>
<tr>
<td>Bolton Medical</td>
<td>129</td>
</tr>
<tr>
<td>Braceplus/Slimstones BV</td>
<td>80</td>
</tr>
<tr>
<td>Cardia Innovation AB</td>
<td>70</td>
</tr>
<tr>
<td>Cardiamed BV</td>
<td>125</td>
</tr>
<tr>
<td>Cardio Medical GmbH</td>
<td>10</td>
</tr>
<tr>
<td>CareFusion</td>
<td>53</td>
</tr>
<tr>
<td>Casmed</td>
<td>90</td>
</tr>
<tr>
<td>Chase Medical</td>
<td>133</td>
</tr>
<tr>
<td>Circulite Inc</td>
<td>4-8</td>
</tr>
<tr>
<td>Cook Medical</td>
<td>59-6w1</td>
</tr>
<tr>
<td>CorMatrix Cardiovascular Inc</td>
<td>31</td>
</tr>
<tr>
<td>Coroneo Inc</td>
<td>122</td>
</tr>
<tr>
<td>Correx Inc</td>
<td>24</td>
</tr>
<tr>
<td>Cryolife Europa Ltd</td>
<td>79</td>
</tr>
<tr>
<td>CTSNet</td>
<td>37</td>
</tr>
<tr>
<td>Delacroix-Chevalier</td>
<td>117</td>
</tr>
<tr>
<td>Dendrite Clinical Systems Ltd</td>
<td>98/99</td>
</tr>
<tr>
<td>DePuy Synthes</td>
<td>123</td>
</tr>
<tr>
<td>EACTS - The European Association For Cardio-Thoracic Surgery</td>
<td>35</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>104</td>
</tr>
<tr>
<td>Estech Inc</td>
<td>107-109</td>
</tr>
<tr>
<td>Ethicon - Johnson &amp; Johnson</td>
<td>120</td>
</tr>
<tr>
<td>Euromacs</td>
<td>112</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth No:</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Eurosets SRL</td>
<td>78</td>
</tr>
<tr>
<td>Fehling Instruments GmbH &amp; Co KG</td>
<td>118</td>
</tr>
<tr>
<td>Geister Medizintechnik GmbH</td>
<td>34</td>
</tr>
<tr>
<td>Genesee Biomedical Inc</td>
<td>119</td>
</tr>
<tr>
<td>Geomed Medizin-Technik GmbH &amp; Co KG</td>
<td>69</td>
</tr>
<tr>
<td>Gunze Limited</td>
<td>23</td>
</tr>
<tr>
<td>Hamamatsu Photonics France</td>
<td>68</td>
</tr>
<tr>
<td>Heart And Health Foundation</td>
<td>72</td>
</tr>
<tr>
<td>Heart Hugger / General Cardiac Technology</td>
<td>26</td>
</tr>
<tr>
<td>Heartware Inc</td>
<td>32</td>
</tr>
<tr>
<td>Integra Lifesciences</td>
<td>11</td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>100/101</td>
</tr>
<tr>
<td>ISMICS-International Society For Minimally Invasive</td>
<td></td>
</tr>
<tr>
<td>Cardiothoracic Surgery</td>
<td>38</td>
</tr>
<tr>
<td>Jarvik Heart Inc</td>
<td>81</td>
</tr>
<tr>
<td>JenaValve Technology GmbH</td>
<td>63/64</td>
</tr>
<tr>
<td>Jotec GmbH</td>
<td>121</td>
</tr>
<tr>
<td>Karl Storz GmbH &amp; Co KG</td>
<td>43/47</td>
</tr>
<tr>
<td>KLS Martin Group</td>
<td>94/95</td>
</tr>
<tr>
<td>Labcor Laboratorios Ltda</td>
<td>51</td>
</tr>
<tr>
<td>Lepu Medical Technology (Beijing) Co Ltd</td>
<td>66</td>
</tr>
<tr>
<td>LSI Solutions</td>
<td>110/111</td>
</tr>
<tr>
<td>Mani Inc Japan</td>
<td>102</td>
</tr>
<tr>
<td>Maquet Cardiopulmonary AG</td>
<td>86</td>
</tr>
<tr>
<td>Master Surgery Systems AS</td>
<td>15</td>
</tr>
<tr>
<td>MDD Medical Device Development GmbH</td>
<td>74</td>
</tr>
<tr>
<td>Medafor Inc</td>
<td>3</td>
</tr>
<tr>
<td>Medex Research Ltd</td>
<td>65</td>
</tr>
<tr>
<td>Medistim ASA</td>
<td>116</td>
</tr>
<tr>
<td>Medos AG</td>
<td>40</td>
</tr>
<tr>
<td>Medtronic International Trading Sàrl</td>
<td>105</td>
</tr>
<tr>
<td>Micardia Corporation</td>
<td>88/89</td>
</tr>
<tr>
<td>Micromed CV</td>
<td>9</td>
</tr>
<tr>
<td>Neochord Inc</td>
<td>67</td>
</tr>
<tr>
<td>Neomend Inc</td>
<td>131</td>
</tr>
<tr>
<td>On-X Life Technologies Inc™</td>
<td>42</td>
</tr>
<tr>
<td>Oxford University Press</td>
<td>30</td>
</tr>
<tr>
<td>Peters Surgical</td>
<td>124</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth No:</td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Praesidia Srl</td>
<td>62</td>
</tr>
<tr>
<td>Qualitemp Srl</td>
<td>128</td>
</tr>
<tr>
<td>Redax Srl</td>
<td>25</td>
</tr>
<tr>
<td>Rumex International Co</td>
<td>18</td>
</tr>
<tr>
<td>Sanofi Biosurgery</td>
<td>71</td>
</tr>
<tr>
<td>Scanlan International Inc</td>
<td>33</td>
</tr>
<tr>
<td>Siemens AG Healthcare Sector</td>
<td>87</td>
</tr>
<tr>
<td>Smartcanula LLC</td>
<td>91</td>
</tr>
<tr>
<td>Sorin Group</td>
<td>85</td>
</tr>
<tr>
<td>St Jude Medical</td>
<td>106</td>
</tr>
<tr>
<td>Starch Medical Inc</td>
<td>96</td>
</tr>
<tr>
<td>STS-The Society Of Thoracic Surgeons</td>
<td>36</td>
</tr>
<tr>
<td>Sunshine Heart</td>
<td>73</td>
</tr>
<tr>
<td>Symetis SA</td>
<td>41</td>
</tr>
<tr>
<td>Syncardia Systems Inc</td>
<td>126/127</td>
</tr>
<tr>
<td>Terumo Europe Cardiovascular Systems (TECVS)</td>
<td>77</td>
</tr>
<tr>
<td>The Society For Heart Valve Disease</td>
<td>103</td>
</tr>
<tr>
<td>Thoratec Corporation</td>
<td>113</td>
</tr>
<tr>
<td>Tianjin Plastics Research Institute Co Ltd (TPRI)</td>
<td>55</td>
</tr>
<tr>
<td>TransMedics Inc</td>
<td>132</td>
</tr>
<tr>
<td>Transonic Systems Europe BV</td>
<td>19</td>
</tr>
<tr>
<td>Valvexchange Inc</td>
<td>130</td>
</tr>
<tr>
<td>Wexler Surgical Inc</td>
<td>20/21</td>
</tr>
<tr>
<td>Wisepress Online Bookshop</td>
<td>1/2</td>
</tr>
<tr>
<td>WL Gore &amp; Associates GmbH</td>
<td>97</td>
</tr>
</tbody>
</table>
A&E Medical Corporation
2310 South Miami Boulevard, Suite 240
Durham, NC 27703, USA
Tel: +1-9193619191 Fax: +1-9193619991
Email: ed.degler@aemedical.com; Web: www.aemedical.com
A&E Medical products include the MYO/Wire® temporary pacing wires designed to provide secure placement and ease of removal. The more pliable MYO/Wire II monofilament wire conforms to the contours of the sternum and is less prone to breakage during tightening. The MYO/Punch rotating surgical punch is designed to cut a clean and round hole. The Doublewire high strength sternal closure system is designed for obese, COPD, diabetic, and other sternal dehiscence high risk patients. Country of origin: USA

AATS-American Association For Thoracic Surgery
500 Cummings Center, Suite 4550
Beverly, MA 01915, USA
Tel: +1-9789278330
Email: meaton@aats.org; Web: www.aats.org
Founded in 1917 by the earliest pioneers in the field of thoracic surgery, the American Association for Thoracic Surgery (AATS) is now an international organization of over 1300 members consisting of the world’s foremost cardiothoracic surgeons representing 37 countries. The Annual Meeting, research grants and awards, educational symposia and courses, and the AATS official journal, the Journal of Thoracic and Cardiovascular Surgery all strengthen the commitment to its mission of Promoting Scholarship in Thoracic and Cardiovascular Surgery.

Abbott Vascular International BVBA
Park Lane, Culliganlaan 2B
1831 Diegem, Belgium
Tel: +32-27141591 Fax: +32-27141232
Email: els.maes@av.abbott.com; Web: www.abbottvascular.com
Abbott Vascular, a division of global health care company Abbott, is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

Andocor NV
Kwikaard 104
2980 Zoersel, Belgium
Tel: +32-33801595 Fax: +32-33801590
Email: info@andocor.com; Web: www.andocor.com
Andocor is a company that designs and manufactures cardiovascular cannulae and catheters used during open-heart surgery. Beside our standard brand products, we also offer OEM services.

Asanus Medizintechnik GmbH
Take off Gewerbepark 2
78579 Neuhausen ob Eck, Germany
Tel: +49-7467947414 Fax: +49-7467947450
Email: ercan.kenar@asanus.de; Web: www.asanus.de
Asanus is a powerful complete supplier for more than 18,000 different surgical and minimally invasive instruments for the areas visceral surgery, cardio thoracic surgery, vascular surgery, microsurgery, neurosurgery, ophthalmology and others. With the development of sectoral software for sterile products management, the logistics and the quality management linked with the integral service in the process management of sterile goods, Asanus has developed its business activities in the surgical area and has adapted according to the market needs.
Atricure Europe BV
Schiphol Boulevard 127 Tower A, Room 3.10
1110 BG Schiphol, Netherlands
Tel: +31-201005560 Fax: +31-207005561
Email: EdeBoer@atricure.com; Web: www.atricure.com

AtriCure, Inc. is focused on innovative RF and cryothermia surgical ablation systems for the treatment of atrial fibrillation. AtriCure's unique method of RF energy titration creates precise low-heat, low energy lesions on cardiac tissue. AtriCure also received CE Mark approval to market the AtriClip for LAA exclusion.

B. Braun Surgical SA
Carretera de Terrassa, 121
8191 Rubi, Spain
Tel: +34-935866452 Fax: +34-936996330
Email: closure.technologies@bbraun.com; Web: www.bbraun.com

B. Braun is one of the world's leading healthcare suppliers and has been standing for quality and reliability for more than 170 years. Aesculap, as one of the company's most important divisions, offers complete solutions for all core processes in the operating theatre. We are specially focused in cardiovascular surgery with a product range that includes surgical instruments, sutures and haemostats, as well as various power, navigation and container systems.

Baxter Healthcare SA
Postfach
8010 Zurich, Switzerland
Tel: +41-448786609 Fax: +41-448786378
Email: steffen_schieteringer@baxter.com; Web: www.baxter.com

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Berlin Heart GmbH
Wiesenweg 10
12247 Berlin, Germany
Tel: +49-3081872650
Email: schubert@berlinheart.de; Web: www.berlinheart.com

Berlin Heart is the only company worldwide that develops, produces, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size. EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. INCOR® is an implantable axial-flow LVAD for adults. The Berlin Heart EXCOR® Pediatric VAD is approved for use by the FDA under a Humanitarian Device Exemption. All other products are not FDA approved.

BioCer Entwicklungs-GmbH
Ludwig-Thoma Strasse 36c
95447 Bayreuth, Germany
Tel: +49-9217877700 Fax: +49-92178777079
Email: info@biocer-gmbh.de; Web: www.biocer-gmbh.de

HaemoCer™ Absorbable Polysaccharide Hemostat (APH) is a proprietary patent pending technology created via BioCer's Polysaccharide Ultra-Hydrophilic Resorbable Engineering (PURE) process. HaemoCer™ APH incorporates a sophisticated, plant-based polymer crosslinking that creates ultra-hydrophilic, biocompatible particles. Upon contact with blood HaemoCer™ enhances the natural clotting cascade by rapidly dehydrating the blood and accelerating the concentration of platelets, red blood cells and coagulation proteins at the bleeding site.
Biomet Microfixation is a leading global healthcare provider of orthopedic products. Our thoracic portfolio includes the Pectus Bar for repair of Pectus Excavatum and the SternaLock Blu Primary Closure System for sternal closure. The Blu System aligns and stabilizes the sternum after sternotomy and enables easier closure after minimally invasive access.

Bioventrix Inc is committed to improving upon the treatment of heart failure through the development of the Revivent™ Myocardial Anchoring System, a catheter-based approach for less invasive ventricular enhancement. The Revivent System enhances cardiac function without directly incising the heart and without the use of cardiopulmonary bypass, both of which can lead to post-operative adverse events. The Revivent System is designed to offer a less invasive, rapid recovery treatment that improves cardiac function and a patient’s quality of life.

Bolton Medical currently manufactures Relay Plus and Relay NBS Plus Thoracic Stent-Grafts. These products are indicated for the treatment of main thoracic aortic pathologies such as aneurysms, penetrating ulcers, pseudoaneurysms, and intramural hematomas in International Market. To date, approximately 6,000 Relay and Relay NBS Stent-Grafts have been implanted worldwide. Bolton anticipates The United States FDA approval of Relay in 2012.

BracePlus©: Extra confidence after sternotomy surgery. BracePlus© is an aid to support all patients in their recovery after sternotomy surgery, it is especially suitable for patients with COPD, obesity and sternum complications. It gives the patient confidence to cough and mobilise. Due to the unique and patented mechanism, controlled pressure is put onto the sternum. The stiffness and the stability of the product ensure that the healing sternum is perfectly supported.

Cardia Innovation AB is the manufacturer of CarbonAid CO2 diffuser used for de-airing during open heart surgery to prevent air embolism.
Cardiamed BV
P.O. Box 172
5460 AD Veghel, Netherlands
Tel: +31-413378554 Fax: +31-413353876
Email: info@cardiamed.com; Web: www.cardiamed.com

Cardiamed Rotating Heart Valve – Easy to Implant. CardiaMed is a joint-venture between MedEng and M.R. Medical. The headquarters of CardiaMed are based in the Netherlands. Both companies have many years of experience in producing and selling innovative medical devices. The patented CardiaMed prosthetic heart valve is the next step in the evolution of heart valve replacements. The leaflets, made of solid pyrolytic carbon, rotate freely inside the ring (patented) with every beat of the heart. No holes in the ring, so no washing problems.

Cardio Medical GmbH
Industriestr. 3A
D-30855 Langenhagen, Germany
Tel: +49-5117248548 Fax: +49-5117248550
Email: info@cardiomedical.de; Web: www.cardiomedical.de

Your innovative partner of medical technology. This year the company Cardio Medical GmbH celebrates its 18th anniversary. The company markets advanced medical quality products for cardiac, thoracic and vascular surgery under its own label Cardio Vision. It has been 6 years now that the company offers its high-tech surgical products for minimally invasive surgery and future technologies made in Germany.

CareFusion
Kantstrasse 33/1
78573 Wurmlingen, Germany
Tel: +49-74619650113 Fax: +49-74619650222
Email: alessandra.ilardo@CareFusion.com; Web: www.carefusion.com

At CareFusion, we are united in our vision to improve the safety and lower the cost of healthcare for generations to come.

Our products at EACTS:
PleurX catheter system provides effective at-home palliation of symptoms associated with recurrent pleural effusions and malignant ascites.
ChloraPrep skin antiseptic is a preferred patient preoperative skin prep for a variety of reasons. V.Mueller; for more than 115 years, V. Mueller instrumentation has been a leading developer, manufacturer and provider of surgical instruments and services.

Casmed
44 E. Industrial Rd
Branford, CT 6405 USA
Tel: +1-2033156331 Fax: +1-2034889438
Email: jnardella@casmed.com; Web: www.casmed.com

CASMED presents the innovative FORE-SIGHT Absolute Tissue Oximeter, a non-invasive device that provides immediate, reliable data for assessing a patient’s tissue oxygenation status. FORE-SIGHT is the first and only device in its class that provides a non-trend, absolute measure of tissue oxygen saturation for all patients, regardless of age or weight. Made in the USA.

Chase Medical
1876 Firman Drive
Richardson, TX 75081, USA
Tel: +1-9727837005 Ext. 212 Fax: +1-9722353446
Email: jbastasich@vannevargroup.com

Chase Medical group is dedicated to providing cardiac surgeons innovative devices and training to provide patients effective treatment options. The SVR System is one example of Vannevar’s Group innovative product development. Another is the Triumph System - an aortic balloon occlusion cannula used for minimally invasive valve procedures and all other arrested heart procedures. We also offer a complete line of beating heart products such as stabilizers, shunts, blower misters and apical lift devices to assist surgeons in off-pump CABG procedures.
Circulite Inc
Booth No: 4-8
250 Pehle Avenue Park 80 West, Suite 403
Saddle Brook, NJ 7663, USA
Tel: +1-2015432430 Fax: +1-2015432015
Email: mloeffler@circulite.com; Web: www.circulite.net

Circulite Inc. is developing disruptive solutions to improve the treatment of heart failure. The SYNERGY® Circulatory Assist System features a micro-blood pump that provides up to 4.25 L/min blood flow. SYNERGY is designed for long-term use in ambulatory heart failure patients who are not responding to standard medical treatment. The system is implanted in an off-pump mini-thoracotomy procedure and the pump is placed in a pacemaker-like pocket. In a clinical study, SYNERGY improved hemodynamics, exercise capacity, and overall quality of life.

Cook Medical
Booth No: 59-61
O’Halloran Road National Technology Park
Limerick, Ireland
Tel: +353-61250551 ext 2551 Fax: +353-61239420
Email: karen.gough@CookMedical.com; Web: www.cookmedical.com

Cook Medical Lead Management Division, the pioneering leader in lead extraction Technologies, invites attendees to view the newest, most innovative devices for lead removal including: EVOLUTION Mechanical Dilator Sheath, EVOLUTION-Shortie for vascular access during extraction procedures, BULLDOG Lead Extender for lumenless leads and the new LIBERATOR Beacon Tip Locking Stylet.

CorMatrix Cardiovascular Inc
Booth No: 31
286 S, Main St Suite 200
Alpharetta, GA 30009, USA
Tel: +1-6785662628 Fax: +1-6785662680
Email: ecm@cormatrix.com; Web: www.cormatrix.com

CorMatrix® Cardiovascular markets its ECM® Technology biomaterial devices for pericardial closure, cardiac tissue repair, and carotid repair and is currently conducting preclinical studies to evaluate future applications in heart failure as well as other cardiovascular applications.

Coroneo Inc
Booth No: 122
9250, Avenue du Parc Suite 514
Montreal, H2N 1Z2, Canada
Tel: +1-5143369230x202 Fax: +1-5143349778
Email: paolitto@coroneo.com; Web: www.coroneo.com

Coroneo provides unique devices that achieve less-invasive cardiac procedures. Featured will be: EXTRA-AORTIC Annuloplasty Ring to correct aortic insufficiency in valve repair surgery; COR-VALV System to enhance exposure during aortic & mitral valve surgery with fully-adaptable tissue retractors for both intercostal and sternotomy approaches; SWIFT-LOOP vessel loops with integral pledget for effective control of coronary blood flow during robotic and minimally invasive surgery; COR-VASC reusable stabilizer; and Titanium Pediatric Retractors.

Correx Inc
Booth No: 24
135 Beaver Street Suite 203
Waltham, MA 02452-8424, USA
Tel: +1-7818991130 Fax: +1-7818991134
Email: b.kenney@correxinc.com; Web: www.correxinc.com

Correx is a medical device company located in Waltham, Massachusetts, USA. Founded in 2004, Correx is commercializing minimally-invasive delivery instrumentation and implants to increase surgeon adoption of Aortic Valve Bypass (AVB) and to facilitate surgical treatment of other forms of structural heart disease. Our goal is to make Aortic Valve Bypass a standard of care for patients with critical aortic stenosis.
Cryolife Europa Ltd

Bramley House, The Guildway Old Portsmouth Road
GU3 1LR Guildford, UK
Tel: +44-1483441030 Fax: +44-1483452860
Email: brown.claire@cryolife.com; Web: www.cryolife.com

CryoLife; the leader in the processing and distribution of implantable living human tissues.
BioGlue® Surgical Adhesive which is used as sealant, adhesive and for tissue reinforcement is clinically proven in over 750,000 procedures.
PerClot®, the next generation haemostat. PerClot is a natural plant based haemostat that is simple to use and effective.
BioFoam® a unique mixed cell adhesive foam which creates haemostasis, delivered as a liquid it rapidly expands to form a haemostatic foam sealing tissue and promoting cell aggregation.

CTSNet

633 N. St. Clair St. 23rd Floor
Chicago, IL 60611-3658, USA
Tel: +1-3122025838 Fax: +1-3122025803
Email: dbennewitz@sts.org; Web: www.ctsnet.org

CTSNet (www.ctsnet.org) located in Chicago, IL, USA, is a unique professional international community of surgeons and medical professionals practicing in cardiothoracic surgery and related disciplines. CTSNet is the leading international source of online educational resources and research for cardiothoracic surgeons and associated medical professionals. CTSNet also hosts and supports the Websites of 50 professional cardiothoracic surgery organizations—including 32 international organizations.

Delacroix-Chevalier

Z.I. La Vendue BP 2152
52906 Chaumont Cedex 9, France
Tel: +33-325021032 Fax: +33-325021020
Email: fpicard@landanger.com; Web: www.delacroix-chevalier.com

Delacroix-Chevalier, the famous French instrument manufacturer since 1920, brings a constant stream of innovations to the market with an emphasis on the game changing Minimally Invasive Video Surgical Techniques for Heart & Lung surgeries. We thank you for enjoying daily use of our best-seller instruments and having warmly accepted our new MIS comprehensive instruments line. Please do visit our booth to discover more new and exciting devices.

Dendrite Clinical Systems Ltd

The Hub Station Road
Henley-on-Thames, RG9 1AY, UK
Tel: +44-1491411288 Fax: +44-1491411399
Email: finance@e-dendrite.com; Web: www.e-dendrite.com

Dendrite Clinical Systems is a specialist supplier of cardiac database systems for hospitals and national registries, with installations in over 40 countries around the globe. Dendrite has published the series of EACTS Adult Cardiac Surgical Database Reports and developed, and is currently hosting, the EUROMACS Registry for collecting data on mechanical circulatory support devices. Dendrite's flexible software can create a database for any clinical scenario and to track any outcome. Please visit BOOTH 98/99 for a software demonstration.

DePuy Synthes

Luzernstrasse 21
4528 Zuchwil, Switzerland
Tel: +41-327204060 Fax: +41-327204061
Email: info@synthes.com; Web: www.depuysynthes.com

The new DePuy Synthes Companies offer the world's most comprehensive portfolio of orthopaedic products and services for joint reconstruction, trauma, spine, sports medicine and cranio-maxillofacial therapies. DePuy Synthes Companies are also a global leader in neurological solutions with products and services for neurosurgery, neurovascular, spine and cranio-maxillofacial therapies.
<table>
<thead>
<tr>
<th><strong>EACTS</strong></th>
<th><strong>Booth No: 35</strong></th>
</tr>
</thead>
</table>
| The European Association For Cardio-Thoracic Surgery | EACTS House Madeira Walk  
Windsor, SL4 1EU, UK  
Tel: +44-1753832166 Fax: +44-1753620407  
Email: info@eacts.co.uk; Web: www.eacts.org |
| **Journals:** |  |
| EJCTS: European Journal of Cardio-Thoracic Surgery  
ICVTS: Interactive CardioVascular and Thoracic Surgery  
MMCTS: Multimedia Manual of Cardiothoracic Surgery |

<table>
<thead>
<tr>
<th><strong>Edwards Lifesciences</strong></th>
<th><strong>Booth No: 104</strong></th>
</tr>
</thead>
</table>
| Edwards Lifesciences | Route de l’Etraz 70  
1260 Nyon, Switzerland  
Tel: +41-2227874300 Fax: +41-227874347  
Email: Damien_mayor@edwards.com; Web: www.edwards.com |
| **Journals:** |  |
| EJCTS: European Journal of Cardio-Thoracic Surgery  
ICVTS: Interactive CardioVascular and Thoracic Surgery  
MMCTS: Multimedia Manual of Cardiothoracic Surgery |

<table>
<thead>
<tr>
<th><strong>Estech Inc</strong></th>
<th><strong>Booth No: 107-109</strong></th>
</tr>
</thead>
</table>
| Estech Inc | Groenendijk 39  
4926 RE Lage Zwaluwe, Netherlands  
Tel: +31-650298600 Fax: +31-168484790  
Email: fred.vanaart@planet.nl; Web: www.estech.com |
| **New!** Estech introduces the Bipolar/Monopolar COBRA FUSION probe for thoracoscopic AF ablation at the EACTS. The innovative technology applied in this product sets new standards in ablation. Visit our booth and ask for a demonstration. Estech develops and markets Cardiac Ablation, Valve Surgery and Off-Pump CABG Products. |

<table>
<thead>
<tr>
<th><strong>Ethicon -Johnson &amp; Johnson</strong></th>
<th><strong>Booth No: 120</strong></th>
</tr>
</thead>
</table>
| Ethicon -Johnson & Johnson | Leonardo Da Vinci Laan 20  
1831 Diegem, Belgium  
Tel: +32-477582624  
Email: lstorme@its.jnj.com; Web: www.ethicon.com |
| Ethicon, part of the Johnson & Johnson family of companies, is the worldwide leader in suture technology, and is one of the most recognizable and well-respected brand names in the hospital environment. The division has a long history of innovation in providing products - including sutures, topical adhesives - that enhance patient care. |
Euromacs unites individuals and institutions with the goal of running a European registry for data from patients with mechanical circulatory support systems. The data collected will then be made available for research purposes. Further, the registry will allow comparison between European and international data in the field of mechanical circulatory support. Euromacs is based in Berlin, Germany.

Founded in 1991, Eurosets is a leading manufacturer of medical devices for Cardiac Surgery. Located in the middle of the Italian biomedical district (Medolla MO).

Our product lines are:
Cardiopulmonary, Blood Management, Orthopaedic Drainage, OEM, Chest Drainage, Surgical Support, Wound Management

“Innovation and Technology for a better Patient outcome” is our mission and daily commitment to help the doctors to work in the best condition guaranteeing a whole tailored sanitary assistance.

Fehling Instruments is a traditional family-owned enterprise in the field of surgical instruments. Continuously striving to improve function and economy of products has led to outstanding innovations in material and design. The introduction of ceramic technologies was a major step towards perfection of surgical instruments which are subject to abrasion.

Efficient surgery. Less invasive. Optimum results. Our aim is to help develop technical innovations for evolving more patient friendly minimally invasive surgical procedures that yet can maintain or even exceed the long term results of proven conventional procedures. In close cooperation with surgeons and industry partners we are therefore advancing our comprehensive product range for Cardiovascular and Thoracic Surgery, with a focus on less traumatic, minimally invasive procedures, to restore the function of the heart.

Design beyond standard. Genesee BioMedical, Inc. based in Denver, Colorado develops and manufactures instruments and devices for cardiothoracic surgery. Unique Genesee products include sternal and thoracic retractors for adult and pediatric cardiac surgery, coronary artery graft markers, myocardial temperature probes and suture guards. All products are CE marked.
Geomed Medizin-Technik GmbH & Co KG
Ludwigstaler Strasse 27
78532 Tuttlingen, Germany
Tel: +49-7461935540 Fax: +49-7461935593
Email: marketing@geomed.de; Web: www.geomed.de

Geomed Medizin-Technik is one of the leading German manufacturer of Cardio Vascular, Thoracic and general surgery Instruments. For more than 85 years we are developing and manufacturing guaranteed high quality instruments. Due to our close co-operation with well-known international surgeons we are glad to offer our world-wide partners a wide and deep range of instruments, as well as various surgical sets. Geomed – The world of surgical instruments.

Gunze Limited
Nihonbashi 2-10-4
Tokyo, 103 0027, Japan
Tel: +81-332768718 Fax: +81-332768696
Email: kei.watanuki@gunze.co.jp; Web: www.gunze.co.jp/e/medical

Gunze Medical Division mainly manufactures and sells bioabsorbable medical devices using highly biocompatible polymers, and porcine derived collagen. We are the only company in Japan with such a comprehensive range of bioabsorbable medical materials and aim to move toward tissue engineering, which is attracting attention. “NEOVEIL” as bioabsorbable reinforcement felt and “GRANDFIX” as bioabsorbable bone fixation devices will be exhibited at our booth during the meeting. For more specific information, please visit our booth at your convenience.

Hamamatsu Photonics France
19, rue du Saule Trapu
BP 229 91882 Massy Cédex, France
Tel: +33-169537100 Fax: +33-169537110
Email: infos@hamamatsu.fr; Web: www.hamamatsu.fr

Hamamatsu Photonics is a world leader in the manufacturers of opto-electronic devices, including many for the medical market. The new NIRO-200NX Monitor enables the monitoring of the cerebral or systemic oxygenation. As it provides not only the oxygenation data but also can detect the haemodynamic functions in the tissue it is a perfect tool for monitoring and improvement of the patient management during cardiac surgery. Our NIRO monitors are routinely used in many hospitals.

Heart And Health Foundation
Bagdat Caddesi Akin Çıkmazi Sok. Kurtoglu Apt. No: 4/1
K:8 D:9 Suadiye, Istanbul, Turkey
Tel: +90-2164652722 Fax: +90-2164651058
Email: yaman.yamaner@marekon.org; Web: www.uccvs2013.org

Heart and Health Foundation of Turkey cordially invites you to the 9th International Congress of Update in Cardiology and Cardiovascular Surgery, on March 21 – 24, 2013 in Antalya, Turkey. The 9th congress will provide a significantly brilliant scientific programme for the delegates & the industry at a premium venue. Live broadcast sessions & interactive presentations from distinguished local & international institutions and presentations of experts of their fields will create a unique scientific environment.

Heart Hugger / General Cardiac Technology
6489 Camden Avenue #106
San Jose, CA 95120, USA
Tel: +1-4083952100 Fax: +1-4083952113
Email: craig@hearthugger.com; Web: www.hearthugger.com

Heart Hugger is a patient operated Sternum Support Harness applied post-op to splint thoracic surgical wounds. Its benefits include pain management, better patient compliance with respiratory therapy, faster return to premorbid respiratory levels, fewer wound complications, better post-op mobility and easier patient handling for hospital staff. Heart Hugger benefits post open-heart, lung volume reduction, fractured rib and other chest trauma patients. Manufactured in the USA by General Cardiac Technology, Los Gatos, CA (www.hearthugger.com).
Heartware Inc

205 Newbury Street
Framingham, MA 0170, USA
Tel: +1-6178522974

Email: klee@heartwareinc.com; Web: www.heartware.com

Treatment of advanced heart failure. Through a cadence of progressively smaller devices implanted using less invasive techniques, HeartWare expects to treat an increasing proportion of heart failure patients and to access them at an earlier stage of their disease progression. HeartWare’s lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System has CE-Mark approval and is currently the subject of a 150-patient US IDE clinical trial.

Integra Lifesciences

Immeuble Séquoia 2 97 Allée Alexandre Borodine
Parc Technologique de la Porte des Alpes
69800 Saint-Priest, France
Tel: +33-437475900 Fax: +33-437475699

Email: agnes.cretien@integralife.com; Web: www.integralife.eu

Integra is a leader in Acute Care Surgical Products. The company’s portfolio includes quality instrumentation solutions for sterile processing and OR needs in laparoscopic, general, cardiovascular, neuro, plastic and reconstructive surgery. Products include Luxtec® illumination systems and cables, instruments from Jarit®, Redmond™, Padgett®, Omni-Tract® table-mounted retractors and CIMS® Consulting Services.

US Office:

Integra 311 Enterprise Drive
Plainsboro, NJ 08536, USA
Tel: +1-8009974868 U.S.A/Canada
Tel: +1-6092750500 International
Fax: +1-6092755363

Intuitive Surgical

Chemin des Muriers, 1
1170 Aubonne, Switzerland
Tel: +41-218212042 Fax: +41-218212001

Email: benedicte.maupin@intusurg.com; Web: www.intuitivesurgical.com

ISMICS-International Society

For Minimally Invasive Cardiothoracic Surgery

500 Cummings Center Suite 4550
Beverly, MA 01915, USA
Tel: +1-9789278330 Fax: +1-9785248890

Email: echouinard@prri.com; Web: www.ismics.org

ISMICS 2013 Annual Scientific Meeting, 12-15 June 2013, Hilton Prague, Prague, Czech Republic, www.ismics.org
The Jarvik 2000, the smallest CE marked VAD available, supports the full cardiac output of advanced heart failure patients with BSA of 1.2 to 2.5 M2. Positioned within the ventricle, the Jarvik 2000 has no inflow cannula, which increases aortic pulsatility. Two models are available, with conventional abdominal drive cable, and the unique “behind-the-ear” connector, which eliminates the need for exit site dressings allowing showering and even swimming. Intermittent Low Speed mode for opening the aortic valve is available in both models. Jarvik Heart is actively developing miniaturized pumps such as the Infant and Child VADs.

Jena Valve Technology GmbH
Guerickestr. 25
80805 Munich, Germany
Tel: +49-89552790828 Fax: +49-89552790879
Email: schricker@jenavalve.de; Web: www.jenavalve.de

JenaValve™ Technology is a medical device company focused on developing transcatheter valve implantation systems to treat patients suffering from aortic valve disease. The company has both transapical and transfemoral TAVI systems to address the needs of the cardiac surgeon and cardiologist, respectively. The company's products are currently targeted at high-risk patients unsuitable for open heart surgery. JenaValve Technology’s headquarters are in Munich, Germany. Additional company information is available at www.jenavalve.com

Jotec GmbH
Lotzenaecher 23
72379 Hechingen, Germany
Tel: +49-7471922319 Fax: +49-7471922100
Email: angela.kremer-wohlfahrt@jotec.com; Web: www.jotec.com

JOTEC provides innovative solutions for vascular disease to Vascular and Cardiac Surgeons, interventional Radiologists and Cardiologists. According to the highest standards of innovation and quality JOTEC develops, manufactures and markets medical devices for peripheral and aortic vascular disease. The product portfolio comprises stent grafts, stents, surgical grafts as well as endovascular accessories. Continuous product improvements and new developments aim to offer best possible solutions for both – patient and physician.

Karl Storz GmbH & Co KG
Mittelstraße 8
78532 Tuttingen, Germany
Tel: +49-74617088744 Fax: +49-7461708377
Email: Verena.Schittek@karlstorz.com; Web: www.karlstorz.com

Karl Storz is a renowned manufacturer that is well established in all fields of endoscopy and can be considered as market leader in rigid endoscopy. The still family held company was founded in 1945 in Tuttingen, Germany, and has grown to one with a worldwide presence and 5800 employees. Karl Storz offers a range of both rigid and flexible endoscopes for a broad variety of applications. Today's product range also includes fully integrated concepts for the OR and servicing.
KLS Martin Group is an innovative company ready to invest, based on a clear growth strategy. At the EACTS Annual Meeting we will present:

**Sternal Talon®** - The innovative sternal closure system designed for high-risk patients and reconstruction procedures.

**Limax® 120** – the innovative Laser System for metastatic resection. The diode-pumped Nd:YAG laser Limax® 120 satisfies the highest demands for treatment quality and operating convenience in Thoracic and Endobronchial Surgery.

**Instruments** – a broad range of high quality cardiovascular instruments.

Labcor Laboratorios Ltda, manufacturer of Porcine and Pericardium heart valves since 1984, distributes its CE Mark products in over 22 countries, mainly in Europe, Latin America and the Middle East. Labcor produces a complete line of tissue products for cardiac surgery, its commitment to life and dedication to new technologies have made the company leader in the field for new preservations and anti-calsification solutions.

Lepu Medical Technology (Beijing) Co Ltd is a high-tech enterprise specialized in research & development, production, sales and service of interventional medical devices. We possess over 10 categories of cardiovascular interventional, transcatheter, anesthetic, and IVD Products with CE Mark. The main products include Sirolimus-eluting coronary stent system, PTCA balloon dilatation catheters, occluders, prosthetic heart valves and etc. Partner®, one of famous sirolimus-eluting stents produced by Lepu, occupies about 30% market-share in China.

COR-KNOT® delivers instant security with automated knotting and integrated suture trimming in one easy step. COR-KNOT® may reduce cardiopulmonary bypass and cross-clamp time in your OR. Visit the LSI Solutions booth and see the newest edition to the COR-KNOT® family, the CK Standard.
Mani Inc Japan
8-3 Kiyohara Industrial Park
Utsunomiya, Tochigi, 321-3231, Japan
Tel: +81-286678346 Fax: +81-286678305
Email: surgical@ms.mani.co.jp; Web: http://www.mani.co.jp/en/index

Product Information: Mani Vessel Knife with ultimate sharp edge that provides better usability. Mani Stainless Steel Wire with high strength needle that achieves better penetration, ductility and bending strength.

Company Information: For clinicians in general surgery, ophthalmic procedures and dental treatments, Mani has been providing high quality, reliable and innovative instruments in over 120 countries for more than 50 years.

Maquet Cardiopulmonary AG
Kehler Strasse 31
76437 Rastatt, Germany
Tel: +49-72229321196 Fax: +49-72229321888
Email: Christine.Schaefer@maquet.com; Web: www.maquet.com

Maquet Cardiovascular offers products for cardiac assist (counterpulsation therapy), CABG surgery, thoracic, aortic, endovascular and peripheral vascular surgery, interventional cardiology and extracorporeal circulation. The latest acquisition of Atrium Medical complements Maquet Cardiovascular therapy options and provides additional ground-breaking therapies. Maquet continues to invest in the development of solutions that advance clinical practice, improve patient outcomes and enhance quality of life.

Master Surgery Systems AS
Hanchegaten 20
3186 Horten, Norway
Tel: +47-41507244 Fax: +47-33082645
Email: arne@mastersurgerysystems.no; Web: www.mastersurgerysystems.no

Master Surgery Systems has comprehensive knowledge about flow measurements after more than 15 years accumulated experience. We are introducing a new fully digital transit time flow meter for graft patency verification. The software driven system is integrated in a 15” touch screen allowing the system to be mounted off the floor in the OR. We offer a wide range of flow probes for native and bypass vessels. In addition, a wide range of clamp-on probes for flow measurements in tubes during LVAD or ECMO procedures. Visit the flow experts for an update.

MDD Medical Device Development GmbH
Steigäcker 20 Industrial Area
78582 Balgheim, Germany
Tel: +49-742492208 Fax: +49-742492242
Email: info@m-d-d.net; Web: www.m-d-d.net

Development / Production / Distribution of Cardiovascular Instruments and Accessories Disposables

Medafor Inc
2700 Freeway Boulevard Suite 800
Minneapolis, MN 55430 USA
Tel: +1-8776332367 Fax: +1-7635711035
Email: jharff@medafor.com; Web: www.medafor.com

Medafor Inc manufactures and distributes Arista®AH hemostatic powder and other products and applicators under the MPH® Technology platform for the control of surgical bleeding.
Medex Research Ltd
2 Chapel Street
Chichester, PO19 1BU, UK
Tel: +44-1243790779 Fax: +44-1243790778
Email: sarinam@medexresearch.com; Web: www.medexresearch.com
A Global market research agency devoted to supporting manufacturers of medical devices and diagnostics in strategic planning and communication

Medistim ASA
Fernanda Nissensgt. 3, PB 4744 Nydalen
421 Oslo, Norway
Tel: +47-23059698 Fax: +47-23059661
Email: Camilla.hauge@medistim.com; Web: www.medistim.com
Medistim is the innovator and market leader within intra-operative transit time flow measurement (TTFM) and ultrasound imaging. We develop, manufacture and bring to market the quality assessment systems VeriQ and VeriQ C for cardiac, vascular and transplant surgery. Our TTFM technology became part of the ESC/EACTS guidelines on myocardial revascularization in 2010, and in 2011 our VeriQ TTFM system was recommended by the National Institute for Health and Clinical Excellence (NICE) for routine use within the UK national health system (NHS).

Medos AG
Obere Steinfurt 8-10
52222 Stolberg, Germany
Tel: +49-240296640 Fax: +49-2402966460
Email: j.reiners@medos-ag.com; Web: www.medos-ag.com
Medos is a leading German medical device company offering a full range of product solutions for cardiac surgery and peripheral applications. Medos focuses on the continuous development of innovative therapy solutions for cardiac surgeons and perfusionists. After two and a half decades Medos is very well established as a provider of products for extracorporeal organ support and organ replacement. Manufacturing exclusively in Germany, Medos is present worldwide in order to ensure a personal contact to its customers.

Medtronic International Trading Sàrl
31 Route du Molliau Case Postale
1131 Tolochenaz, Switzerland
Tel: +41-218027098 Fax: +41-218027928
Email: cathy.persidis@medtronic.com; Web: www.medtronic.com
At Medtronic, we’re committed to Innovating for Life by pushing the boundaries of medical technology and actually changing the way the world treats chronic disease. Find Opportunity in Change and consider Medtronic’s intuitive solutions in Structural Heart and Aortic Diseases including: tissue, mechanical and transcatheter valves; irrigated RF and cryosurgical ablation devices; aortic stent graft systems; and OPCAB, MIS CABG, cannulae and perfusion products. For more information on our company, please visit www.medtronic.com.

Micardia Corporation
30 Hughes, Suite 206
Irvine, CA 92618, USA
Tel: +1-9499514888 Fax: +1-9499514812
Email: Rgibbs@micardia.com; Web: www.micardia.com
MiCardia Corporation is a privately held medical device company in Irvine, CA, dedicated to designing, developing and commercializing innovative products for treating mitral valve disease. Up to 30% of annuloplasty patients will experience recurrent mitral regurgitation within 6-18 months after surgical intervention. The enCorSQ offers the world’s first beating heart, real-time, late correction of recurrent mitral regurgitation, weeks or months post-procedure, by reshaping the device without the need for an additional open heart procedure.
Since its early beginning at NASA, the U.S. Space Program, and the Texas Medical Center in Houston in 1988, MicroMed has been committed to developing, manufacturing and marketing innovative mechanical circulatory support solutions for patients suffering from severe congestive heart failure. Through close collaboration with cardiovascular specialists worldwide, MicroMed offers state-of-the-art technologies such as the HeartAssist5 Ventricular Assist Device (VAD) System, currently the world’s smallest, full-output VAD available.

NeoChord Inc
Am Hermertsberg 7
64342 Seeheim, Germany
Tel: +49-1724528995

Email: ukasten@neochord.com; Web: www.neochord.com

NeoChord, a Minneapolis, Minnesota medical device company, intends to transform mitral valve repair by providing minimally invasive technology that enables beating heart, sternal sparing implantation of artificial chordae tendinae.

Neomend Inc
60 Technology Drive
Irvine CA 92618, USA
Tel: +1-9499161630x124 Fax: +1-949783 3331

Email: sylvia.gannam@neomend.com; Web: www.neomend.com

Neomend, Inc. is an emerging growth company engaged in the development and commercialization of innovative surgical sealants that lend themselves to significantly improved patient outcomes. Neomend’s patented ProGel® technology is a hydrogel polymer that can be chemically engineered for optimization of key sealant properties in order to effectively meet the needs of targeted surgical procedures. The versatility of the Progel platform has Neomend, Inc. in a unique position to surpass industry standards in the design, development and clinical performance of surgical sealants and adhesion barrier products for various clinical applications.

On-X Life Technologies Inc™
1300 E. Anderson Lane, Bldg B
Austin, TX 78752 USA
Tel: +1-5123398000 Fax: +1-5123393636

Email: marketing@onxlti.com; Web: www.onxlti.com

On-X® Heart Valves: Patented natural design and On-X® Carbon offer reduced turbulence in a mechanical valve to rival the clinical and hemodynamic performance of bioprostheses. FDA IDE approved PROACT (Prospective Randomized On-X® Anticoagulation Clinical Trial) is in process.

Oxford University Press
Great Clarendon Street
Oxford, OX2 6DP, UK
Tel: +44-01865 556767

Email: online@oup.com; Web: www.oup.com

Come and visit the Oxford University Press stand to browse our range of surgery books and take advantage of our 20% conference discount as well as picking up your free sample copies of leading medical journals, including the European Journal of Cardio-Thoracic Surgery, and Interactive CardioVascular and Thoracic Surgery and more.
Experts in cardiovascular surgery, Péters Surgical offers a wide range of sutures:
- Corolene® polypropylene monofilament with a minimal memory
- Premio® PVDF monofilament designed for cardiopediatric surgery
- Cardionyl® unique monofilament suture for mitral valve repair
- Cardioxyl® and Cardioflon® respectively siliconized and teflonized extra strong polyester braids for valve and ring fixation
- Acier, soft and strong stainless steel wire for sternal closure

Péters Surgical also manufactures Uniring®: Universal Annuloplasty System.

Praesidia Srl manufactures and distributes Flexigrip Sternal Closure System, made of Nitinol thermoreactive clips. Through its affiliate companies Praesidia is presenting the DoveTail Divergent Sternal Retractor. Praesidia is active as well in surgical and intensive care markets.

Qualiteam is devoted to develop, manufacture and distribute products to advance postoperative care for patients and give functional convenience for staff. Our goal is to improve patient’s hospital experience and accelerate recovery leading to cost savings for healthcare providers. We focus on product efficiency without jeopardizing patient comfort making wound care easy for health care personnel while being safe and less painful for patients. Come visit our booth where we show how our products can assist you to improve your patient’s recovery.

Redax developed a full range of chest drains with innovative design allowing for additional stability. Chest Drains are available in different models – Dry and Wet – also for autotransfusion. Redax has also developed a “Mobile Drainage System” based on a portable vacuum unit for easier portability and early mobilization of patients. Thoracic Catheters and Fluted Silicone Drains belong to the cardio-thoracic range of products too. Recently we developed an innovative Percutaneous Centesis Kit for pleural effusion and emergency application.

Rumex International is a US company specialized in the field of microsurgical instruments. We bring cutting edge technology to the hands of surgeons at affordable prices. Stop by and learn about our innovative cardiovascular line including German Super Cut Scissors and Titanium needle holders with TC inserts.
Sanofi Biosurgery
Booth No: 71
55 Cambridge Parkway
Cambridge, MA 2142, USA
Tel: +1-6172527647
Email: lauren.loomis@sanofi.com; Web: www.sanofi.com
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Scanlan International Inc
Booth No: 33
One Scanlan Plaza
St. Paul, MN 55107, USA
Tel: +1-6512980997 or 8003289458 Fax: +1-6512980018
Email: info@scanlangroup.com; Web: www.scanlanINTERNATIONAL.com

Siemens AG Healthcare Sector
Booth No: 87
H IM AX Siemensstrasse 1
91301 Forchheim, Germany
Tel: +49-9191186520 Fax: +49-9191189914
Email: anne.figel@siemens.com; Web: www.siemens.com
The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective.

Smartcanula LLC
Booth No: 91
21 Avenue du Tribunal Fédéral
1005 Lausanne, Switzerland
Tel: +41-213142279 Fax: +41-213202442
Email: info@smartcanula.com; Web: www.smartcanula.com
Smartcanula LLC develops, manufactures, and distributes next generation cannulas for cardiopulmonary bypass, and minimally invasive heart surgery. The Venous smartcanula® is collapsed with a mandrel prior to insertion over a guide wire and re-expanded in situ: full flow can be achieved with remote access and gravity drainage alone. Augmentation with a centrifugal pump is not necessary. In addition to the Venous and Arterial smartcanula®, the new SmartCentral which is designed for improved routine central venous cannulation will be presented.
Sorin Group is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems, cannulation), cardiac rhythm management, and heart valve repair and replacement.

St. Jude Medical develops medical technology designed to put more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful patient outcomes. Learn more at sjmprofessional.com.

Starch Medical Inc. is an US based company, engaged in the design, manufacture and sale of innovative, absorbable surgical hemostats synthesized from Absorbable Modified Polymers, AMP materials are biocompatible, absorbable polysaccharides containing no animal or human components.

STS is a not-for-profit organization representing more than 6,400 surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible heart, lung, esophageal, and other surgical procedures for the chest. Founded in 1964, the mission of STS is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. STS Headquarters is located in Chicago, Illinois, USA.

C-Pulse is an extra-aortic balloon pump using counterpulsation technology to treat moderate to severe heart failure. It can be performed minimally invasively, outside the bloodstream, and the patient can disconnect from the system. It is designed to improve heart function by increasing cardiac output, increasing coronary perfusion, and decreasing afterload.
Symetis SA
Booth No: 41
Chemin de la Venoge 11
1024 Ecublens, Switzerland
Tel: +41-216940244 Fax: +41-216510161
Email: solange.guye@symetis.com; Web: www.symetis.com

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurate™ Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Syncardia Systems Inc
Booth No: 126/127
1992 E. Silverlake Road
Tucson, AZ 85713 USA
Tel: +1-5205451234 Fax: +1-5209031783
Email: vwessel@syncardia.com; Web: www.syncardia.com

The SynCardia temporary Total Artificial Heart (TAH-t) is the world’s only FDA and CE approved Total Artificial Heart. The TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The Freedom™ portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients inside and outside the hospital. Visit our booth for updates on the clinical study, the 50cc TAH-t and destination therapy.

Terumo Europe Cardiovascular Systems (TECVS)
Booth No: 77
Ludwig-Erhard-Strasse 6
65760 Eschborn, Germany
Tel: +49-61968023538 Fax: +49-61968023550
Email: Jessica.herczeg@terumo-europe.com; Web: www.terumo-europe.com

Terumo Europe Cardiovascular Systems is an integral part of the Terumo’s family of cardiovascular businesses and is committed to developing innovative technologies for the treatment of cardiovascular disease. In Europe, Terumo Cardiovascular Systems provides products and service such as Capiox® Oxygenators, customized Tubing Sets, Pall® filter brand products, VirtuoSaph Plus®, the Endoscopic Vein Harvesting System and Kymerax™ a handheld robotic system.

Vascutek, a Terumo Company
Booth No: 77
Newmains Avenue
Inchinnan, Renfrewshire PA4 9RR
Scotland, UK
Tel: +44-1418125555 Fax: +44-14181207170
Contact: Helen Paterson. Email: hp@vascutek.com; Web: www.vascutek.com

Vascutek, a Terumo Company, will present its full range of Gelweave™ cardiothoracic grafts and BioValsalva™, the “Biological Bentall” conduit for aortic valve and root replacement. The company’s proven porcine heart valves, aspire™ and elan™ as well as the Porcine Pericardial Patch will also be on display. Visit us at our booth for a Live Demonstration!

The Society For Heart Valve Disease
Booth No: 103
500 Cummings Center, Ste 4550
Beverly, MA 01915, USA
Tel: +1-9789278330 Fax: +1-9785240498
Email: sneece@prri.com; Web: www.shvd.org

The SHVD is an organization formed to undertake, promote, support and encourage research and the education of the public in the causes of heart valve disease, the prevention of, and the treatment of heart valve disease, or any related cardiac disease, illness or condition. SHVD is comprised of cardiologists, cardiothoracic surgeons, researchers, allied health professionals, students, and institutional representatives from around the globe. SHVD’s next biennial meeting, held in conjunction with the HVSA, is 22-24 June 2013 in Venice, Italy.
Thoratec Corporation
6035 Stoneridge Drive
Pleasanton, CA 94588, USA
Tel: +1-9258478600 Fax: +1-9258478574
Email: sandie.hastings@thoratec.com; Web: www.thoratec.com

Thoratec® Corporation is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. For more information, visit the company’s website at http://www.thoratec.com.

Tianjin Plastics Research Institute Co Ltd (TPRI)
No. 24, Keda 1 Road, Microelectronics Park, Jinnan District
300350 Tianjin, China
Tel: +86-2227592537 Fax: +86-2227592537
Email: tjsmedical@yahoo.com.cn and ybliap@yahoo.com.cn; Web: www.medplastic.com

Tianjin Plastics Research Institute established in 1965 and dedicates in cardioplegia disposable products. Our main products are extra-corporeal circuit products, Arterial filter, Blood reservoir, Arterial & Venous Cannula, Aortic Root Cannula and various components such as connectors, tubes, isolator, gas filter, clamps and so on.

TransMedics Inc
200 Minuteman Road, Suite 302
Andover, MA 01810, USA
Tel: +1-9785520957 Fax: +1-8785520978
Email: jdonohue@transmedics.com; Web: www.transmedics.com

Headquartered in Andover, Massachusetts, TransMedics™ is a medical device company founded in 1998 to address the unmet need for better, more effective organ transplant technologies. The Company has developed the first commercial, portable warm blood perfusion system that allows for a new type of organ transplant, called a living organ transplant. This technology, called an Organ Care System, or OCS, is designed to maintain organs in a warm, functioning state outside of the body during transport from organ donor to recipient. The OCS could potentially increase organ availability and improve outcomes for the growing population of patients with end stage organ failure in need of a transplant, bridging the widening gap between the number of organs available and the number of recipients awaiting transplants.

European Office:
TransMedics BV
Centaurusweg 123
5015 TC Tilburg, The Netherlands

Transonic Systems Europe BV
Punterweg 31
6222 NW Maastricht, Netherlands
Tel: +31-434077200 Fax: +31-434077201
Email: tamara.theunissen@transonic.nl; Web: www.transonic.com

Transonic Systems is the recognized global leader in biomedical flow measurement technology. For 29 years its devices have been used in groundbreaking research and to provide quantitative flow measurements during cardiac, vascular, transplant and neurosurgeries, ECMO, angioplasty, and hemodialysis. During CABG surgery, simply slip a perivascular flowprobe around a bypass graft for on-the-spot quantitative confirmation of bypass flow to guarantee early graft patency.
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valvexchange Inc</td>
<td>130</td>
</tr>
<tr>
<td>6080 Greenwood Plaza Blvd.</td>
<td></td>
</tr>
<tr>
<td>Greenwood Village, CO 80111, USA</td>
<td></td>
</tr>
<tr>
<td>Tel: +1-7204545550 Fax: +1-8886449940</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:jvallez@valvexchange.com">jvallez@valvexchange.com</a>; Web: <a href="http://www.valvexchange.com">www.valvexchange.com</a></td>
<td></td>
</tr>
<tr>
<td>A medical device company located in the United States with a two-part exchangeable tissue heart valve. The company is currently in the early clinical trial stage and anticipates to receive approval in 2013.</td>
<td></td>
</tr>
<tr>
<td>Wexler Surgical Inc</td>
<td>20/21</td>
</tr>
<tr>
<td>11333 Chimney Rock Road #110</td>
<td></td>
</tr>
<tr>
<td>Houston, TX 77035, USA</td>
<td></td>
</tr>
<tr>
<td>Tel: +1-71373236900 Fax: +1-7137236906</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:julie.machado@wexlersurgical.com">julie.machado@wexlersurgical.com</a>; Web: <a href="http://www.wexlersurgical.com">www.wexlersurgical.com</a></td>
<td></td>
</tr>
<tr>
<td>Wexler Surgical designs and manufactures a variety of titanium and stainless steel specialty surgical instruments and products for Cardiac, Vascular, Thoracic, and Micro Surgery. Come see our new VATS/MICS and Optimus instrument lines. Visit us online at <a href="http://www.wexlersurgical.com">www.wexlersurgical.com</a> for information about our products and services.</td>
<td></td>
</tr>
<tr>
<td>Wisepress Online Bookshop</td>
<td>1/2</td>
</tr>
<tr>
<td>25 High Path</td>
<td></td>
</tr>
<tr>
<td>London, SW19 2JL, UK</td>
<td></td>
</tr>
<tr>
<td>Tel: +44-2087151812 Fax: +44-2087151722</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:bookshop@wisepress.com">bookshop@wisepress.com</a>; Web: <a href="http://www.wisepress.com">www.wisepress.com</a></td>
<td></td>
</tr>
<tr>
<td>Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.</td>
<td></td>
</tr>
<tr>
<td>WL Gore &amp; Associates GmbH</td>
<td>97</td>
</tr>
<tr>
<td>Hermann-Oberth-Strasse 24</td>
<td></td>
</tr>
<tr>
<td>85640 Putzbrunn, Germany</td>
<td></td>
</tr>
<tr>
<td>Tel: +49-8946122408 Fax: +49-89461242408</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:joster@wlgore.com">joster@wlgore.com</a>; Web: <a href="http://www.goremedical.com">www.goremedical.com</a></td>
<td></td>
</tr>
<tr>
<td>W. L. Gore &amp; Associates, Inc. is the worldwide leader in expanded polytetrafluoroethylene (ePTFE) technology. The Medical Division of Gore specialises in the design and manufacture of innovative medical devices for use in vascular, interventional, cardiac, general, orthopaedic, neurological, dental, and plastic surgery.</td>
<td></td>
</tr>
</tbody>
</table>
27th EACTS Annual Meeting
Vienna, Austria
5 - 9 October 2013

To find out more or to register for the event visit:
www.eacts.org

Raising Standards through Education and Training